Movatterモバイル変換


[0]ホーム

URL:


US3791932A - Process for the demonstration and determination of reaction components having specific binding affinity for each other - Google Patents

Process for the demonstration and determination of reaction components having specific binding affinity for each other
Download PDF

Info

Publication number
US3791932A
US3791932AUS00221447AUS3791932DAUS3791932AUS 3791932 AUS3791932 AUS 3791932AUS 00221447 AUS00221447 AUS 00221447AUS 3791932D AUS3791932D AUS 3791932DAUS 3791932 AUS3791932 AUS 3791932A
Authority
US
United States
Prior art keywords
enzyme
hcg
determination
determined
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00221447A
Inventor
A Schuurs
B Weemen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzona Inc
Original Assignee
Akzona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzona IncfiledCriticalAkzona Inc
Application grantedgrantedCritical
Publication of US3791932ApublicationCriticalpatent/US3791932A/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

The present invention relates to a process for the determination of a component of the reaction between a specific binding protein and the substance being specifically bound by such a protein comprising reacting the component to be determined with its binding partner in an insolubilized form, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a determined amount of a coupling product of the substance to be determined with an enzyme, and finally determining the enzyme activity of the liquid or solid phase of the reaction mixture obtained.

Description

United States Patent [191 Schuurs et al.
[451 Feb. 12, 1974 [75] Inventors: Antonius Hermanus Wilhelmus Maria Schuurs; Bauke Klaas Van Weemen, both of Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,
22 Filed: Jan. 27, 1972 21 App]. No.: 221,447
[30] Foreign Application Priority Data Feb. 10, 1971 Netherlands 7101728 [52] US. Cl. 195/l03.5 R, 424/12, 23/230 B [51] Int. Cl. G0ln 31/14 [58] Field of Search 195/103.5 R; 23/230 B; 424/12 [56] References Cited UNITED STATES PATENTS 3,654,090 4/1972 Schuurs et al. 195/1035 R Primary Examiner-Alvin E. Tanenholtz Assistant ExaminerMax D. Hensley Attorney, Agent, or Firm--Hugo E. Weisberger [57] ABSTRACT The present invention relates to a process for the determination of a component of the reaction between a specific binding protein and the substance being specifically bound by such a protein comprising reacting the component to be determined with its binding partner in an insolubilized form, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a determined amount of a coupling product of the substance to be determined with an enzyme, and finally determining the enzyme activity of the liquid or solid phase of the reaction mixture obtained.
4 Claims, N0 Drawings PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF REACTION COMPONENTS HAVING SPECIFIC BINDING AFFINITY FOR EACH OTHER For the demonstration and determination of substances playing a prominent part in biochemical processes, i.e. low molecular substances, such as vitamins and steroids, or high molecular ones, such as proteins and carbohydrates, it is often possible to employ reactions of these substances with proteins having a specific binding affinity for these substances. Thus, it is possible to determine the concentration of a steroid by employing a protein capable of binding this steroid specifically. As examples of such combinations are mentioned cortisol and transcortin, l7B-oestradiol and the oestradiol-binding receptor protein of the uterus.
It is also possible to link a low molecular substance chemically with a protein, and to inject this conjugate into a test animal, which then reacts by forming antibodies against, among others, the low molecular substance. The latter is in this case to be regarded as a socalled hapten. The antibodies against the hapten may be regarded as a special case of specific binding proteins.
High molecular substances, such as simple and conjugated proteins and carbohydrates, are capable of causing the formation of antibodies on being injected into animals in the correct experimental conditions. Between these antibodies and the injected high molecular substance, the antigen, there is again question of specific binding affinity.
Determination methods in which these specific binding affinities are employed, are often based on the competition between the substance to be determined in the sample and the known quantity of the same substance, labelled radioactive, for a limited quantity of its binding partner. The quantity of substance to be determined determines what part of the radioactive labelled substance can be bound by its binding partner. It is also possible to determine an unknown quantity of specific binding protein by reacting a sample of it with a certain quantity of radioactive labelled, specific binding substance. The terms by which these methods are designated in the literature, depend upon the nature of the specific binding protein. They speak of competitive protein binding assays, where receptor or transport proteins are used, and of"radioimmunological determinations" where antibodies are employed as specificbinding protein.
Instead of labelling one of the components of the above-described reactions with a radioactive isotope, it is also possible to employ an enzyme as a labelling substance. Where use is made of the binding affinity between a low molecular substance and its specif c binding protein, the low molecular substance can be coupled with an enzyme. The coupling product, low molecular substance/enzyme, can then be used in experimental set-ups as described above. Where use is made of the binding affinity between an antigen and its antibody, the antigen may, for example, be coupled with an enzyme instead of labelling it with a radioactive isotope as is conventional in radioimmunological methods.
For all the methods in which such a labelled reaction component is employed, a suitable method for separating the free labelled compound attached to the binding partner, is essential. Dependent upon the nature of the substances participating in the reaction, various separation methods can be employed, for example electrophoresis, gel filtration, selective adsorption, application of one of the reaction components in an insolubilised form, and application of antibodies against one of the reaction components, also in an insolubilised form.
In spite of the high sensitivity that can be achieved by these methods, it is not always possible to demonstrate or determine substances occurring in extremely low concentrations in, for example, serum or urine. Thus, it is very difficult and often impossible to demonstrate adrenocorticotrophic hormone (ACTH) by a radioimmunological method, unless one has the disposal of a very rare antiserum containing antisubstances with an extremely high binding affinity for ACTH.
Also determinations of smaller peptide hormones such as oxytocin in non-extracted serum, causes great difficulties, because the required sensitivity cannot be reached.
Although, in principle, the immunological crossreaction between HCG and LH enables both hormones to be determined with one test-system, most methods for the determination of human chorionic gonadotrophin (HCG) by a coupling product of HCG and an enzyme cannot be used for the demonstration and determination of luteinizing hormone (LH). This is due to the fact that LH occurs in much lower concentrations in blood and urine than HCG during pregnancy, so that the sensitivity of the test systems are insufficient. This shortage of sensitivity can be decreased by extracting the substance to be determined from the medium in which it occurs or by concentrating the medium. These methods, however, are very laborious, and the results often unsatisfactory.
A process has now been found for the demonstration and determination of a component of the reaction between specific binding proteins and the substances that can be specifically bound by these proteins, using the known binding affinity of such components for each other, which comprises reacting the component to be determined with its binding partner, which has been or is insolubilised, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a coupling product, obtained by binding a substance capable of reacting specifically with one of the reaction components, to an enzyme, and finally determining the enzyme activity of the liquid or the solid phase in the reaction mixture obtained, which is a measure for the quantity of the substance to be determined.
The binding partner required for the determination of the component present in an unknown quantity, is employed in an insoluble form. The determination can take place by adding the binding partner to the reaction mixture in an insoluble form and reacting the mixture in a heterogeneous medium, but the binding partner can also be added in a dissolved form, after which it can be insolubilised by adding antisubstances against it.
The substance capable of reacting specifically with one of the reaction components, and which is employed coupled with an enzyme, may be the other reaction component, but also a third substance that must possess a specific affinity for one of the components of the reaction.
The method can be applied to the various reaction systems described above, i.e. antigen/antibody, hapten- /antibody and a low molecular substance/specific binding protein. As third substance a second antibody may occur, that is to say, an antibody against the gammaglobulin fraction of the species of animal in which the first antibodies have been generated. This situation may occur in the systems antigen/(first) antibody and hapten/(first) antibody. As third substance may also occur an antibody against a specific binding protein.
The essence of the method is the performance in two steps, in between which a separation takes place of the liquid and the solid phase of the reaction mixture. With the solid phase the second step is performed. Only in this stage the enzyme coupling product is employed and the enzyme activity determined.
The most important advantages of the method found are:
l. the first step can be performed in a larger volume than is desirable or possible for the second step. This is of great importance when the substance to be determined occurs in too low concentrations to be determined by known methods.
2. In the liquid to be examined substances may be present influencing the reactions in the second step unfavourably. Especially the enzyme present in the coupling product and the enzymatic catalysing reaction may be sensitive to disturbing substances in the test liquid.
The method found can especially be employed for the determination of substances present in body liquids such as hormones, their antibodies and specific binding proteins, as well as enzymes. Also factors of bloodclotting, fibrinolysis and complement systems, pathological proteins in body liquids, as well as antibodies against pathogenic microorganisms and iso-antibodies can be determined in this manner.
The medium in which the first step of the determination takes place often consists for a large part of test liquid, such as urine or serum. If considered necessary, it can be adjusted to the pH required for the immunochemical reaction, viz. between 5 and 9, by adding a dry buffer salt or a small volume of a concentrated buffer solution. The medium of the second step is also a buffer of a pH required for the immunochemical reaction. For this purpose phosphate buffers, citrate buffers, tris(hydroxy methyl)-aminomethane, and imidazole buffers can be employed. It may be necessary to use for the relative enzyme reaction a buffer of another composition and pH, which depends upon the enzyme employed.
The manufacture of the insolubilised reaction component can take place in various manners, i.a. dependent upon the properties of this reaction component. Thus, antibodies, specific binding proteins and proteinlike antigen can be insolubilised by cross-linking, for example, glutaric aldehyde and chloroformic acid ethyl ester, by physical adsorption or chemical coupling with an insoluble carrier, such as cellulose compounds, agarose, cross-linked dextran, polystyrene and the like, or by coupling with antibodies against the relative protein coupled with an insoluble carrier. Low molecular substances can be bound by methods dependent upon the structure of the low molecular substance and the carrier material. Some of the low molecular substances may already possess groups capable of reacting with the reactive parts on the carrier material: in other cases such groups will have to be introduced by organic chemical reactions.
The manufacture of the enzyme coupling products is also performed by methods dependent upon the properties of the molecules incorporated into the coupling product. A covalent bond of proteins to enzymes can be effected by reagents such as carbodiimides, diisocyanates, glutaric aldehyde and bis-diazobenzidine. The coupling of low molecular substances can take place in various manners. Some of these substances may already possess groups that can be cross-linked with reactive groups of the enzyme; in other cases such groups will have to be introduced by organic chemical reactions. It stands to reason that in the manufacture of these coupling products the original binding properties of the substances bound to the enzyme may not change very much; no more may the enzyme activity be decreased considerably.
The choice of the enzyme that is to form a part of the coupling product, is determined by properties such as the specific binding activity (a high conversion rate raises the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme catalysing a conversion in which coloured reaction components are involved, is simple. Such colorimetric determinations can be automated in a simple manner.
According to the invention it is also possible to employ enzymes catalysing those conversions in which reaction components are involved that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automated.
In the manufacture of the coupling products enzymes such as catalase, peroxidase, B-glucuronidase, B-B- glucosidase, ,B-D-galactosidase, urease, glucoseoxidase and galactose-oxidase are preferred, especially the group of the oxidoreductases.
The determinations according to the invention are broadly performed as follows: A certain volume of a test liquid, for example 10 ml, containing a very low concentration of the component to be determined, is mixed with a certain quantity of an insolubilised reaction partner of the substance to be determined. The test liquid may be urine, in which the component to be determined occurs in low concentration, or serum, which has been diluted to diminish the influence of disturbing factors. In order to enable the reaction to be performed in the heterogeneous system, the mixture is agitated. The resulting solid phase is separated from the test liquid, for example by centrifugation, and washed, if considered necessary. The first part of the determination can also be performed by incubating the test liquid with a certain quantity of the reaction partner of the substance to be determined in a dissolved form, after which a quantity of insolubilised antibody against that reaction partner is added and the mixture agitated and finally centrifuged. Separation by filtration and decantation is also possible.
The second part of the determination is performed by resuspending the insoluble substance, which forms the The enzyme activity of a phase of the reaction mixture is demonstrated or measured by incubating that phase with a substrate and other substances required for the relative enzyme reaction.
Preferably a reaction is employed in which a coloured compound is formed, or removed, whose adsorption can be easily quantitatively determined.
The form in which the reagents can be used are manifold. The component of the reaction system coupled with an enzyme may have been dissolved in a buffer, or freeze-dried. Also a solid carrier can be used, for example a strip of paper impregnated with the enzyme coupling product.
The insoluble component can be processed in the form of particles of various sizes, such as grains, plates and rods, or in the form of a strip of some or other carrier material.
For the performance of the process according to the invention a test-pack is usually employed, chiefly consisting of:
a. a certain quantity of the enzyme coupling product;
b. a corresponding quantity of one of the components of the reaction system in an insoluble form;
c. a substrate for the determination of the quantity of the enzyme employed.
The test-pack can contain the necessary auxiliaries, if required, to make a dilution series of the sample to be tested for a quantitative determination, such as test tubes, pipettes and flasks containing a diluent. For the determination of antigens or haptens, or their antibodies, the test-pack contains at least:
a. a certain quantity of the coupling product of the antigen or hapten, or an antibody against it, and an enzyme;
b. a corresponding quantity of an insolubilised component of the reaction system antigen/antibody, or hapten/antibody, and
c. a substrate for the determination of the enzyme activity.
The invention is further illustrated by the following examples, which are on no account intended to limit the invention.
EXAMPLE I Determination of human chorionic gonadotrophin (HCG) in serum.
a. Preparation of HCG-HRP. Five mg of HCG and 20 mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.2. After 40 u/ltr of 25 percent glutaric aldehyde solution had been added, the mixture was shaken at room temperature for 2 hours. Then the mixture was centrifuged for 5 minutes at 250 g, after which it was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.2. The fractions whose highest percentage of enzyme activity was bound by antibodies against HCG, were used in the test system.
b. Preparation of antibodies against HCG. Antibodies against HCG were generated in rabbits as described by Schuurs et. al. in Acta Endocr. (Kbh.) 59, (1968).
c. Preparation of the immuno-adsorbent, anti-HCG- cellulose. The y-globulin fraction of the anti-HCG- serum described under 1)) was prepared by precipitation with 18 percent (w/v) solid Na SO The precipitate was washed and then taken up in so much 0.05 M borate buffer of pH 8.6 that the ultimate protein concentration was 10 mg/ml. M-aminobenzyloxy methyl cellulose (350 mg) prepared by Gurvichs method, described in Biokhimiya 26, 934 (1961 was suspended in 50 ml of distilled water and diazotized by adding 10 ml of 36 percent hydrochloric acid and, dropwise, 10 ml of 10 percent NaNo -solution. The suspension was centrifuged and washed, and the precipitate resuspended in 43 ml of 0.05 M sodium borate of pH 8.6. 'yglobulin solution prepared 7 ml were added to this suspension. The mixture was stirred for 26 hours at 4C, centrifuged, and finally washed with 1 ltr of 0.02 M phosphate buffer of pH W V p 7 d. 'otr'ni'ifififiafimofi serum. A dilution series of HCG (8-4-2-l-0.5-0.25-0 l.U./ml) was prepared with a dilution liquid consisting of one part of mans serum and 2 part of 0.05 M phosphate buffer of pH 6.2. Of each of the thus prepared HCG dilutions 0.5 ml was rotated for 2 hours at room temperature with 0.5 ml of the immuno-adsorbent suspension (4 mg/ml), prepared in accordance with c), and then centrifuged. The precipitate was washed twice, each time with 2 ml of 0.05 M phosphate buffer of pH 6.2. The precipitate was mixed with 1.0 ml of HCG-HRP solution in a suitable dilution, as well as in 0.05 M phosphate buffer of pH 6.2, and rotated again at room temperature for 2 hours.
After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of a substrate solution consisting of 10 ul of 30% H 0 and 20 mg of 5-amino salicylic acid in ml of0.02 M phosphate buffer of pH 6.0. After 30 minutes the extinction was measured at 460 nm.
In the test system described a HCG concentration of 0.25 I.U./ml caused a measurable increase in the enzyme activity in the supernatant liquid, while a concentration of 1 I.U./ml caused the maximum increase. in this test the centrifugation step proved to be of decisive significance, as omission of this step gave rise to wrong measuring results of the enzyme activity, La. owing to turbidity of the serum and the peroxidase-like activity of it.
The HCG content of serum of pregnant women could be determined in this experimental set-up provided that the serum sample was diluted in the ratio of at least 1:3.
EXAMPLE II Determination of HCG in low concentrations by means of an enzyme/antigen coupling product.
a. Preparation of antisubstances against rabbit-yglobulin. Rabbit-y-globulin was isolated from normal rabbit serum by precipitating it with 18 percent (w/v) solid Na SO Antibodies against it were generated in a sheep. The injection scheme was:
Day Quantity Freunds adjuvant Manner of injection 0.5 mg lntramuscularly 14 0.5 mg Do.
28 1 mg Do.
42 1 mg Intravenously 56 1 mg Do.
On day 70 the sheep was exsanguinated.
b. Preparation of [sheep-anti-(rabbit-'y-globulin)]- cellulose. The 'y-globulin fraction of the sheep serum described under a) was prepared by precipitating it with 16 percent (w/v) solid sodium sulphate. This y-globulin fraction was bound to maminobenzyloxymethyl-cellulose, as described in example I c).
c. Determination of human chorionic gonadotrophin (HCG). A dilution series of HCG was prepared in 0.01 M phosphate buffer of pH 6.0, which also contained 2 percent (v/v) normal sheep serum. The dilution series was in the range of 10 to 320 I.U./ l, the dilution factor being 2. v
To 5 ml of a HCG solution was added 0.1 ml of a rabbit (anti-HCG) serum (see example I b), diluted with the same buffer to the desired strength. The mixture was left to stand at room temperature for 30 minutes, after which 1.5 mg of [sheep-anti(rabbit-y-globulin)] cellulose were added and the mixture was rotated for 2 hours.
The cellulose was centrifuged for minutes at 3,000 rpm. and resuspended in 1 ml of a solution of HCG- l-IRP coupling product, prepared in accordance with example I a), diluted to the desired strength with 0.01 M phosphate buffer of pH 6.0 with 2 percent normal sheep serum. The mixture was stirred again for 2 hours. After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 m] of it to 1.5 ml of enzyme substrate consisting of 10 pl of 30 percent H 0 and 20 mg of 5-amino-salicylic acid in 150 ml of 0.01 M phosphate buffer of pH 6.0. The mixture was left to stand for 30 minutes at 25, after which the extinction was measured at 460 nm. In the supernatant liquid 100 percent enzyme activity is measured provided that no anti-HCG serum is added to the system.
A dilution series of HCG, prepared with childrens urine as dilution liquid, gave an identical pattern so that also measurings in urine samples can be performed.
The centrifugation step effects a ten times higher sensitivity than can be reached in a system without centrifugation.
EXAMPLE III Determination of HCG and LH in low concentrations by means of an enzyme/antibody coupling product.
a. Preparation of the immune-adsorbent HCG cellulose. This immuno-adsorbent was prepared by the method mentioned in example I c), but instead of rabbit-y-globulin, 100 mg of HCG were coupled to 500 mg of m-aminobenzyloxymethyl cellulose.
b. Purification of antibodies against HCG. Ten ml of rabbit-anti-HCG serum, prepared in accordance with example I b), was diluted with 90 ml of 0.05 M citrate of pH 5.0 and slowly led over the immuno-adsorbent, which has packed in a column and mixed with 10 parts of Sephadex G-25. The immunoadsorbent was washed with the same buffer till no more protein was eluted. The antisubstances were eluted with 0.05 M citrate of pH 2.0. The fractions were collected in one half volume of 0.25 M NaHCO;,, tested for their content of antibodies and protein, and the suitable fractions were frozen.
c. Preparation of the coupling product (anti-HCG)- HRP. Twenty mg of horse radish peroxidase (HRP) were dissolved in 2 ml of an antibody solution having a protein content of 2 mg/ml. To this solution were added 8 pl of 25 percent glutaric aldehyde solution, after which the mixture was shaken for 2 hours at room temperature. Finally the mixture was fractionated over a Sephadex G-200 column in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme activity were bound to HCG cellulose, were used in the test system.
d. Determination of HCG and LH. Ten ml of a HCG dilution series of HCG and 10 ml ofa HCG dilution series of LH were mixed with 5 mg of anti-HCG cellulose, prepared in accordance with example I c), which was suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, and the mixtures rotate at room temperature for 2 hours. The immunoadsorbent was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0.
To the immuno-adsorbent 1 ml of the (anti-HCG)- HRP coupling product was added in the desired dilution, after which the mixture was rotated again for 2 hours. Finally, after centrifugation, the enzyme activity of the supernatant liquid was determined as described in the previous examples.
By this method a concentration of from 5 to 10 I.U. of HCG and 10 to 20 I.U. of LH per litre respectively could be determined. If the centrifugation step is omitted the optimum sample size is 0.5 nl and the sensitivity about I.U. of HCG per litre, or about 200 I.U. of LH per litre, so that the method according to the invention yields a 10-20 fold increase in sensitivity.
EXAMPLE IV Determination of HCG and anti-HCG.
a. Rabbit-serum was fractionated over DEAE cellulose in accordance with the prescription of H.A. Sober and others in J. Am. Chem. Soc. 78, 756 (1956). The isolated y-globulin fraction, which was immuno-electrophoretically pure, was partly used for generating antibodies in a sheep in accordance with the scheme of example [I a), while besides 100 mg of rabbit-y-globulin was coupled to 500 mg of m-aminobenzyloxymethyl cellulose by the method described in example I c).
From the sheep [anti-(rabbit-y-y-globulin)] serum prepared the specific antibodies were isolated by the method described in example II b) with the immune-adsorbent III b. The coupling product [anti-(rabbit-y-globulinH- HRP was prepared analogous to the coupling product (anti-HCG)-HRP, described in example lll c).
0. Determination of anti-HCG. A dilution series of rabbit-(anti-HCG) serum was prepared with 0.05 M phosphate buffer of pH 6.0.
Rabbit-(anti-HCG) serum (0.5 ml) was rotated with 0.25 mg of HCG-cellulose for 2 hours (see example 111 a). The reaction mixture was centrifuged and the precipitate washed four times with phosphate buffer, each time with 3 ml, after which the precipitate was resuspended in 1 ml of a solution of the coupling product b. The mixture obtained was again rotated for 2 hours. After centrifugation the enzyme activity in the supernatant liquid was determined, as described in example l d).
d. Determination of HCG. With the reagents prepared, HCG was determined by incubating solutions of it with 0.5 ml of rabbit-(anti-HCG)-serum in a dilution which in the system described under just causes an almost maximum reduction in enzyme activity in the supernatant liquid, and performing the process described under c) with the mixture obtained.
Where use was made of ml of HCG solution, it
proved to be possible to demonstrate concentrations of about 1.U./l of HCG.
EXAMPLE v Determination of insulin in serum.
a. Preparation of insulin-(glucose-oxidase). Five mg of hog insulin and 25 ml of glucose-oxidase were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.5. To this solution 5 'yl of 25 percent glutaraldehyde solution were added, after which the mixture was shaken at room temperature for 90 minutes. The mixture was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme ac tivity could be bound by antibodies against insulin were used in the test system.
b. Preparation of antibodies against insulin. Ten caviae were injected intramuscularly, once a week, with 1 mg of hog insulin in complete Freunds adjuvant, over a period of from 4 to 8 weeks. After having been left alone for 2 weeks the animals were injected intravenously with another milligram of insulin without adjuvant. Another 2 weeks later the animals were exsanguinated. Hypoglycemia occurring occasionally was combated by intraperitoneal administration of glucose.
c. Preparation of anti-substances against cavia 'y-globulin. Cavia -y-globulin was prepared by adding one volume of a saturated ammonium sulphate solution to two volumes of cavia serum. The resulting precipitate was washed twice with 33 percent saturated (NH S0 solution and then taken up in a physiological salt solution. A sheep was immunized with increasing dosages of the 'y-globulin prepared, viz. 0, 5, 1 and 2 mg. The injections were given every 2 weeks, the immunogen being mixed with complete Freunds adjuvant. Two weeks after the last injection another 2 mg of y-globulin, in a physiological salt solution, were given. One week later the animal was exsanguinated.
d. Preparation of insoluble antibodies against cavia 'y-globulin. Ten gm of microcrystalline cellulose were activated by adding it, while stirring, to 400 ml of 2.5 percent (w/v) CNBr solution, after which the pH was adjusted to 10.5 with an 1 N NaOH- solution, and it was maintained at it for 2 minutes. The cellulose was washed with ice water and with 0.1 M NaHCO;,. To 10 ml of sheep-anti-(cavia y-globulin) serum 1.6 gm of NaSO, were added. After stirring for 1 hour at room temperature the precipitate was centrifuged, washed twice with 20 ml of 16 percent (w/v) Na SO. solution, and finally taken up in 10 ml of 0.1 M NaHCO;,.
The activated cellulose was mixed with 40 ml ofa 0.1
M NaHCO;, solution and the 10 ml of y-globulin solution. This suspension was rotated for 40 hours at 4C and washed, twice with 5 ml of 0.5 M NaHCO twice with 500 ml of 0.05 M citrate of pH 1.1, and two times with 500 ml of 0.05 M phosphate of pH 6.2.
e. Determination of insulin in serum. Four ml of an insulin dilution series in the range of from O-lOO ng/ml, were incubated at room temperature, for 4 hours, with 1.0 ml ofanti-insulin serum (with 0.15 M phosphate buffer of pH 6.0, diluted to the desired strength). After that 5 mg of the immunoadsorbent prepared under a), suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, were added, and the resulting mixture rotated overnight at 4C. Then the immuno-adsorbent was centrifuged and washed three times with 5 ml of 0.05 M phosphate buffer of pH 6.0 (each time with 5 ml), to which 2 percent sheep serum had been added. After that 1.0 ml of insulin-glucose oxidase, diluted to the desired strength with the wash buffer, was added to the immunoadsorbent. The mixture obtained was again rotated overnight and centrifuged, after which the enzyme activity in the supernatant liquid was measured by incubating 0.5 ml of it with 2.5 ml of a substrate solution, and the extinction measured at 460 nm. The substrate solution contained mg of glucose, 10 ugm of peroxidase and 1 mg of S-aminosalicylic acid per 2.5 ml of 0.05 M phosphate buffer of pH 6.0.
The centrifugation step, in this case serving both to raise the maximum volume of the test liquid to be employed and to remove serum factors disturbing the reaction, caused a lO-fold increase in sensitivity, so that a concentration of a few ng/ml of insulin could be demonstrated.
EXAMPLE VI Determination of oestradiol.
a. Preparation of oestradiol-l7-succinyl-l-1RP. Fifty mg of oestradiol-l7-haemisuccinate and 0.08 ml of tri-n-butylamine were dissolved in 2.5 ml of diox ane. To the cold solution (2C) 15 u] of isobutylchlorocarbonate were added. After 30 minutes this solution was mixed with mg of horse radish peroxidase (HRP) in 7.5 ml of a mixture of dioxane and water (2:3), which had been adjusted to pH 9.5 with caustic soda. This solution was stirred for 4 hours at 2C, after which it was dialysed for 18 hours. The precipitate obtained after the pH of the dialysate had been adjusted to 4.6 was centrifuged, washed, and taken up in 5 ml of distilled water, which had been adjusted to pH 8. The material was purified further by precipitating it twice with 10 ml of acetone. The ultimate product was taken up in 10 ml of 0.05 M phosphate buffer of pH 7.8.
b. Preparation of oestradiol-l7-succinyl-BSA. The preparation was prepared by the mixed anhydride method as described under a). The starting material was 100 mg of oestradiol-l7-haemisuccinate and mg of bovine serum albumin (BSA).
0. Preparation of anti-substances against oestradiol. A sheep was injected every 4 weeks with 4 mg of oestradiol-l7-succinyl-BSA in complete Freunds adjavant. With regular intervals blood was taken from the sheep. The serum was adsorbed with BSA.
Day Quantity Freund's adjuvant Manner of injection 200 ugm lntramuscularly 14 400 ugm Do.
28 800 tgm Do.
42 800 agm lntravenously Two weeks after the last injection the animals were exsanguinated.
e. Preparation of the immuno-adsorbent [rabbitanti(-sheep-y-globulin)] cellulose.
The 'y-globulin fraction of the anti-sera described under 12) was prepared by precipitation with 18 percent w/v Na SO The product obtained was coupled with cellulose by Gurvichs method described in example I c).
f. Determination of oestradiol. A dilution series of oestradiol (00.5124-8l6 ng/ml) was prepared in phisphate buffer of pH 6.0. Five ml of sample were mixed with 0.5 ml of the sheep-antioestradiol-serum in the desired dilution. After incubating the mixture for 2 hours at room temperature 1 ml of immunoadsorbent suspension (see e) of 60 mg/ml was added, after which the mixture was rotated for 4 hours at room temperature. The cellulose was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0 containing 2 percent BSA. Then 1 ml of oestradiol-17-succinyl- HRP, diluted to the desired strength with the buffer with which the mixture was washed, was added to the cellulose. The mixture was rotated for 1 hour, after which it was centrifuged again and the enzyme activity in the supernatant liquid was measured as described in example I.
By the method described concentrations of 1 ng/ml of oestradiol could be demonstrated, which means an increase in sensitivity by a factor 10, compared with the test without centrifugation step.
EXAMPLE Vll Determination of cortisol.
a. Preparation of cortisol-21-galactose-oxidase.
Fifty mg of cortisol-2l-haemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride method as described in example VI a).
b. Preparation of insoluble transcortine. One hundred mg of transcortine purified by DEAE cellulose chromatography, followed by hydroxylapatite chromatography, were coupled with 3 gm of Sepharose 4B by the CNBr method: Sepharose 4B suspension (3 gm) was activated by mixing it with 4 ml of 2.5 percent (w/v) CNBr-solution in distilled water, after which the pH was adjusted to 1 N NaOH between 10 and 11, at which value it was maintained for 6 minutes. Then the Sepharose was washed with ice-water and with 0.1 M NaHCO;,, after which mg of transcortine in 20 ml 0g 0.1 M NaHCO:, were added, and the suspension was shaken at 4C for 24 hours, After being washed successively with 0.5 M NaHCO;,, 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer, to which 0.1 percent merthiolate had been added.
0. Determination of cortisol. A cortisol dilution series, in the range of from 0.25-16 ng/ml was prepared in 0.05 M phosphate buffer of pH 6.0. File ml of each cortisol solution (in 0.5 M phosphate buffer of pH 6.0) were rotated overnight with 5 mg of transcortine-Sepharose, at 4C. After centrifugation 1 ml of cortisol-2l-galactose oxidase solution, diluted to a suitable concentration in the buffer mentioned before, was added, after which the mixture was rotated for 2 hours at 4C. After recentrifugation the enzyme activity in the supernatant liquid was determined by adding 0.5 ml of it to 1.5 ml of substrate constisting of 100 mg of D- galactose, 20 mg of S-amino-salicylic acid and 10 ugm of peroxidase in ml of 0.02 M phosphate buffer of pH 6.0. Finally, after 30 minutes, the extinction was measured at 460 nm.
By this method about 1 ng/ml cortisol could be demonstrated, which means an increase in sensitivity by a factor 10.
We claim:
1. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:
a. providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form;
b. reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase;
c. separating the solid phase from the liquid phase;
d. adding to said solid phase a given quantity of a coupling product of the component to be determined with an enzyme; and
e. determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.
2. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:
a. providing a given quantity of the binding partner of the component to be determined in a soluble form;
b. adding a given quantity of an antibody against said binding partner, which antibody is in an insoluble 14 sure of the quantity of the reaction component to be determined.
3. The process of claim 1 in which the enzyme is an oxido-reductase.
4. The process of claim 2 in which the enzyme is an oxido-reductase.

Claims (3)

  1. 2. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of: a. providing a given quantity of the binding partner of the component to be determined in a soluble form; b. adding a given quantity of an antibody against said binding partner, which antibody is in an insoluble form, to form a reaction mixture having a solid phase and a liquid phase; c. separating the solid phase from the liquid phase; d. adding to said solid phase a given quantity of a coupling product of the component to be determined with an enzyme; and e. determining the enzyme activity of either the liquid phase or the solid phase, which activity is a measure of the quantity of the reaction component to be determined.
US00221447A1971-02-101972-01-27Process for the demonstration and determination of reaction components having specific binding affinity for each otherExpired - LifetimeUS3791932A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
NL717101728ANL154600B (en)1971-02-101971-02-10 METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.

Publications (1)

Publication NumberPublication Date
US3791932Atrue US3791932A (en)1974-02-12

Family

ID=19812444

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US00221447AExpired - LifetimeUS3791932A (en)1971-02-101972-01-27Process for the demonstration and determination of reaction components having specific binding affinity for each other

Country Status (16)

CountryLink
US (1)US3791932A (en)
JP (1)JPS5247011B1 (en)
AU (1)AU468151B2 (en)
BE (1)BE779209A (en)
BR (1)BR7200729D0 (en)
CA (2)CA958314A (en)
CH (1)CH573115A5 (en)
DE (1)DE2206103B2 (en)
DK (1)DK150170C (en)
ES (1)ES399608A1 (en)
FI (1)FI53894C (en)
FR (1)FR2126760A5 (en)
GB (1)GB1363565A (en)
NL (1)NL154600B (en)
SE (1)SE451098B (en)
ZA (1)ZA72548B (en)

Cited By (972)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3875011A (en)*1972-11-061975-04-01Syva CoEnzyme immunoassays with glucose-6-phosphate dehydrogenase
US3904367A (en)*1973-08-151975-09-09Gen ElectricContrast enhancement for immunological film detection
US3951748A (en)*1974-11-111976-04-20Medical Products, Inc.Sensitized matrix for detection of disease
US4016043A (en)*1975-09-041977-04-05Akzona IncorporatedEnzymatic immunological method for the determination of antigens and antibodies
DE2643829A1 (en)*1975-09-291977-04-14Cordis Corp PROCEDURE FOR DETERMINING THE PRESENCE OF ANTIGENT ASSOCIATED WITH HEPATITIS
US4039652A (en)*1973-10-111977-08-02Miles Laboratories, Inc.Column method of immunoassay employing an immobilized binding partner
FR2367286A1 (en)*1976-10-071978-05-05Mochida Pharm Co Ltd NEW PROCESS AND REAGENTS FOR IMMUNOCHEMICAL DOSAGE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES
US4116776A (en)*1976-04-191978-09-26International Radioimmune Systems, Inc.Diagnostic blood test and kit for detecting human chorionic gonadotropin
US4200508A (en)*1977-02-091980-04-29Hidematsu HiraiMethod and composition for detecting antigenic substances
US4203802A (en)*1971-05-141980-05-20Syva CompanyInhibitable enzyme amplification assay
WO1980002747A1 (en)*1979-05-311980-12-11Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
US4240751A (en)*1978-11-091980-12-23Akzona IncorporatedMethod and apparatus for specific binding substances
US4254223A (en)*1978-04-181981-03-03Akzona IncorporatedApparatus for colorimetric determination
US4269938A (en)*1979-03-081981-05-26Eastman Kodak CompanyAssay of peroxidatively active materials
US4275149A (en)*1978-11-241981-06-23Syva CompanyMacromolecular environment control in specific receptor assays
WO1981002792A1 (en)*1980-03-201981-10-01Res Triangle InstDetection of antibiotics in milk
US4302534A (en)*1977-03-161981-11-24Israel Institute For Biological ResearchChemiluminescent enzyme immunoassay
US4318707A (en)*1978-11-241982-03-09Syva CompanyMacromolecular fluorescent quencher particle in specific receptor assays
US4323647A (en)*1980-10-151982-04-06University Of MiamiSteric hindrance enzyme immunoassay
US4331444A (en)*1979-03-011982-05-25Fuji Photo Film Co., Ltd.Competitive immunoassay using silver halide fogging agent
US4337063A (en)*1979-03-011982-06-29Fuji Photo Film Co., Ltd.Competitive immunoassay using spectral sensitizer label
USRE31006E (en)*1968-09-241982-08-03Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
WO1982002601A1 (en)*1981-01-231982-08-05Hospital Supply Corp AmericanSolid phase system for ligand assay
US4343896A (en)*1975-02-011982-08-10Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
EP0060700A1 (en)*1981-03-131982-09-22Immuno-Mycologics, Inc.Assay method and device
US4362531A (en)*1980-04-151982-12-07Technicon Instruments CorporationAgglutination immunoassays carried out with agent to reduce non-specific interferences
US4374925A (en)*1978-11-241983-02-22Syva CompanyMacromolecular environment control in specific receptor assays
US4376110A (en)*1980-08-041983-03-08Hybritech, IncorporatedImmunometric assays using monoclonal antibodies
WO1983000877A1 (en)*1981-08-311983-03-17Icl ScientGlucose oxidase immunohistochemical detection of antinuclear antibodies
US4424279A (en)1982-08-121984-01-03QuidelRapid plunger immunoassay method and apparatus
US4446238A (en)*1981-03-191984-05-01Janssen Pharmaceutica N.V.Bright field light microscopic method of localizing tissue antigens
US4446232A (en)*1981-10-131984-05-01Liotta Lance AEnzyme immunoassay with two-zoned device having bound antigens
US4452886A (en)*1981-09-211984-06-05Henry Robert PNovel photon absorbing or emitting polymers and their use as reagents in immunoassay systems
US4469787A (en)*1982-05-141984-09-04Mallinckrodt Inc.Immunoassay involving soluble complex of second antibody and labeled binding protein
US4474878A (en)*1975-09-291984-10-02Cordis Laboratories, Inc.Sandwich EIA for antigen associated with hepatitis
US4486530A (en)*1980-08-041984-12-04Hybritech IncorporatedImmunometric assays using monoclonal antibodies
US4503143A (en)*1982-08-201985-03-05Btc Diagnostics Limited PartnershipEnzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
US4506009A (en)*1982-03-301985-03-19University Of CaliforniaHeterogeneous immunoassay method
WO1985002260A1 (en)*1983-11-081985-05-23QuidelRapid plunger immunoassay method and apparatus
US4530900A (en)*1982-09-131985-07-23Seragen Diagnostics Inc.Soluble insoluble polymers in enzymeimmunoassay
WO1985003950A1 (en)*1984-03-081985-09-12Scripps Clinic And Research FoundationA sv40 expression vector containing hbxag as an expression marker
WO1985004397A1 (en)1984-03-231985-10-10OncogenPlatelet related growth regulator
US4592995A (en)*1981-03-301986-06-03Dainippon Pharmaceutical Co., Ltd.Reagent for streptococcal anti-esterase assay
US4604365A (en)*1981-06-021986-08-05Electro-Nucleonics, Inc.Immunoprecipitation assay
US4642285A (en)*1975-09-291987-02-10Diamedix CorporationSandwich EIA for antigen
US4665020A (en)*1984-05-301987-05-12United States Department Of EnergyFlow cytometer measurement of binding assays
US4713347A (en)*1985-01-141987-12-15Sensor Diagnostics, Inc.Measurement of ligand/anti-ligand interactions using bulk conductance
USRE32696E (en)*1975-09-041988-06-14Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
US4753875A (en)*1981-11-021988-06-28Ryan James WMethod for assaying proteases with tagged proteinaceous inhibitors
US4808522A (en)*1986-04-241989-02-28Moskovsky Gosudarstvennx Universitet Imeni M. V. Lomonoso VAEnzyme immunoassays using inorganic pyrophosphatase
US4812396A (en)*1984-11-051989-03-14E. I. Du Pont De Nemours And CompanyMethod for detecting enzymatic activity using particle agglutination
US4812395A (en)*1984-11-051989-03-14E. I. Du Pont De Nemours And CompanyMethod for detecting enzymatic activity using particle agglutination
US4824784A (en)*1985-04-081989-04-25Hygeia Sciences, IncorporatedChromogenic solution for immunoassay
US4868108A (en)*1985-12-121989-09-19Hygeia Sciences, IncorporatedMultiple-antibody detection of antigen
US4931385A (en)*1985-06-241990-06-05Hygeia Sciences, IncorporatedEnzyme immunoassays and immunologic reagents
US5047330A (en)*1983-08-171991-09-10Commissariat A L'energie AtomiqueCompound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
US5102788A (en)*1988-11-211992-04-07Hygeia Sciences, Inc.Immunoassay including lyophilized reactant mixture
US5328828A (en)*1988-12-231994-07-12Syntex (U.S.A.) Inc.Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
US5334513A (en)*1988-05-171994-08-02Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5348867A (en)*1991-11-151994-09-20George GeorgiouExpression of proteins on bacterial surface
US5468647A (en)*1988-05-171995-11-21Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
WO1997005886A1 (en)*1995-08-041997-02-20Board Of Regents, The University Of Texas SystemCompositions for conferring immunogenicity to a peptide
US5610077A (en)*1980-06-201997-03-11Unilever Patent Holdings B.V.Processes and apparatus for carrying out specific binding assays
US5614504A (en)*1990-08-011997-03-25The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5672475A (en)*1993-05-061997-09-30Chiron Diagnostics CorporationMixed luminescent conjugate test
US5698686A (en)*1994-10-201997-12-16Arch Development CorporationYeast telomerase compositions
US5726023A (en)*1993-03-171998-03-10University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5726015A (en)*1991-05-151998-03-10Vanderbilt UniversityMethod to determine metastatic potential of tumor cells
US5728807A (en)*1995-05-161998-03-17Ramot-University Authority For Applied Research And Industrial Development, Ltd.Mutated proteins associated with ataxia-telangiectasia
US5777093A (en)*1995-05-161998-07-07Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
US5837535A (en)*1994-06-131998-11-17Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5840322A (en)*1996-12-191998-11-24Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673A (en)*1994-10-251998-12-01Curators Of The University Of MissouriMethod of screening for endometriosis
US5858661A (en)*1995-05-161999-01-12Ramot-University Authority For Applied Research And Industrial DevelopmentAtaxia-telangiectasia gene and its genomic organization
US5869445A (en)*1993-03-171999-02-09University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US5874423A (en)*1992-09-101999-02-23Yissum Research Development Co. Of The Hebrew University Of JerusalemDigitalis-like compounds
US6187563B1 (en)1998-08-072001-02-13Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US6284496B1 (en)1997-10-032001-09-04University Of South FloridaDNA vector for determining the presence of out-of-reading-frame mutations
US6312901B2 (en)1996-07-082001-11-06Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6331275B1 (en)1996-07-082001-12-18Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6342349B1 (en)1996-07-082002-01-29Burstein Technologies, Inc.Optical disk-based assay devices and methods
US6344443B1 (en)1998-07-082002-02-05University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US6391563B1 (en)1980-07-282002-05-21Akzo Nobel N.V.Method for the determination of antigens with the aid of three or more monoclonal antibodies
WO2002044736A2 (en)2000-11-302002-06-06Molecular Skincare LimitedDiagnosis and treatment of epidermal or skin diseases
US6406920B1 (en)1980-06-202002-06-18Inverness Medical Switzerland GmbhProcesses and apparatus for carrying out specific binding assays
US20020106661A1 (en)*1996-07-082002-08-08Burstein Laboratories, Inc.Optical disk-based assay devices and methods
US6440682B1 (en)*1999-05-282002-08-27Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US20020142287A1 (en)*2000-12-142002-10-03Hirotaka YamamotoHigh throughput assay to detect inhibitors of the map kinase pathway
US6482389B1 (en)1997-10-172002-11-19University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US20020172980A1 (en)*2000-11-272002-11-21Phan Brigitte ChauMethods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20030003464A1 (en)*2000-11-272003-01-02Phan Brigitte C.Dual bead assays including optical biodiscs and methods relating thereto
US6531277B2 (en)1994-10-252003-03-11The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US20030064058A1 (en)*2001-09-072003-04-03Nadir AskenasyMethods of utilizing bone marrow stem cells for inducing immunological tolerance
US20030086914A1 (en)*1999-06-252003-05-08Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organs
US20030104491A1 (en)*2000-04-302003-06-05Cabantchik Ioav ZviMolecules and methods using same for measuring non-transferrin bound iron
WO2003046201A2 (en)2001-11-212003-06-05Kimberly-Clark Worldwide, Inc.Detection and identification of enteric bacteria
US20030114410A1 (en)*2000-08-082003-06-19Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030124116A1 (en)*1997-08-212003-07-03Quark Biotech, Inc.Hypoxia-regulated genes
US20030152909A1 (en)*1994-11-162003-08-14Mitrani Eduardo N.In vitro micro-organs, and uses related thereto
US6610838B1 (en)1997-09-102003-08-26Symbicom AktiebolagP13 antigens from Borrelia
US20030211490A1 (en)*2000-01-242003-11-13Hanan SteinPlants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US6656471B1 (en)1998-11-172003-12-02Board Of Regents, The University Of Texas SystemHIV-specific T-cell induction
US6689757B1 (en)1996-02-122004-02-10M.L. Laboratories PlcMethods for vaccination and vaccines therefor
WO2004018698A2 (en)2002-08-202004-03-04Genitrix, LlcLectin compositions and methods for modulating an immune response to an antigen
US20040052769A1 (en)*2000-11-302004-03-18Yair ReisnerMethods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20040076976A1 (en)*2000-11-022004-04-22Pan Shen QuanAopb gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
US20040121442A1 (en)*2002-05-052004-06-24Ilan ChetFungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
WO2004060135A2 (en)2003-01-022004-07-22Rappaport Family Institute For Research In The Medical SciencesMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US20040146949A1 (en)*2002-10-252004-07-29Jun TanMethods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US6770622B2 (en)2001-06-082004-08-03Gary A. JarvisN-terminally truncated galectin-3 for use in treating cancer
US6787318B1 (en)1999-06-012004-09-07Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20040197334A1 (en)*2003-04-022004-10-07Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040248093A1 (en)*2000-11-272004-12-09Coombs James HowardMagneto-optical bio-discs and systems including related methods
US20050002953A1 (en)*2003-05-062005-01-06Jens HeroldSARS-coronavirus virus-like particles and methods of use
US20050008624A1 (en)*2002-01-242005-01-13Tony PeledExpansion of renewable stem cell populations
US20050022269A1 (en)*2001-07-192005-01-27Joseph HirschbergPolypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US20050020499A1 (en)*2003-05-272005-01-27Bar Ilan UniversityMethods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20050032126A1 (en)*2003-03-032005-02-10Coombs James H.Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
US20050031618A1 (en)*2001-01-312005-02-10Dror MevorachInduction of tolerance by apoptotic and/or necrotic cells
US20050054097A1 (en)*2002-11-172005-03-10Tony PeledEX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US20050054103A1 (en)*2003-03-072005-03-10Tony PeledExpansion of renewable stem cell populations using modulators of PI 3-kinase
US6867005B2 (en)2001-10-242005-03-15Beckman Coulter, Inc.Method and apparatus for increasing the dynamic range and accuracy of binding assays
US20050069923A1 (en)*1996-07-082005-03-31Mullis Kary BanksDual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US6875582B1 (en)1999-08-192005-04-05Omniscience Pharmaceuticals, Inc.Methods and targets of antibiotic resistance
WO2005033145A1 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Antibodies to nik, their preparation and use
WO2005033142A2 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Anti-nik antibodies and uses thereof
US20050085432A1 (en)*2001-12-262005-04-21Aviva LapidotMethods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20050113327A1 (en)*1999-08-302005-05-26Levava RoizMethods of and compositions for inhibiting the proliferation of mammalian cells
WO2005051423A2 (en)2003-11-302005-06-09Yeda Research And Development Co. LtdMethods and agents for immune modulation and methods for identifying immune modulators
US20050152912A1 (en)*2003-03-262005-07-14Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050158822A1 (en)*2004-01-202005-07-21Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20050158809A1 (en)*2002-04-162005-07-21The Regents Of The University Of CaliforinaMethods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
US20050176143A1 (en)*1999-02-042005-08-11Technion Research & DevelopmentMethod and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050191285A1 (en)*1993-03-172005-09-01University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050202098A1 (en)*2001-01-312005-09-15TolarenDisease therapy using dying or dead cells
US20050214827A1 (en)*1996-07-082005-09-29Burstein Technologies, Inc.Assay device and method
US20050220774A1 (en)*2002-03-182005-10-06Tony PeledMethods of inducing differentiation in ex vivo expanded stem cells
US20050255101A1 (en)*2002-02-132005-11-17Technion Research And Development Foundation Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050271643A1 (en)*2003-08-142005-12-08Iryna SorokulovaBacterial strains, compositions including same and probiotic use thereof
US20060008479A1 (en)*1996-04-012006-01-12University Of WashingtonMethods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20060019340A1 (en)*1999-06-082006-01-26David NaorCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6998232B1 (en)1999-09-272006-02-14Quark Biotech, Inc.Methods of diagnosing bladder cancer
US20060035980A1 (en)*2003-04-182006-02-16Scanlan Thomas SThyronamine derivatives and analogs and methods of use thereof
US20060039897A1 (en)*2002-03-262006-02-23Tamar LotanStinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060051426A1 (en)*2001-12-052006-03-09Gershon GolombNanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US20060079941A1 (en)*2004-10-122006-04-13Eli OvsyshcherMethods and implantable devices for treating supraventricular arrhythmias
US7033747B2 (en)2001-04-112006-04-25Nagaoka & Co., LtdMulti-parameter assays including analysis discs and methods relating thereto
US20060095241A1 (en)*2004-10-292006-05-04Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060099273A1 (en)*2000-09-282006-05-11Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20060123516A1 (en)*2003-05-222006-06-08Gil RonenMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20060127366A1 (en)*1999-06-252006-06-15Mitrani Eduardo NMethod and device for inducing biological processes by micro-organs
US20060134680A1 (en)*2004-12-222006-06-22Alexander KotlyarHomogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20060148078A1 (en)*2002-11-292006-07-06Sharon Gerecht-NirMethod of dynamically culturing embryonic stem cells
US20060159769A1 (en)*2000-09-282006-07-20Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1683874A2 (en)2000-08-292006-07-26YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US7087395B1 (en)2001-01-162006-08-08Quest Diagnostics Investments IncorporatedVitamin D assay
WO2006090388A2 (en)2005-02-252006-08-31The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterFruit cell culture extract for treating inflammation
US7101839B1 (en)1999-08-302006-09-05Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US20060211064A1 (en)*2005-03-182006-09-21Hyesook KimDetection of hypertension using glucuronidated metabolic products
US20060234947A1 (en)*2002-01-312006-10-19Tel Aviv University Future Technology Development L.PPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060234203A1 (en)*2005-04-192006-10-19Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060257429A1 (en)*2003-10-232006-11-16Dreier Kimberly JVaccine for periodontal disease
US20060260002A1 (en)*2003-06-192006-11-16Gil RonenNucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20060257865A1 (en)*2001-10-232006-11-16Simon MallalMethod for identification and development of therapeutic agents
US20060278093A1 (en)*2004-01-132006-12-14Eytan BidermanFeeding formula appliance
WO2006134602A2 (en)2005-06-162006-12-21Ramot At Tel Aviv University Ltd.Isolated cells and populations comprising same for the treatment of cns diseases
US20060292559A1 (en)*2005-06-232006-12-28Beckman Coulter, Inc.Cell-based microarrays, and methods for their preparation and use
US20070032421A1 (en)*2003-12-122007-02-08Efrat LevyMethods and compositions relating to cystatin C
WO2007020638A2 (en)2005-08-152007-02-22Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A2 (en)2005-08-242007-03-01Yeda Research And Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007031996A1 (en)2005-09-122007-03-22Rappaport Family Institute For Research In The Medical SciencesCompositions and methods for diagnosing and treating an inflammation
WO2007034487A1 (en)2005-09-222007-03-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20070077652A1 (en)*2004-09-162007-04-05Tony PeledMethods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US20070087437A1 (en)*2005-10-142007-04-19Jifan HuMethods for rejuvenating cells in vitro and in vivo
US7223902B1 (en)1999-11-192007-05-29Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US20070160546A1 (en)*2000-09-282007-07-12Tamar LotanUse of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070184530A1 (en)*2006-02-032007-08-09Fuad FaresLong-acting veterinary polypeptides and methods of producing and administering same
WO2007091254A1 (en)2006-02-062007-08-16Rappaport Family Institute For Research In The Medical SciencesMethods and kit for diagnosing t1dm
US20070196369A1 (en)*2002-02-202007-08-23Hoogenboom Henricus Renerus JMHC-peptide complex binding ligands
US7270810B2 (en)2000-01-052007-09-18Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20070225242A1 (en)*2005-06-212007-09-27The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
WO2007110869A2 (en)2006-03-282007-10-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to warfarin resistance
WO2007124299A2 (en)2006-04-212007-11-01Novartis AgAntagonist anti-cd40 antibody pharmaceutical compositions
US20070281883A1 (en)*2006-06-052007-12-06Hanna RosenfeldDevelopment of follicle stimulating hormone agonists and antagonists in fish
US20080004234A1 (en)*2004-07-062008-01-03Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
WO2008010228A2 (en)2006-07-202008-01-24Yeda Research And Development Co. Ltd.Photosyntheticorganisms and compositions and methods of generating same
WO2008026198A2 (en)2006-08-282008-03-06Yeda Research And Development Co. Ltd.Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US7347972B1 (en)1998-07-222008-03-25Jin Po LeeMultiple analyte assay device
US20080082678A1 (en)*2005-01-162008-04-03Zlango Ltd.Communications Network System and Methods for Using Same
WO2008041183A2 (en)2006-10-052008-04-10Technion Research & Development Foundation Ltd.Microtubes and methods of producing same
US20080131419A1 (en)*2004-09-292008-06-05Yissum Research Development Company Of The Hebrew University Of JerusalemRecombinant Human T2 Rnase and Uses Thereof
US20080138840A1 (en)*2006-09-082008-06-12Collins Michael TAssay for antibodies to mycobacterium paratuberculosis
WO2008084410A2 (en)2007-01-042008-07-17Humabs LlcHuman cytomegalovirus neutralising antibodies and use thereof
WO2008093341A2 (en)2007-01-312008-08-07Technion Research & Development Foundation Ltd.Electrospun scaffolds and methods of generating and using same
WO2008093342A2 (en)2007-02-012008-08-07Technion Research & Development Foundation Ltd.Albumin fibers and fabrics and methods of generating and using same
WO2008097870A2 (en)2007-02-022008-08-14Baylor Research InstituteAgents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc- asgpr)
US20080199895A1 (en)*2006-10-052008-08-21Yeda Research And Development Co. Ltd.Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20080216022A1 (en)*2005-01-162008-09-04Zlango Ltd.Iconic Communication
US20080233140A1 (en)*2007-02-232008-09-25Baylor Research InstituteTherapeutic Applications of Activation of Human Antigen-Presenting Cells Through Dectin-1
US20080241170A1 (en)*2007-02-022008-10-02Baylor Research InstituteVaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells
WO2008120202A2 (en)2007-03-292008-10-09Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A1 (en)2007-04-022008-10-09Ramot At Tel Aviv University Ltd.Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
US20080254044A1 (en)*2007-02-022008-10-16Baylor Research InstituteMultivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
US20080254047A1 (en)*2007-02-232008-10-16Baylor Research InstituteActivation of Human Antigen-Presenting Cells Through CLEC-6
US7442781B2 (en)2001-08-162008-10-28Urifer Ltd.Diagnosis, prevention and treatment of cancer
US20080267984A1 (en)*2007-02-232008-10-30Baylor Research InstituteActivation of Human Antigen-Presenting Cells Through Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1)
WO2008132753A2 (en)2007-05-012008-11-06Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for detecting fetal cells in the maternal blood
US20080279828A1 (en)*2002-01-252008-11-13Tony PeledMethods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20090004158A1 (en)*1998-02-172009-01-01Tony PeledMethods of controlling proliferation and differentiation of stem and progenitor cells
US20090013087A1 (en)*2005-01-182009-01-08Zlango Ltd.Communications Network System and Methods For Using Same
WO2009010968A2 (en)2007-07-152009-01-22Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
US20090053224A1 (en)*2007-08-022009-02-26Arresto BiosciencesLox and loxl2 inhibitors and uses thereof
US20090068207A1 (en)*2005-04-152009-03-12Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US20090068669A1 (en)*2007-09-122009-03-12Elias GeorgesSlc9a3r1 directed diagnostics for neoplastic disease
WO2009034574A2 (en)2007-09-122009-03-19Yeda Research And Development Co. Ltd.Methods of treating tumors in immune-privileged sites
EP2050826A2 (en)2007-10-162009-04-22Roche Diagnostics GmbHReagents and methods for detecting neisseria gonorrhoeae
US20090118132A1 (en)*2004-11-042009-05-07Roche Molecular Systems, Inc.Classification of Acute Myeloid Leukemia
EP2058275A1 (en)2003-01-072009-05-13Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US20090123553A1 (en)*2002-12-092009-05-14Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US20090126042A1 (en)*2004-06-142009-05-14Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090143321A1 (en)*2005-07-072009-06-04Avraham HochbergNucleic acid agents for downregulating h19 and methods of using same
EP2071021A2 (en)2007-12-122009-06-17University of South FloridaBone marrow-derived neuronal cells
US20090156471A1 (en)*2004-07-152009-06-18Ramot At Tel Aviv University Ltd.Use of anti-amyloid agents for treating and typing pathogen infections
WO2009083958A2 (en)2007-12-272009-07-09Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US20090209041A1 (en)*2002-09-062009-08-20Tel Aviv University Future Technology Development L.P.Peptides and methods for inhibiting amyloid formation
WO2009104174A2 (en)2008-02-212009-08-27Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
US20090233295A1 (en)*2008-01-292009-09-17Elias GeorgesTrim59 directed diagnostics for neoplastic disease
US20090253170A1 (en)*2003-06-192009-10-08Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7605149B1 (en)1998-07-132009-10-20University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
EP2116618A1 (en)2008-05-092009-11-11Agency for Science, Technology And ResearchDiagnosis and treatment of Kawasaki disease
US20090293146A1 (en)*2006-12-202009-11-26Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US7625707B2 (en)2003-10-022009-12-01Ramot At Tel Aviv University Ltd.Antibacterial agents and methods of identifying and utilizing same
US20090305302A1 (en)*2008-03-182009-12-10Collins Michael TMycobacterial culture screening test for mycobacterium avium complex bacteria
EP2149585A1 (en)2003-11-042010-02-03Novartis Vaccines and Diagnostics, Inc.Antagonist anti-CD40 monoclonal antibodies and methods for their use
WO2010017544A2 (en)2008-08-082010-02-11Genisphere, Inc.Long-acting dna dendrimers and methods thereof
WO2010016806A1 (en)2008-08-082010-02-11Agency For Science, Technology And Research (A*Star)Vhz for diagnosis and treatment of cancers
US20100055033A1 (en)*2006-04-072010-03-04The Government Of The United States Of America As Represented By The SecretaryAntibody compositions and methods for treatment of neoplastic disease
WO2010029545A2 (en)2008-09-112010-03-18Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
WO2010031006A1 (en)2008-09-122010-03-18Cryopraxis Criobiologia Ltda.Ischemic tissue cell therapy
US20100068135A1 (en)*2005-08-082010-03-18Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US7687057B2 (en)1998-01-092010-03-30Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
WO2010035261A2 (en)2008-09-292010-04-01Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereof
US20100081177A1 (en)*2008-09-052010-04-01TransAlgae LtdDecreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
US20100080813A1 (en)*2008-07-252010-04-01Institute For Research In BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
EP2174668A2 (en)2004-11-142010-04-14Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2010042481A1 (en)2008-10-062010-04-15University Of ChicagoCompositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100092386A1 (en)*2007-04-232010-04-15David SegevSystem for delivering therapeutic agents into living cells and cells nuclei
US20100105608A1 (en)*2002-01-312010-04-29Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20100105759A1 (en)*2007-01-162010-04-29Abraham HochbergH19 silencing nucleic acid agents for treating rheumatoid arthritis
EP2182052A1 (en)2002-10-072010-05-05Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
WO2010049897A2 (en)2008-10-302010-05-06Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
EP2186530A1 (en)2000-11-172010-05-19Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
WO2010055525A1 (en)2008-11-172010-05-20Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en)2008-11-192010-05-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
US20100135994A1 (en)*2008-07-162010-06-03Baylor Research InstituteHiv vaccine based on targeting maximized gag and nef to dendritic cells
WO2010061383A1 (en)2008-11-262010-06-03Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
WO2010064231A1 (en)2008-12-022010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A1 (en)2008-12-032010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
US20100154077A1 (en)*2007-04-092010-06-17Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
WO2010071610A1 (en)2008-12-192010-06-24Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
WO2010076642A1 (en)2008-12-292010-07-08Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
WO2010076794A1 (en)2008-12-312010-07-08Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
WO2010076756A2 (en)2008-12-292010-07-08Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076788A2 (en)2008-12-292010-07-08Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010086867A2 (en)2009-02-022010-08-05Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
US20100196403A1 (en)*2007-01-292010-08-05Jacob HochmanAntibody conjugates for circumventing multi-drug resistance
WO2010086856A2 (en)2009-02-012010-08-05Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
EP2216033A2 (en)2003-03-062010-08-11Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
WO2010089707A1 (en)2009-02-042010-08-12Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
US20100209415A1 (en)*2009-01-062010-08-19Victoria SmithChemotherapeutic methods and compositions
WO2010097794A1 (en)2009-02-262010-09-02Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
US20100221233A1 (en)*2003-12-152010-09-02University Of South FloridaCompositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
WO2010100595A2 (en)2009-03-022010-09-10Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103517A1 (en)2009-03-122010-09-16Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A1 (en)2009-03-302010-10-07Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A1 (en)2009-04-012010-10-07The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en)2009-04-082010-10-14Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
EP2243492A1 (en)2003-11-042010-10-27Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2243491A1 (en)2003-11-042010-10-27Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
WO2010135663A2 (en)2009-05-212010-11-25The United States Of America , As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods for the detection of hiv-1/hiv-2 infection
WO2010137017A2 (en)2009-05-272010-12-02Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137020A1 (en)2009-05-282010-12-02Yeda Research And Development Co. Ltd.Methods of treating inflammation
WO2010137013A1 (en)2009-05-272010-12-02Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137021A2 (en)2009-05-272010-12-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
US20100319088A1 (en)*2007-07-242010-12-16Gil RonenPolynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
WO2010150259A1 (en)2009-06-242010-12-29Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2011005341A2 (en)2009-04-032011-01-13University Of ChicagoCompositions and methods related to protein a (spa) variants
WO2011004361A2 (en)2009-07-092011-01-13Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2011004379A1 (en)2009-07-102011-01-13Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
WO2011010309A1 (en)2009-07-212011-01-27Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
US20110020357A1 (en)*2008-04-092011-01-27Technion Research & Development Foundation Ltd.Anti human immunodeficiency antibodies and uses thereof
EP2279726A2 (en)2005-05-262011-02-02Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2011013130A2 (en)2009-07-312011-02-03Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US20110033473A1 (en)*2008-04-092011-02-10Yoram ReiterAnti influenza antibodies and uses thereof
US7888003B2 (en)2004-09-082011-02-15The United States Of America As Represented By The Department Of Health And Human ServicesMethods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
US20110044907A1 (en)*2009-08-212011-02-24Derek MarshallIn vivo screening assays
WO2011021171A1 (en)2009-08-212011-02-24Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
US20110044981A1 (en)*2009-08-212011-02-24Spangler RhyannonMethods and compositions for treatment of pulmonary fibrotic disorders
WO2011021194A2 (en)2009-08-172011-02-24Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
EP2289567A2 (en)2003-12-222011-03-02Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
US20110052501A1 (en)*2008-01-312011-03-03Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2011024172A2 (en)2009-08-272011-03-03Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
EP2292762A2 (en)2002-12-202011-03-09Board of Regents, The University of Texas SystemVMP-like sequences of pathogenic Borrelia species and strains
EP2295980A1 (en)2002-10-302011-03-16Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
WO2011030332A2 (en)2009-09-082011-03-17Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A1 (en)2009-09-082011-03-17Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011030329A1 (en)2009-09-102011-03-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011033511A1 (en)2009-09-172011-03-24Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011033506A2 (en)2009-09-172011-03-24Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2301575A1 (en)2003-11-042011-03-30Novartis Vaccines and Diagnostics, Inc.Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
US20110076739A1 (en)*2009-08-212011-03-31Mccauley ScottCatalytic domains from lysyl oxidase and loxl2
US20110076272A1 (en)*2009-08-212011-03-31Victoria SmithTherapeutic methods and compositions
US20110081706A1 (en)*2009-10-022011-04-07TransAlgae LtdMethod and system for efficient harvesting of microalgae and cyanobacteria
EP2308994A1 (en)2001-03-232011-04-13Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
EP2312315A1 (en)2005-05-182011-04-20Novartis AGMethods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2011046570A1 (en)2009-10-162011-04-21The University Of Medicine And Dentistry Of New JerseyMethod for treating chronic nerve tissue injury using a cell therapy strategy
US20110091454A1 (en)*2004-01-272011-04-21Alex DiberMethods and systems for annotating biomolecular sequences
WO2011045796A1 (en)2009-10-142011-04-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2011048600A1 (en)2009-10-212011-04-28Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
US20110097771A1 (en)*2008-05-222011-04-28Eyal EmmanuelIsolated polynucleotides and polypeptides and methods of using same for increasing plant utility
EP2316950A1 (en)2000-03-272011-05-04Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2316441A1 (en)2005-02-172011-05-04Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
EP2319857A2 (en)2003-03-042011-05-11Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
WO2011055366A1 (en)2009-11-082011-05-12Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
WO2011058557A1 (en)2009-11-122011-05-19Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011058555A1 (en)2009-11-122011-05-19Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
WO2011061736A1 (en)2009-11-172011-05-26Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
WO2011063198A2 (en)2009-11-202011-05-26St. Jude Children's Research HospitalMethods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011064773A1 (en)2009-11-242011-06-03Collplant Ltd.Method of generating collagen fibers
WO2011064669A2 (en)2009-11-302011-06-03Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2330132A1 (en)2003-04-042011-06-08Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2011067745A2 (en)2009-12-062011-06-09Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
US20110145946A1 (en)*2008-08-182011-06-16Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
WO2011072091A1 (en)2009-12-092011-06-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
US20110150874A1 (en)*2006-05-192011-06-23Teva Pharmaceutical Industries Ltd.Fusion proteins, uses thereof and processes for producing same
US20110147993A1 (en)*2008-04-102011-06-23Objet Geometries Ltd.System and method for three dimensional model printing
EP2338896A2 (en)2002-12-122011-06-29R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
WO2011080674A2 (en)2009-12-282011-07-07Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080740A1 (en)2009-12-292011-07-07Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
US20110177112A1 (en)*2007-11-022011-07-21The Johns Hopkins UniversityMulti- component l2 vaccine for prevention of human papilloma virus infection
WO2011086509A1 (en)2010-01-122011-07-21Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011092700A1 (en)2010-01-272011-08-04Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
US8000900B2 (en)2004-09-212011-08-16Microsoft CorporationAssociation-based predictions of pathogen characteristics
WO2011099006A2 (en)2010-02-112011-08-18Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
EP2359854A1 (en)2000-08-082011-08-24Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
US20110207144A1 (en)*2009-08-212011-08-25Derek MarshallIn vitro screening assays
WO2011104708A2 (en)2010-02-242011-09-01Ben Gurion University Of The Negev Research And Development AuthorityMethods for inhibiting necrosis
WO2011107939A1 (en)2010-03-012011-09-09Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en)2010-03-042011-09-09Yeda Research And Development Co. Ltd.Methods of measuring protein stability
EP2365087A2 (en)2003-05-222011-09-14Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2011111050A2 (en)2010-03-112011-09-15Jacob EdreiMethods of generating hydrogen
WO2011111034A1 (en)2010-03-082011-09-15Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
EP2366775A1 (en)2006-03-232011-09-21Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110229495A1 (en)*2003-07-072011-09-22Wagner David HMethods for predicting development of auto-immune diseases and treatment of same
EP2368569A2 (en)2006-01-182011-09-28University Of ChicagoCompositions and methods related to staphylococcal bacterium proteins
WO2011125015A2 (en)2010-04-052011-10-13Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011127032A1 (en)2010-04-052011-10-13University Of ChicagoCompositions and methods related to protein a (spa) antibodies as an enhancer of immune response
WO2011128897A1 (en)2010-04-122011-10-20Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A1 (en)2010-04-182011-10-27Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011135527A2 (en)2010-04-282011-11-03Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2011138776A2 (en)2010-05-062011-11-10Hervana Ltd.Biologic female contraceptives
WO2011138785A2 (en)2010-05-052011-11-10Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011138778A2 (en)2010-05-042011-11-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011141914A1 (en)2010-05-132011-11-17Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
EP2390312A1 (en)2005-11-292011-11-30Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
WO2011151833A1 (en)2010-06-032011-12-08Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
WO2011154940A1 (en)2010-06-072011-12-15Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
WO2011158243A2 (en)2010-06-162011-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
WO2011158242A2 (en)2010-06-162011-12-22Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
US8088160B2 (en)2000-07-202012-01-03Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
WO2012003474A2 (en)2010-07-022012-01-05The University Of ChicagoCompositions and methods related to protein a (spa) variants
WO2012007945A2 (en)2010-07-122012-01-19The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterIsolated polynucleotides and methods and plants using same for regulating plant acidity
WO2012007919A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007950A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007951A1 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012011113A2 (en)2010-07-222012-01-26Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012014208A2 (en)2010-07-272012-02-02Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012014207A2 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014205A1 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012017439A2 (en)2010-08-042012-02-09Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012025925A1 (en)2010-08-242012-03-01Rappaport Family Institute For Research In The Medical SciencesMethods of improving transplantation using sdf-1alpha
WO2012025914A1 (en)2010-08-222012-03-01Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
EP2425841A1 (en)2000-11-242012-03-07Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
WO2012032526A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012032525A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
WO2012032510A1 (en)2010-09-072012-03-15Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012034067A1 (en)2010-09-092012-03-15The University Of ChicagoMethods and compositions involving protective staphylococcal antigens
WO2012032521A2 (en)2010-09-072012-03-15Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032519A2 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of diagnosing parkinson's disease
WO2012032520A1 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012035539A1 (en)2010-09-152012-03-22Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
WO2012038956A1 (en)2010-09-202012-03-29Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
EP2441840A1 (en)2005-07-182012-04-18Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
WO2012052878A1 (en)2010-10-192012-04-26Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012052872A2 (en)2010-10-172012-04-26Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012056452A2 (en)2010-10-272012-05-03Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1 (en)2010-10-282012-05-03Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
WO2012059922A2 (en)2010-11-032012-05-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012059925A2 (en)2010-11-042012-05-10Ben-Gurion University Of The Negev Research And Development AuthorityAcyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012066495A2 (en)2010-11-172012-05-24Ben Gurion University Of The Negev Research And Development AuthorityT-cell therapy to neurodegenerative diseases
EP2457999A2 (en)2002-12-162012-05-30Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
WO2012075111A1 (en)2010-11-302012-06-07Novartis AgUses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012073238A1 (en)2010-12-022012-06-07Technion Research & Development Foundation Ltd.Methods of generating corneal cells and cell populations comprising same
EP2463382A1 (en)2010-12-072012-06-13Enterologics, Inc.Method for identifying E. Coli M-17
WO2012081029A1 (en)2010-12-152012-06-21Kadimastem Ltd.Insulin producing cells derived from pluripotent stem cells
WO2012090205A2 (en)2010-12-282012-07-05Kamedis Ltd.Plant extracts for the treatment and prevention of infections
WO2012098537A1 (en)2011-01-202012-07-26Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012104851A1 (en)2011-01-312012-08-09Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
EP2487182A2 (en)2005-07-072012-08-15FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
US8252588B2 (en)2003-04-082012-08-28Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
EP2492279A1 (en)2011-02-252012-08-29Laboratorios Del. Dr. Esteve, S.A.Rapid immunogen selection method using lentiviral display
WO2012114339A1 (en)2011-02-232012-08-30Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A1 (en)2011-03-032012-09-07Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012117406A2 (en)2011-03-022012-09-07Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012120500A2 (en)2011-03-062012-09-13Merck Serono S.A.Low fucose cell lines and uses thereof
WO2012120518A1 (en)2011-03-082012-09-13Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
EP2500428A2 (en)2007-07-112012-09-19Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
WO2012123949A1 (en)2011-03-172012-09-20Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012123938A1 (en)2011-03-172012-09-20Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012127475A1 (en)2011-03-242012-09-27Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012127320A1 (en)2011-03-222012-09-27Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012131680A2 (en)2011-03-282012-10-04Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
EP2508596A2 (en)2002-02-212012-10-10Bayer HealthcareMN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
WO2012137207A1 (en)2011-04-062012-10-11Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012137202A1 (en)2011-04-052012-10-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012140519A2 (en)2011-04-152012-10-18Pluristem Ltd.Methods and systems for harvesting cells
WO2012150600A2 (en)2011-05-042012-11-08Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012153336A2 (en)2011-05-122012-11-15Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012153333A1 (en)2011-05-092012-11-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012156976A1 (en)2011-05-162012-11-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
EP2526952A1 (en)2003-07-152012-11-28Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2527441A2 (en)2007-07-152012-11-28Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
WO2012160526A2 (en)2011-05-232012-11-29Ofir MenasheFormulations of microorganism comprising particles and uses of same
US8323636B2 (en)2006-02-032012-12-04Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
EP2529754A1 (en)2007-05-032012-12-05Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
WO2012164565A1 (en)2011-06-012012-12-06Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
WO2012164380A2 (en)2011-05-312012-12-06Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012172555A1 (en)2011-06-142012-12-20Yeda Research And Development Co. Ltd.Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A1 (en)2011-06-232012-12-27Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
US8352031B2 (en)2004-03-102013-01-08Impulse Dynamics NvProtein activity modification
WO2013011507A1 (en)2011-07-202013-01-24Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
WO2013011347A1 (en)2011-07-182013-01-24Institute For Research In BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
EP2550982A1 (en)2011-07-272013-01-30Technion Research & Development Foundation Ltd.Devices for surgical applications
WO2013018098A2 (en)2011-08-022013-02-07Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
WO2013018060A2 (en)2011-08-042013-02-07Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013021389A2 (en)2011-08-092013-02-14Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013024481A1 (en)2011-08-142013-02-21Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
EP2561889A2 (en)2002-08-012013-02-27Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US8388954B2 (en)2003-04-092013-03-05Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
WO2013035071A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Novel risk biomarkers for lung cancer
WO2013035099A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013035070A1 (en)2011-09-072013-03-14Yeda Research And Development Co. Ltd.Olfactory signature and odorant mixture having the same
US8415318B2 (en)2001-10-192013-04-09Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
EP2581445A1 (en)2007-08-152013-04-17Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
WO2013054331A1 (en)2011-10-112013-04-18Tel Hashomer Medical Research Infrastructure And Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US8426166B2 (en)2006-02-032013-04-23Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
WO2013056377A1 (en)2011-10-212013-04-25Augurex Life Sciences CorporationAntigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en)2011-10-272013-05-02Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013067076A2 (en)2011-11-032013-05-10Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
EP2591789A2 (en)2007-09-192013-05-15Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
WO2013070821A1 (en)2011-11-082013-05-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A1 (en)2011-11-232013-05-30Danziger Dan Flower FarmOtomeria plants
WO2013076730A1 (en)2011-11-272013-05-30Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
EP2599790A1 (en)2007-11-262013-06-05Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
WO2013084190A1 (en)2011-12-082013-06-13Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093920A2 (en)2011-12-222013-06-27Yeda Research And Development Co. Ltd.A combination therapy for a stable and long term engraftment
WO2013093921A1 (en)2011-12-202013-06-27Collplant Ltd.Collagen coated synthetic polymer fibers
US8478535B2 (en)2004-10-292013-07-02Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
WO2013098813A1 (en)2012-01-012013-07-04Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013098820A1 (en)2011-12-282013-07-04Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
EP2620493A1 (en)2008-05-282013-07-31Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
WO2013114373A1 (en)2012-02-012013-08-08Protalix Ltd.Inhalable liquid formulations of dnase i
WO2013114363A2 (en)2012-01-302013-08-08Yeda Research And Development Co.Ltd.Antimicrobial agents
WO2013121427A1 (en)2012-02-132013-08-22Gamida-Cell Ltd.Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013121405A1 (en)2012-02-192013-08-22Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013121416A1 (en)2012-02-142013-08-22Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2013124816A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
WO2013124817A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
EP2633854A1 (en)2008-12-052013-09-04Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
WO2013128454A1 (en)2012-03-012013-09-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013132495A1 (en)2012-03-072013-09-12Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1 (en)2012-03-152013-09-19Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2641606A1 (en)2008-05-272013-09-25Pluristem Ltd.Methods of treating inflammatory colon diseases
WO2013140389A1 (en)2012-03-222013-09-26Ramot At Tel-Aviv University Ltd.Plif multimeric peptides and uses thereof
WO2013140247A1 (en)2012-03-202013-09-26Humabs Biomed SaAntibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013153553A2 (en)2012-04-132013-10-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2013160895A1 (en)2012-04-242013-10-31Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
WO2013162746A1 (en)2012-04-262013-10-31University Of ChicagoStaphylococcal coagulase antigens and methods of their use
WO2013168164A1 (en)2012-05-092013-11-14Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013174003A1 (en)2012-05-242013-11-28Mountgate Group LimitedCompositions and methods related to prevention and treatment of rabies infection
WO2013175480A1 (en)2012-05-242013-11-28A.B. Seeds Ltd.Compositions and methods for silencing gene expression
WO2013183048A1 (en)2012-06-032013-12-12Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
WO2013183052A1 (en)2012-06-042013-12-12Prolor Biotech Inc.Pegylated oxm variants
WO2014006621A1 (en)2012-07-032014-01-09Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
WO2014020608A1 (en)2012-07-312014-02-06Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014020599A1 (en)2012-07-292014-02-06Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014024183A1 (en)2012-08-062014-02-13Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
EP2698377A1 (en)2012-08-172014-02-19Laboratorios Del. Dr. Esteve, S.A.Enhanced rapid immunogen selection method for HIV gp120 variants
WO2014033723A1 (en)2012-09-032014-03-06A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A1 (en)2012-09-122014-03-20Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
US8680246B2 (en)2010-02-042014-03-25Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2014052588A1 (en)2012-09-272014-04-03Research Development FoundationAttenuated chikungunya virus
EP2716654A1 (en)2005-10-242014-04-09Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
WO2014057490A1 (en)2012-10-092014-04-17Ramot At Tel-Aviv University Ltd.Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014064682A1 (en)2012-10-242014-05-01Yeda Research And Development Co. Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A1 (en)2012-10-292014-05-08Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
WO2014083567A2 (en)2012-11-292014-06-05Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
US8759292B2 (en)2006-02-032014-06-24Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
US8775526B2 (en)2006-01-162014-07-08Zlango Ltd.Iconic communication
WO2014106837A2 (en)2013-01-012014-07-10A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
WO2014108854A1 (en)2013-01-092014-07-17Fusimab Ltd.Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014108850A2 (en)2013-01-092014-07-17Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
WO2014111936A1 (en)2013-01-172014-07-24Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
WO2014118785A1 (en)2013-02-042014-08-07Ramot At Tel-Aviv University Ltd.Generation of cytotoxic tumor specific cell lines and uses thereof
WO2014136117A1 (en)2013-03-062014-09-12Protalix Ltd.USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014138696A1 (en)2013-03-072014-09-12University Of Maryland, BaltimoreImmunotherapeutic potential of modified lipooligosaccharides/lipid a
WO2014136114A1 (en)2013-03-062014-09-12Protalix Ltd.TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
EP2781223A1 (en)2007-10-192014-09-24Rappaport Family Institute for Research in the Medical SciencesCompositions comprising semaphorins for the treatment of angiogenesis related diseases
WO2014147622A1 (en)2013-03-212014-09-25Collplant Ltd.Compositions comprising collagen and prp for tissue regeneration
US8846393B2 (en)2005-11-292014-09-30Gamida-Cell Ltd.Methods of improving stem cell homing and engraftment
WO2014155376A1 (en)2013-03-242014-10-02Biokine Therapeutics Ltd.Methods of treating myeloid leukemia
EP2789626A2 (en)2008-09-242014-10-15Tel Hashomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
US8865158B2 (en)2012-05-222014-10-21Ramot At Tel-Aviv University Ltd.Bacteriophages for reducing toxicity of bacteria
US8871207B2 (en)2008-07-252014-10-28Humabs, LLCNeutralizing anti-influenza A virus antibodies and uses thereof
WO2014174470A1 (en)2013-04-232014-10-30Yeda Research And Development Co. Ltd.Isolated naive pluripotent stem cells and methods of generating same
WO2014174520A1 (en)2013-04-252014-10-30Yeda Research And Development Co. Ltd.Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014174511A1 (en)2013-04-212014-10-30Yeda Research And Development Co. Ltd.Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014188423A1 (en)2013-05-212014-11-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Treatment of mast cell related pathologies
WO2014191995A2 (en)2013-05-272014-12-04Rakuto Bio Technologies Ltd.Enzymatic system-containing cosmetic compositions
EP2816117A2 (en)2004-09-292014-12-24Collplant Ltd.Collagen producing plants and methods of generating and using same
WO2014207744A1 (en)2013-06-242014-12-31Ramot At Tel-Aviv University Ltd.Omentum based scaffold and delivery system
US8945588B2 (en)2011-05-062015-02-03The University Of ChicagoMethods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US8946155B2 (en)2006-02-032015-02-03Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2015015489A1 (en)2013-07-302015-02-05Biolinerx Ltd.Antibody for treating diabetes and autoimmune diseases
EP2839839A1 (en)2007-02-282015-02-25Yeda Research And Development Company LimitedNuclear targeting sequences
WO2015033344A1 (en)2013-09-052015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015033343A1 (en)2013-09-032015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for expressing recombinant polypeptides
WO2015033337A1 (en)2013-09-032015-03-12Technion Research & Development Foundation Limited.A flap for de-novo tissue regeneration
WO2015037009A1 (en)2013-09-162015-03-19Plexicure Ltd.Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015040609A1 (en)2013-09-172015-03-26Yeda Research And Development Co. Ltd.Erk-derived peptides and uses thereof
WO2015049677A1 (en)2013-10-012015-04-09Kadimastem Ltd.Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)
WO2015059695A1 (en)2013-10-212015-04-30Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2015059690A1 (en)2013-10-242015-04-30Yeda Research And Development Co. Ltd.Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A1 (en)2013-10-312015-05-07Biokine Therapeutics Ltd.Methods of treating acute myeloid leukemia with a flt3 mutation
WO2015079413A2 (en)2013-11-282015-06-04Yeda Research And Development Co. Ltd.Synaptojanin-2 inhibitors and uses thereof
WO2015079411A1 (en)2013-11-282015-06-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Rna polymerase i inhibitors and uses thereof
US9057092B2 (en)2006-03-062015-06-16Zetiq Technologies Ltd.Methods and compositions for identifying a cell phenotype
WO2015087327A1 (en)2013-12-102015-06-18Yeda Research And Development Co. Ltd.Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-coa and bacteria expressing same
EP2889041A1 (en)2005-07-262015-07-01Rutgers, The State University of New JerseyKit of reagents for tuberculosis assay
US9096645B2 (en)2010-11-152015-08-04Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9096865B2 (en)2009-06-102015-08-04Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2015114633A1 (en)2014-01-302015-08-06Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd.Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A2 (en)2014-02-032015-08-06Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of eliminating stem cells
WO2015118537A2 (en)2014-02-052015-08-13Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A1 (en)2014-02-062015-08-13Yeda Research And Development Co. Ltd.Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015118547A1 (en)2014-02-102015-08-13Protalix Ltd.Method of maintaining disease stability in a subject having gaucher's disease
WO2015121859A1 (en)2014-02-112015-08-20Brainstorm Cell Therapeutics Ltd.Method of qualifying cells
US9121022B2 (en)2010-03-082015-09-01Monsanto Technology LlcMethod for controlling herbicide-resistant plants
WO2015132784A1 (en)2014-03-032015-09-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method and device for detection of pseudomonas aeruginosa
EP2923709A1 (en)2014-03-282015-09-30Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccine
US9150644B2 (en)2011-04-122015-10-06The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9156865B2 (en)2007-04-232015-10-13Deliversir LtdSystem for delivering therapeutic agents into living cells and cells nuclei
WO2015159293A2 (en)2014-04-142015-10-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159295A1 (en)2014-04-172015-10-22Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
EP2936976A1 (en)2008-04-212015-10-28Danziger Innovations Ltd.Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
US9175266B2 (en)2012-07-232015-11-03Gamida Cell Ltd.Enhancement of natural killer (NK) cell proliferation and activity
WO2015166492A2 (en)2014-04-282015-11-05Yeda Research And Development Co. Ltd.Microbiome response to agents
US9182403B2 (en)2009-05-192015-11-10Zetiq Technologies Ltd.Kits for and methods of differential staining of cervical cancer cells and/or tissues
WO2015170324A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions for mosquito control and uses of same
WO2015177800A2 (en)2014-05-222015-11-26Yeda Research And Development Co. Ltd.Recombinant microorganisms capable of carbon fixation
WO2015186128A1 (en)2014-06-022015-12-10Kadimastem Ltd.Methods of inducing myelination and maturation of oligodendrocytes
WO2015186129A1 (en)2014-06-022015-12-10Technion Research & Development Foundation Limited.Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015198334A2 (en)2014-06-252015-12-30Tel Hashomer Medical Research Infrastructure And Services Ltd.Identification of cancer stem cells and use of same for diagnosis and treatment
WO2015198320A1 (en)2014-06-242015-12-30Insight Biopharmaceuticals Ltd.Methods of purifying antibodies
EP2960250A1 (en)2008-07-162015-12-30Institute for Research in BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
WO2016005985A2 (en)2014-07-092016-01-14Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming cells
WO2016009436A1 (en)2014-07-152016-01-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of cd44 and uses thereof
US9249407B2 (en)2006-02-032016-02-02Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016016894A1 (en)2014-07-302016-02-04Yeda Research And Development Co. Ltd.Media for culturing pluripotent stem cells
WO2016024278A1 (en)2014-08-142016-02-18Memed Diagnostics Ltd.Computational analysis of biological data using manifold and a hyperplane
EP2990421A1 (en)2009-04-302016-03-02Tel HaShomer Medical Research Infrastructure and Services Ltd.Anti ceacam1 antibodies and methods of using same
WO2016030899A1 (en)2014-08-282016-03-03Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral scleroses
EP2992895A1 (en)2014-09-082016-03-09Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Three-component-multistage malaria vaccine
WO2016038616A1 (en)2014-09-142016-03-17Yeda Research And Development Co. Ltd.Nmda receptor antagonists for treating gaucher disease
WO2016038609A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Anti-her3 antibodies and uses of same
WO2016038610A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038617A1 (en)2014-09-112016-03-17The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of producing mogrosides and compositions comprising same and uses thereof
WO2016042561A2 (en)2014-09-212016-03-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Downregulating mir-132 for the treatment of lipid related disorders
EP3006039A1 (en)2004-03-022016-04-13Acceleron Pharma Inc.Alk7 polypeptides for use in promoting fat loss
WO2016055950A1 (en)2014-10-082016-04-14Novartis AgCombination of human cytomegalovirus neutralizing antibodies
EP3009449A1 (en)2008-07-162016-04-20Institute for Research in BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
WO2016064887A1 (en)2014-10-202016-04-28Gen-Probe IncorporatedRed blood cell lysis solution
EP3020410A1 (en)2008-04-182016-05-18Collplant Ltd.Methods of generating and using procollagen
WO2016075697A1 (en)2014-11-132016-05-19Enzootic Holdings Ltd.Functional sex-reversal of decapod crustacean females
WO2016075546A2 (en)2014-11-142016-05-19Antonio LanzavecchiaAntibodies that neutralize ebola virus and uses thereof
WO2016079736A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Methods of treating diseases related to mitochondrial function
WO2016079731A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Method of analyzing microbiome
WO2016079739A2 (en)2014-11-202016-05-26Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
EP3026057A2 (en)2009-03-092016-06-01Ramot at Tel Aviv University Ltd.Compositions for prevention and treatment of neurodegenerative diseases
WO2016084088A1 (en)2014-11-262016-06-02Ramot At Tel-Aviv University Ltd.Targeted elimination of bacterial genes
WO2016084084A1 (en)2014-11-272016-06-02Danziger Innovations Ltd.Nucleic acid constructs for genome editing
WO2016092555A2 (en)2014-12-112016-06-16Yeda Research And Development Co. Ltd.Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016092554A1 (en)2014-12-112016-06-16Memed Diagnostics Ltd.Marker combinations for diagnosing infections and methods of use thereof
WO2016103269A1 (en)2014-12-232016-06-30Ramot At Tel-Aviv University Ltd.Populations of neural progenitor cells and methods of producing and using same
WO2016108240A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
WO2016108219A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Methods of treating retinal diseases
WO2016108239A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
WO2016108244A1 (en)2015-01-042016-07-07Protalix Ltd.Modified dnase and uses thereof
WO2016116935A1 (en)2015-01-212016-07-28Yeda Research And Development Co. Ltd.Use of rasa2 as a prognostic and therapeutic marker for melanoma
US9416363B2 (en)2011-09-132016-08-16Monsanto Technology LlcMethods and compositions for weed control
US9422558B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
US9422557B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
WO2016135732A1 (en)2015-02-262016-09-01Yeda Research And Development Co. Ltd.Method of promoting hair growth
WO2016142948A1 (en)2015-03-112016-09-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Decoy oligonucleotides for the treatment of diseases
WO2016147194A1 (en)2015-03-192016-09-22Yeda Research And Development Co. Ltd.Anti amphiregulin antibodies, compositions comprising same and uses thereof
US9458444B2 (en)2006-02-032016-10-04Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US9458438B2 (en)2010-04-122016-10-04Ben Gurion University Of The Negev Research And Development AuthoritySulfotransferase of a red microalga and uses thereof
WO2016157192A1 (en)2015-04-012016-10-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Erodium crassifolium l'her plant extracts and uses thereof
WO2016157190A1 (en)2015-03-312016-10-06Yeda Research And Development Co. Ltd.Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
WO2016160618A2 (en)2015-03-272016-10-06University Of Southern CaliforniaCar t-cell therapy directed to lhr for the treatment of solid tumors
WO2016162870A1 (en)2015-04-072016-10-13Ilana NathanCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2016174652A1 (en)2015-04-302016-11-03Technion Research & Development Foundation LimitedChimeric antigen receptors and methods of their use
WO2016174674A1 (en)2015-04-272016-11-03The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterEgr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
WO2016174673A1 (en)2015-04-292016-11-03The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Anti-phytopathogenic compositions
WO2016178207A1 (en)2015-05-042016-11-10Ramot At Tel-Aviv University Ltd.Methods and kits for fragmenting dna
WO2016181393A1 (en)2015-05-112016-11-17Yeda Research And Development Co. Ltd.Citrin inhibitors for the treatment of cancer
WO2016185469A1 (en)2015-05-212016-11-24Yeda Research And Development Co. Ltd.Bacterial populations for promoting health
WO2016185471A1 (en)2015-05-172016-11-24The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCompositions and methods for treating cancer
WO2016185457A1 (en)2015-05-192016-11-24Yeda Research And Development Co. Ltd.Methods of promoting lymphangiogenesis
WO2016185481A2 (en)2015-05-202016-11-24Yeda Research And Development Co. Ltd.Method of targeting senescent cells
WO2016193969A2 (en)2015-05-292016-12-08Opko Biologics Ltd.Pegylated oxyntomodulin variants
WO2016197064A1 (en)2015-06-042016-12-08Epstein Alan LLym-1 and lym-2 targeted car cell immunotherapy
WO2016199141A2 (en)2015-06-082016-12-15Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
US9522945B2 (en)2012-04-192016-12-20Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
WO2016203477A1 (en)2015-06-182016-12-22Yeda Research And Development Co. Ltd.Conditioning protocols and use of same for tissue regeneration
WO2016203482A2 (en)2015-06-192016-12-22Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016203476A1 (en)2015-06-182016-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and compositions for diagnosing and treating urothelial cancer
WO2016207402A1 (en)2015-06-262016-12-29Institute For Research In BiomedicineProteins comprising a mutated lair-1 fragment and uses thereof
US9540642B2 (en)2013-11-042017-01-10The United States Of America, As Represented By The Secretary Of AgricultureCompositions and methods for controlling arthropod parasite and pest infestations
EP3115451A1 (en)2008-09-022017-01-11Pluristem Ltd.Adherent cells from placenta tissue and use thereof in therapy
WO2017009842A2 (en)2015-07-162017-01-19Biokine Therapeutics Ltd.Compositions and methods for treating cancer
WO2017009853A1 (en)2015-07-162017-01-19Yeda Research And Development Co. Ltd.Genetically modified anti-third party central memory t cells and use of same in immunotherapy
US9551006B2 (en)2010-12-222017-01-24Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
WO2017013661A1 (en)2015-07-222017-01-26Phytopharma International Ltd.Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US9556210B2 (en)2007-04-232017-01-31Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
WO2017017686A1 (en)2015-07-292017-02-02Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017021961A1 (en)2015-08-042017-02-09Yeda Research And Development Co. Ltd.Methods of screening for riboswitches and attenuators
WO2017021972A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of photoreceptors for the treatment of retinal diseases
WO2017021963A1 (en)2015-08-032017-02-09Biokine Therapeutics Ltd.Cxcr4 binding agents for treatment of diseases
WO2017021973A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
US9567569B2 (en)2012-07-232017-02-14Gamida Cell Ltd.Methods of culturing and expanding mesenchymal stem cells
US9567579B2 (en)2003-05-232017-02-14Board Of Regents, The University Of Texas SystemStructure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
WO2017025963A1 (en)2015-08-102017-02-16The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods and pharmaceutical compositions for improving wound healing using cd24
WO2017025967A1 (en)2015-08-132017-02-16Forrest Innovations Ltd.Formulations and compositions for delivery of nucleic acids to plant cells
WO2017033188A1 (en)2015-08-242017-03-02Yeda Research And Development Co. Ltd.Algal oil and biofuel and methods of producing same
WO2017042814A1 (en)2015-09-102017-03-16Yeda Research And Development Co. Ltd.Use of perforin positive immature dendritic cells in disease treatment
EP3159405A1 (en)2010-01-052017-04-26Vascular Biogenics Ltd.Methods for use of a specific anti-angiogenic adenoviral agent
WO2017072757A1 (en)2015-10-252017-05-04Yeda Research And Development Co. Ltd.Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2017072773A1 (en)2015-10-272017-05-04Ilana NathanCompositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2017072772A1 (en)2015-10-292017-05-04Yeda Research And Development Co. Ltd.A method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017072763A1 (en)2015-10-262017-05-04Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017077539A1 (en)2015-11-032017-05-11Ariel-University Research And Development Company Ltd.Compositions for regeneration and repair of neural tissue
WO2017081689A1 (en)2015-11-112017-05-18Ramot At Tel-Aviv University Ltd.Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer
US9663778B2 (en)2009-07-092017-05-30OPKO Biologies Ltd.Long-acting coagulation factors and methods of producing same
EP3176183A1 (en)2015-12-022017-06-07Yeda Research and Development Co. LtdCompositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
WO2017094001A1 (en)2015-11-302017-06-08Kadimastem LtdMethods for differentiating and purifying pancreatic endocrine cells
WO2017118985A1 (en)2016-01-062017-07-13Yeda Research And Development Co. Ltd.Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017122203A1 (en)2016-01-112017-07-20Technion Research & Development Foundation LimitedMethods of determining prognosis of sepsis and treating same
WO2017125931A1 (en)2016-01-212017-07-27The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Parthenocarpic plants and methods of producing same
WO2017130205A1 (en)2016-01-312017-08-03Hadasit Medical Research Services And Development Ltd.Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
US9726581B2 (en)2011-12-222017-08-08Realbio Technologies Ltd.Sequential lateral flow capillary device for analyte determination
WO2017134671A1 (en)2016-02-042017-08-10Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
WO2017138007A1 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceMicrobiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017138008A2 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd.Methods of modulating protein exocytosis and uses of same in therapy
WO2017141253A1 (en)2016-02-162017-08-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
WO2017145162A1 (en)2016-02-232017-08-31Chaya BrodieGeneration of cancer stem cells and use thereof
WO2017149547A1 (en)2016-03-032017-09-08Memed Diagnostics Ltd.Analyzing rna for diagnosing infection type
WO2017153982A1 (en)2016-03-062017-09-14Yeda Research And Development Co. Ltd.Method for modulating myelination
WO2017158610A1 (en)2016-03-172017-09-21Yeda Research And Development Co. Ltd.Methods of isolating barrel-like proteases and identifying peptides processed thereby
US9777288B2 (en)2013-07-192017-10-03Monsanto Technology LlcCompositions and methods for controlling leptinotarsa
WO2017175228A1 (en)2016-04-062017-10-12Technion Research & Development Foundation LimitedInfiltrating immune cell proportions predict anti-tnf response in colon biopsies
WO2017189746A1 (en)2016-04-272017-11-02Gen-Probe IncorporatedBlood cell lysis reagent
US9808534B2 (en)2012-11-202017-11-07Opko Biologics Ltd.Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP3244189A1 (en)2008-12-302017-11-15Jin Po LeeQuantitative analyte assay device and method
US9822134B2 (en)2012-10-222017-11-21Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US9828417B2 (en)2006-02-032017-11-28Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2017203520A1 (en)2016-05-222017-11-30Yeda Research And Development Co. Ltd.Methods of using pulmonary cells for transplantation and induction of tolerance
WO2017203532A1 (en)2016-05-252017-11-30Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceAgents for use treating drug resistant tumors and triple negative breast cancer
WO2017208247A1 (en)2016-06-022017-12-07Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Assay for the removal of methyl-cytosine residues from dna
WO2017212476A1 (en)2016-06-052017-12-14Tel Hashomer Medical Research Infrastructure And Services Ltd.Novel molecules for the treatment of inflammation
WO2017212494A1 (en)2016-06-092017-12-14Opko Biologics Ltd.Long-acting oxyntomodulin formulation and methods of producing and administering same
US9850496B2 (en)2013-07-192017-12-26Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
WO2017221225A1 (en)2016-06-192017-12-28Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Screening for chemotherapy resistance in human haploid cells
EP3263127A1 (en)2011-05-232018-01-03Yeda Research and Development Co. LtdUse of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2018002924A1 (en)2016-06-272018-01-04Yeda Research And Development Co. Ltd.Veto cells generated from memory t cells
WO2018011804A1 (en)2016-07-112018-01-18Bonus Therapeutics Ltd.Cell compositions for tissue regeneration
WO2018011805A2 (en)2016-07-112018-01-18Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Systems and methods for growing cells in vitro
WO2018011795A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Protein signatures for distinguishing between bacterial and viral infections
WO2018011796A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Early diagnosis of infections
WO2018011806A1 (en)2016-07-112018-01-18Yeda Research And Development Co. Ltd.Combination therapy to increase endogenous nitric oxide (no) synthesis
WO2018011799A1 (en)2016-07-112018-01-18Opko Biologics Ltd.Long-acting coagulation factor vii and methods of producing same
WO2018011283A1 (en)2016-07-132018-01-18Humabs Biomed SaNovel antibodies specifically binding to zika virus epitopes and uses thereof
WO2018015881A1 (en)2016-07-182018-01-25Ramot At Tel-Aviv University Ltd.Modular platform for targeted therapeutics
WO2018020489A1 (en)2016-07-242018-02-01Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
US9884901B2 (en)2006-02-032018-02-06Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2018029693A1 (en)2016-08-102018-02-15Ramot At Tel-Aviv University Ltd.Analysis of methylation status and copy number
WO2018029682A1 (en)2016-08-082018-02-15Ramot At Tel-Aviv University Ltd.Bacterial systems for analyzing ubiquitylated polypeptides
WO2018029690A1 (en)2016-08-102018-02-15Memed Diagnostics Ltd.System and method for analysis of biological data
WO2018033911A1 (en)2016-08-142018-02-22Ramot At Tel-Aviv University Ltd.Mesenchymal cell-derived exosomes to treat neurological disorders
WO2018033929A1 (en)2016-08-182018-02-22Yeda Research And Development Co. Ltd.Diagnostic and therapeutic uses of exosomes
WO2018037416A1 (en)2016-08-252018-03-01Yeda Research And Development Co. Ltd.Methods and compositions for treating autoimmune diseases
WO2018047154A1 (en)2016-09-072018-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Anti-nkp46 antibodies and therapeutic use of same
WO2018051347A1 (en)2016-09-142018-03-22Yeda Research And Development Co. Ltd.Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
US9925143B2 (en)2012-04-182018-03-27Ramot At Tel-Aviv University Ltd.Lipidated glycosaminoglycan particles for the delivery of nucleic acids
WO2018060998A1 (en)2016-09-292018-04-05Memed Diagnostics Ltd.Methods of prognosis and treatment
US9938316B2 (en)2013-08-292018-04-10Yeda Research And Development Co. Ltd.Selective inhibitors of α2 isoform of Na,K-ATPase and use thereof for reduction of intra-ocular pressure and as cardiotonic agents
WO2018069885A1 (en)2016-10-132018-04-19Technion Research & Development Foundation LimitedUse of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
US9952211B2 (en)2008-06-292018-04-24Realbio Technologies Ltd.Liquid-transfer device particularly useful as a capturing device in a biological assay process
WO2018073823A2 (en)2016-10-182018-04-26Yeda Research And Development Co. Ltd.Treatment of a circadian rhythm disorder
WO2018087759A1 (en)2016-11-102018-05-17Yeda Research And Development Co. Ltd.Phosphotriesterases for treating or preventing organophosphate exposure associated damage
WO2018096547A1 (en)2016-11-282018-05-31Yeda Research And Development Co. Ltd.Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest
WO2018100574A1 (en)2016-11-302018-06-07Yeda Research And Development Co. Ltd.Methods of treating liver toxicity and disorders
WO2018100511A1 (en)2016-12-012018-06-07Ramot At Tel-Aviv University Ltd.Combined treatment for nerve injuries
WO2018134824A1 (en)2017-01-182018-07-26Yeda Research And Development Co. Ltd.Genetically modified veto cells and use of same in immunotherapy
EP3354723A1 (en)2005-08-292018-08-01Technion Research & Development Foundation Ltd.Media for culturing stem cells
WO2018138668A1 (en)2017-01-252018-08-02Mor Research Applications Ltd.Methods of diagnosing malignant diseases
WO2018142416A1 (en)2017-02-062018-08-09Yeda Research And Development Co. Ltd.Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same
EP3366762A1 (en)2007-05-072018-08-29Protalix Ltd.Large scale disposable bioreactor
WO2018158775A1 (en)2017-03-022018-09-07Yeda Research And Development Co. Ltd.Methods of culturing t cells and uses of same
WO2018167780A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of prognosing and treating cancer
WO2018170494A1 (en)2017-03-162018-09-20Bio Time, Inc.Methods for measuring therapeutic effects of retinal disease therapies
WO2018167778A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of diagnosing and prognosing cancer
US10080799B2 (en)2010-02-122018-09-25Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods and compositions related to glycoprotein-immunoglobulin fusions
WO2018185760A1 (en)2017-04-052018-10-11Yeda Research And Development Co. Ltd.Ex-vivo culture system and methods of using same
WO2018193063A2 (en)2017-04-192018-10-25Institute For Research In BiomedicineNovel malaria vaccines and antibodies binding to plasmodium sporozoites
WO2018207184A2 (en)2017-05-102018-11-15Ariel Scientific Innovations Ltd.Methods of purifying antibodies
WO2018207178A1 (en)2017-05-072018-11-15Yeda Research And Development Co. Ltd.Methods of treating psychiatric stress disorders
WO2018216011A1 (en)2017-05-232018-11-29Technion Research & Development Foundation LimitedAgents which inhibit gads dimerization and methods of use thereof
WO2018216006A1 (en)2017-05-212018-11-29The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCombination of markers for diagnosing cancer
WO2018220581A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing shelf-life of banana
WO2018220579A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing extractability of solids from coffee beans
WO2018220582A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedMethods of selecting cells comprising genome editing events
WO2018229764A1 (en)2017-06-132018-12-20Yeda Research And Development Co. Ltd.Treatment of advanced or progressive multiple sclerosis
US10166295B2 (en)2011-06-022019-01-01Opko Biologics Ltd.Pegylated OXM variants
WO2019012543A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dna targets as tissue-specific methylation markers
WO2019012542A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Detecting tissue-specific dna
WO2019012544A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dual-probe digital droplet pcr strategy for specific detection of tissue-specific circulating dna molecules
US10184131B2 (en)2012-02-062019-01-22A.B. Seeds Ltd.Isolated polynucleotides expressing or modulating microRNAs or targets of same, transgenic plants comprising same and uses thereof
WO2019021284A1 (en)2017-07-242019-01-31Yeda Research And Development Co. Ltd.Combination therapy for the treatment of cancer
WO2019035128A1 (en)2017-08-142019-02-21Yeda Research And Development Co. Ltd.Immunotherapy against transferrin receptor 1 (tfr1)-tropic arenaviruses
WO2019038761A1 (en)2017-08-212019-02-28Savicell Diagnostic Ltd.Methods of diagnosing and treating lung cancer
WO2019038771A1 (en)2017-08-232019-02-28Technion Research & Development Foundation LimitedCompositions and methods for improving alcohol tolerance in yeast
US10221228B2 (en)2006-02-032019-03-05Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2019042555A1 (en)2017-08-312019-03-07Humabs Biomed SaMultispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2019058376A1 (en)2017-09-192019-03-28The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
WO2019094595A2 (en)2017-11-092019-05-16Pinteon Therapeutics Inc.Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
US10294292B2 (en)2014-07-152019-05-21Medimmune, LlcNeutralizing anti-influenza B antibodies and uses thereof
WO2019097514A1 (en)2017-11-142019-05-23Yeda Research And Development Co. Ltd.Hematopoietic stem cells with improved properties
WO2019106680A1 (en)2017-12-032019-06-06Yeda Research And Development Co. Ltd.Treatment of an ischemic heart disease
WO2019106667A1 (en)2017-11-292019-06-06Weedout Ltd.Compositions, kits and methods for controlling weed of the amaranthus genus
WO2019106671A1 (en)2017-11-292019-06-06Ramot At Tel-Aviv University Ltd.Methods of preventing or treating neurogenic shock
WO2019116376A1 (en)2017-12-172019-06-20Yeda Research And Development Co. Ltd.Cop9 signalosome (csn) complex modulators and uses thereof
US10335783B2 (en)2005-01-312019-07-02Realbio Technologies, Ltd.Multistep reaction lateral flow capillary device
US10334848B2 (en)2014-01-152019-07-02Monsanto Technology LlcMethods and compositions for weed control using EPSPS polynucleotides
EP3503729A1 (en)2016-08-282019-07-03The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO)Method of controlling fungal infections in plants
WO2019130313A1 (en)2017-12-282019-07-04Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method to reproduce circadian rhythms on a microfluidic chip
US10351615B2 (en)2006-02-032019-07-16Opko Biologics Ltd.Methods of treatment with long-acting growth hormone
US10359573B2 (en)1999-11-052019-07-23Board Of Regents, The University Of Texas SystemResonant waveguide-granting devices and methods for using same
WO2019145964A1 (en)2018-01-292019-08-01Yeda Research And Development Co. Ltd.Combination of a mek inhibitor and a cdk4/6 inhibitor for the treatment of sarcoma
WO2019150373A1 (en)2018-01-312019-08-08Yeda Research And Development Co. Ltd.Endoplasmic reticulum targeting signal
US10378012B2 (en)2014-07-292019-08-13Monsanto Technology LlcCompositions and methods for controlling insect pests
WO2019155459A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Inhibitors of the 20s proteasome
WO2019155465A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
WO2019167047A1 (en)2018-02-282019-09-06The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods of diagnosing and treating bladder cancer
WO2019175869A1 (en)2018-03-122019-09-19Yeda Research And Development Co. LtdTreatment of a heart disease
US10421785B2 (en)2016-04-112019-09-24Bar-Ilan UniversityDelta receptor agonist peptides and use thereof
WO2019186569A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Use of electric field gradients to control gene expression
WO2019186570A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Methods of disrupting a biofilm and/or preventing formation of same
US10442854B2 (en)2015-06-012019-10-15Medimmune, LlcNeutralizing anti-influenza binding molecules and uses thereof
US10457954B2 (en)2010-08-302019-10-29Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2019211750A1 (en)2018-05-012019-11-07Tropic Biosciences UK LimitedCompositions and methods for reducing caffeine content in coffee beans
WO2019220441A1 (en)2018-05-152019-11-21Hadasit Medical Research Services And Development Ltd.Compositions and methods for treating cancer resistant to an anti-cancer agent
WO2019220437A1 (en)2018-05-152019-11-21Yeda Research And Development Co. Ltd.Vaccination with cancer neoantigens
US10494419B2 (en)2013-10-022019-12-03Medimmune, LlcNeutralizing anti-influenza A antibodies and uses thereof
WO2019229745A1 (en)2018-05-272019-12-05Biolinerx Ltd.Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
WO2019234754A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Nucleic acid constructs and methods of using same
WO2019234750A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of regenerating and transforming cannabis
WO2020003311A1 (en)2018-06-252020-01-02Yeda Research And Development Co. Ltd.Systems and methods for increasing efficiency of genome editing
WO2020008412A1 (en)2018-07-042020-01-09Ukko Inc.Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
WO2020012486A1 (en)2018-07-112020-01-16Kahr Medical Ltd.SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
WO2020012467A2 (en)2018-07-082020-01-16Yeda Research And Development Co. Ltd.Person-specific assessment of probiotics responsiveness
WO2020012478A2 (en)2018-07-112020-01-16Immunity Pharma Ltd.Peptide compounds and therapeutic uses of same
US10550439B2 (en)2014-07-212020-02-04Novellusdx Ltd.Methods for determining drug response of patient specific mutations
US10550196B2 (en)2014-04-272020-02-04Famewave Ltd.Humanized antibodies against CEACAM1
WO2020026241A1 (en)2018-07-312020-02-06Collplant Ltd.Tobacco transgenic event and methods for detection and use thereof
US10557138B2 (en)2013-12-102020-02-11Beeologics, Inc.Compositions and methods for virus control in Varroa mite and bees
US10561706B2 (en)2015-12-282020-02-18B. G. Negev Technologies And ApplicationsIsolated polypeptide and compositions comprising same
WO2020035863A1 (en)2018-08-142020-02-20Yeda Research And Development Co. Ltd.Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
US10568328B2 (en)2013-03-152020-02-25Monsanto Technology LlcMethods and compositions for weed control
WO2020041360A1 (en)2018-08-212020-02-27Quidel CorporationDbpa antibodies and uses thereof
WO2020039440A1 (en)2018-08-242020-02-27Yeda Research And Development Co. Ltd.Methods of modulating m2 macrophage polarization and use of same in therapy
US10577412B2 (en)2015-04-122020-03-03Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.Anti-plasmodium parasite antibodies
US10583084B2 (en)2014-06-262020-03-10Ramot At Tel-Aviv University Ltd.Liposomal formulations for delivery of nucleic acids
WO2020058979A2 (en)2018-09-202020-03-26Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral sclerosis
WO2020065647A1 (en)2018-09-252020-04-02Biolinerx Ltd.Methods of selecting treatment for cxcr4-associated cancer
US10612019B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
US10609930B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
EP3633025A1 (en)2009-11-122020-04-08Technion Research & Development Foundation Ltd.Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2020089892A1 (en)2018-10-282020-05-07Yeda Research And Development Co. Ltd.Prevention of age related clonal hematopoiesis and diseases associated therewith
US10655136B2 (en)2015-06-032020-05-19Monsanto Technology LlcMethods and compositions for introducing nucleic acids into plants
US10662226B2 (en)2016-10-282020-05-26The Regents of the University of CaiifomiaSynthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2020105050A2 (en)2018-11-212020-05-28Yeda Research And Development Co. Ltd.Method of treating cancer and compositions for same
US10668094B2 (en)2015-07-192020-06-02Yeda Research And Development Co. Ltd.Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure
US10683505B2 (en)2013-01-012020-06-16Monsanto Technology LlcMethods of introducing dsRNA to plant seeds for modulating gene expression
US10683363B2 (en)2012-03-302020-06-16The United States Of America As Represented By The Department Of Veteran AffairsTargeting intracellular target-binding determinants with intracellular antibodies
US10683344B2 (en)2015-10-072020-06-16Humabs Biomed SaAntibodies that potently neutralize hepatitis B virus and uses thereof
WO2020132091A2 (en)2018-12-192020-06-25Humabs Biomed SaAntibodies that neutralize hepatitis b virus and uses thereof
WO2020152686A1 (en)2019-01-232020-07-30Yeda Research And Development Co. Ltd.Culture media for pluripotent stem cells
WO2020161724A1 (en)2019-02-102020-08-13Yeda Research And Development Co. Ltd.Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
WO2020165907A1 (en)2019-02-142020-08-20Yeda Research And Development Co. Ltd.Spt5 inhibitors and uses thereof
WO2020170239A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating organoids for high throughput screening of drugs
WO2020170240A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reduction drug-induced nephrotoxicity
US10760086B2 (en)2011-09-132020-09-01Monsanto Technology LlcMethods and compositions for weed control
US10760088B2 (en)2011-05-032020-09-01Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US10765706B2 (en)2015-09-032020-09-08University Of South FloridaMethod of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
WO2020178822A1 (en)2019-03-052020-09-10The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
WO2020183414A2 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedModifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
WO2020183419A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedIntroducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
WO2020185763A1 (en)2019-03-112020-09-17Memorial Sloan Kettering Cancer CenterCd22 antibodies and methods of using the same
WO2020183416A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedPRODUCTION OF dsRNA IN PLANT CELLS FOR PEST PROTECTION VIA GENE SILENCING
WO2020188572A1 (en)2019-03-192020-09-24Yeda Research And Development Co. Ltd.Bistable type ii opsins and uses thereof
WO2020193718A1 (en)2019-03-272020-10-01INSERM (Institut National de la Santé et de la Recherche Médicale)Recombinant proteins with cd40 activating properties
WO2020194317A1 (en)2019-03-282020-10-01Yeda Research And Development Co. Ltd.Method of treating lipid-related disorders
WO2020202142A2 (en)2019-03-312020-10-08Yeda Research And Development Co. Ltd.Anti-viral and anti-tumoral compounds
US10808249B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
US10806146B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
WO2020222241A1 (en)2019-05-022020-11-05Yeda Research And Development Co. Ltd.Compositions comprising the propeptide of lysyl oxidase and uses thereof
US10829828B2 (en)2011-09-132020-11-10Monsanto Technology LlcMethods and compositions for weed control
WO2020230133A1 (en)2019-05-132020-11-19Yeda Research And Development Co. Ltd.Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
WO2020234875A2 (en)2019-05-192020-11-26Yeda Research And Development Co. Ltd.Identification of recurrent mutated neopeptides
WO2020234888A1 (en)2019-05-222020-11-26Hadasit Medical Research Services And Development Ltd.Methods of culturing human pluripotent cells
WO2020237491A1 (en)2019-05-282020-12-03Shanghaitech UniversityComposition and methods to treat ectodermal dysplasia 2, clouston type
WO2020250232A1 (en)2019-06-122020-12-17Hadasit Medical Research Services And Development Ltd.Methods of generating oligodendrocytes
WO2020255124A1 (en)2019-06-162020-12-24Yeda Research And Development Co. Ltd.Method for stabilizing intracellular rna
WO2020261281A1 (en)2019-06-272020-12-30Ramot At Tel-Aviv University Ltd.Semaphorin 3a antibodies and uses thereof
US10883103B2 (en)2015-06-022021-01-05Monsanto Technology LlcCompositions and methods for delivery of a polynucleotide into a plant
WO2021001784A1 (en)2019-07-042021-01-07Ukko Inc.De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
WO2021005599A1 (en)2019-07-112021-01-14Kahr Medical Ltd.Heterodimers and methods of use thereof
WO2021009740A1 (en)2019-07-162021-01-21Ramot At Tel-Aviv University Ltd.Compositions and methods for the treatment of tuberculosis
WO2021009763A1 (en)2019-07-162021-01-21Yeda Research And Development Co. Ltd.Methods of treating pain
US10906987B2 (en)2016-03-012021-02-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Antibodies specific to human poliovirus receptor (PVR)
WO2021019536A1 (en)2019-07-302021-02-04The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021019526A1 (en)2019-07-292021-02-04Yeda Research And Development Co. Ltd.Methods of treating and diagnosing lung cancer
WO2021028909A1 (en)2019-08-122021-02-18Yeda Research And Development Co. Ltd.Dna repair blood test for predicting response of lung cancer patients to immunotherapy
WO2021033176A1 (en)2019-08-222021-02-25Ariel Scientific Innovations Ltd.Scaled-up methods for purifying antibodies
WO2021038569A1 (en)2019-08-272021-03-04Yeda Research And Development Co. Ltd.Treatment of bacterial vaginosis
WO2021042000A1 (en)2019-08-292021-03-04Vir Biotechnology, Inc.Antibody compositions and methods for treating hepatitis b virus infection
WO2021048852A1 (en)2019-09-112021-03-18Yeda Research And Development Co. Ltd.Methods of treating breast cancer
US10954313B2 (en)2016-01-282021-03-23Sp Nano Ltd.Composition comprising SP1 and carbon based nanoparticles and uses thereof
US10964443B2 (en)2016-01-282021-03-30Sp Nano Ltd.Conductive yarn
WO2021059269A1 (en)2019-09-252021-04-01Yeda Research And Development Co. Ltd.Assembly of protein complexes on a chip
US10968449B2 (en)2015-01-222021-04-06Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US10988764B2 (en)2014-06-232021-04-27Monsanto Technology LlcCompositions and methods for regulating gene expression via RNA interference
US10993990B2 (en)2014-05-162021-05-04Baylor Research InstituteMethods and compositions for treating autoimmune and inflammatory conditions
WO2021084540A1 (en)2019-10-302021-05-06Yeda Research And Development Co. Ltd.Inhibitors of mmej pathway for prevention and treatment of pre-myeloid and myeloid malignancies
WO2021084526A1 (en)2019-10-312021-05-06Yeda Research And Development Co. Ltd.Engineered autotrophic bacteria for co2 conversion to organic materials
WO2021095031A2 (en)2019-11-112021-05-20Ibi-Ag Innovative Bio Insecticides Ltd.Insect control nanobodies and uses thereof
US11015229B2 (en)2014-07-212021-05-25Novellusdx Ltd.Methods and systems for determining oncogenic index of patient specific mutations
WO2021100034A1 (en)2019-11-192021-05-27Protalix Ltd.Removal of constructs from transformed cells
WO2021100041A1 (en)2019-11-202021-05-27Yeda Research And Development Co. Ltd.Treating alzheimer's disease
WO2021099576A1 (en)2019-11-212021-05-27INSERM (Institut National de la Santé et de la Recherche Médicale)Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
EP3831404A1 (en)2014-11-182021-06-09Humabs Biomed S.A.Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
WO2021110126A1 (en)2019-12-042021-06-10珠海泰诺麦博生物技术有限公司Antibody against human cytomegalovirus and use thereof
WO2021130753A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Diagnosis of frontotemporal dementia
WO2021130752A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Systems and methods for identifying cells that have undergone genome editing
WO2021137231A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
WO2021137230A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells and uses of same
WO2021137222A1 (en)2019-12-312021-07-08Ichilov Tech Ltd.Methods of treating atopic dermatitis
WO2021144798A1 (en)2020-01-152021-07-22Immunity Pharma Ltd.Peptide compounds and methods of treating diseases using same
WO2021149053A1 (en)2020-01-222021-07-29Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
WO2021152587A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Treating acute liver disease with tlr-mik inhibitors
WO2021152590A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Articles of manufacture comprising anti pd-l1 antibodies and their use in therapy
WO2021152584A1 (en)2020-01-282021-08-05Ariel Scientific Innovations Ltd.Methods of analyzing cell membranes
WO2021152586A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of analyzing microbiome, immunoglobulin profile and physiological state
WO2021152592A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of treating cancer
WO2021156878A2 (en)2020-02-092021-08-12Nlc Pharma LtdRapid detection test for sars-cov-2
US11091770B2 (en)2014-04-012021-08-17Monsanto Technology LlcCompositions and methods for controlling insect pests
WO2021161310A1 (en)2020-02-102021-08-19Yeda Research And Development Co. Ltd.Method for analyzing cell clusters
WO2021173674A1 (en)2020-02-262021-09-02A2 Biotherapeutics, Inc.Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
WO2021178637A1 (en)2020-03-052021-09-10Iowa State University Research Foundation, Inc.IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
WO2021186431A1 (en)2020-03-162021-09-23Yeda Research And Development Co. Ltd.Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
WO2021199039A1 (en)2020-03-292021-10-07Yeda Research And Development Co. Ltd.Variants of beta-glucocerebrosidase for use in treating gaucher disease
WO2021199047A1 (en)2020-03-312021-10-07Biomuse Ltd.Bacteria for the prevention and treatment of smoke-induced lung damage
WO2021205444A1 (en)2020-04-062021-10-14Yeda Research And Development Co. Ltd.Methods of diagnosing cancer and predicting responsiveness to therapy
WO2021205459A1 (en)2020-04-072021-10-14Ramot At Tel-Aviv University Ltd.Cannabidiol-containing compositions and uses thereof
EP3895697A1 (en)2020-04-162021-10-20Ichilov Tech Ltd.Cell-derived particles presenting heterologous cd24 and use thereof in therapy
WO2021209995A1 (en)2020-04-132021-10-21Exoprother Medical Ltd.Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy
GB202112866D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to fusarium wilt in a banana
GB202112865D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to black sigatoka disease in banana
WO2021229577A1 (en)2020-05-122021-11-18Collplant Ltd.Collagen as a delivery tool for metal-based anti-viral agents
WO2021228836A1 (en)2020-05-132021-11-18INSERM (Institut National de la Santé et de la Recherche Médicale)Recombinant proteins with ox40 activating properties
WO2021234698A1 (en)2020-05-202021-11-25Yeda Research And Development Co. Ltd.Indexing spatial information for a single-cell downstream applications
US11197915B2 (en)2013-10-212021-12-14Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2021260675A1 (en)2020-06-242021-12-30Yeda Research And Development Co. Ltd.Agents for sensitizing solid tumors to treatment
WO2021262840A1 (en)2020-06-242021-12-30Vir Biotechnology, Inc.Engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2022034588A1 (en)2020-08-102022-02-17Yeda Research And Development Co. Ltd.Compositions for diagnosis and treatment of coronavirus infections
WO2022034575A1 (en)2020-08-092022-02-17Yeda Research And Development Co. Ltd.Mage-a1 specific t cell receptor and uses thereof
WO2022038536A1 (en)2020-08-182022-02-24International Rice Research InstituteMethods of increasing outcrossing rates in gramineae
WO2022059015A1 (en)2020-09-212022-03-24Yeda Research And Development Co. Ltd.Method for modulating weight
WO2022064494A2 (en)2020-09-232022-03-31Yeda Research And Development Co. Ltd.Methods and compositions for treating coronaviral infections
WO2022070194A1 (en)2020-10-012022-04-07Yeda Research And Development Co. Ltd.Method of diagnosing breast cancer
WO2022074646A1 (en)2020-10-052022-04-14Protalix Ltd.Dicer-like knock-out plant cells
WO2022074656A1 (en)2020-10-072022-04-14Protalix Ltd.Long-acting dnase
WO2022079719A1 (en)2020-10-152022-04-21Yeda Research And Development Co. Ltd.Method of treating myeloid malignancies
WO2022091100A1 (en)2020-10-292022-05-05Yeda Research And Development Co. Ltd.Polynucleotides for rna editing and methods of using same
WO2022097157A2 (en)2020-11-092022-05-121E Therapeutics, Ltd.Catalytic sequence based methods of treating or preventing bacterial infections
WO2022115498A1 (en)2020-11-262022-06-02Ukko Inc.Modified high molecular weight glutenin subunit and uses thereof
WO2022130384A1 (en)2020-12-172022-06-23Yeda Research And Development Co. Ltd.Controlling ubiquitination of mlkl for treatment of disease
WO2022144882A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna target areas for silencing
WO2022144883A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna targeting dnazymes
WO2022149142A2 (en)2021-01-102022-07-14Supermeat The Essence Of Meat Ltd.Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
WO2022153286A1 (en)2021-01-142022-07-21Yeda Research And Development Co. Ltd.Methods of producing vitamin d
WO2022157774A1 (en)2021-01-212022-07-28Yeda Research And Development Co. Ltd.Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
WO2022164805A1 (en)2021-01-262022-08-04Vir Biotechnology, Inc.Compositions and methods for treating hepatitis b virus infection
US11413336B2 (en)2018-03-232022-08-16Board Of Regents, The University Of Texas SystemCoccidioides antigens and methods of their use
WO2022175952A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Method of generating vaccines
WO2022175951A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Genetically modified bacteria for generating vaccines
US11427647B2 (en)2014-04-272022-08-30Famewave Ltd.Polynucleotides encoding humanized antibodies against CEACAM1
US11433163B2 (en)2014-04-102022-09-06Bonus Therapeutics Ltd.Bone repair compositions
WO2022189558A2 (en)2021-03-102022-09-15Mabylon AgAntibodies against tdp-43 and methods of using the same
EP4059507A1 (en)2015-12-162022-09-21Ramot at Tel-Aviv University Ltd.Particles comprising decellularized omentum
WO2022195589A2 (en)2021-03-162022-09-22Yeda Research And Development Co. Ltd.Methods and devices for ex-utero mouse embryonic development
WO2022208369A1 (en)2021-03-302022-10-06Biomx Ltd.Pseudomonas bacteriophage and uses thereof
WO2022215080A1 (en)2021-04-082022-10-13Yeda Research And Development Co. Ltd.A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
WO2022238947A1 (en)2021-05-122022-11-17Biomx Ltd.Staphylococcus bacteriophage and uses thereof
WO2022254430A1 (en)2021-05-302022-12-08Yeda Research And Development Co. Ltd.Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease
WO2022259242A1 (en)2021-06-062022-12-15Yeda Research And Development Co. Ltd.Combined treatment for cancer
NL2028466B1 (en)2021-06-162022-12-21Sakata Holland B VMethods of sorting matthiola seeds
WO2022264132A1 (en)2021-06-132022-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming human cells
WO2022264076A1 (en)2021-06-162022-12-22Seedx Technologies Inc.Methods of sorting matthiola seeds
WO2023275255A1 (en)2021-07-022023-01-05Tropic Biosciences UK LimitedDelay or prevention of browning in banana fruit
US11547756B2 (en)2016-01-132023-01-10Medimmune, LlcMethod of treating influenza A
US11555199B2 (en)2017-09-192023-01-17Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
WO2023003809A1 (en)2021-07-182023-01-26Gamida-Cell Ltd.Therapeutic nk cell populations
WO2023002492A1 (en)2021-07-222023-01-26Yeda Research And Development Co. Ltd.Codon optimization of nucleic acids
US11571433B2 (en)2018-02-232023-02-07Carmel Haifa University Economic Corporation Ltd.Methods for treating memory impairment and cognitive dysfunction
EP4130028A1 (en)2021-08-032023-02-08Rhazes Therapeutics LtdEngineered tcr complex and methods of using same
WO2023012584A2 (en)2021-08-032023-02-09Genicity LimitedEngineered tcr complex and methods of using same
WO2023018621A1 (en)2021-08-102023-02-16Gamida-Cell Ltd.Engineered nk cells, methods of their production and uses thereof
WO2023042202A1 (en)2021-09-142023-03-23Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
US11648260B2 (en)2018-03-292023-05-16Technion Research And Development Foundation LimittedVesicles comprising a PTEN inhibitor and uses of same
WO2023105526A1 (en)2021-12-082023-06-15Yeda Research And Development Co. Ltd.Multipotent lung progenitor cells for lung regeneration
EP4218771A1 (en)2015-03-272023-08-02Yeda Research and Development Co. LtdMethods of treating motor neuron diseases
WO2023144779A1 (en)2022-01-282023-08-03Pfizer Inc.Coronavirus antigen variants
WO2023209708A1 (en)2022-04-252023-11-02Yeda Research And Development Co. Ltd.Compositions for altering cyclic adp-ribose secondary messenger signalling
US11807857B2 (en)2014-06-252023-11-07Monsanto Technology LlcMethods and compositions for delivering nucleic acids to plant cells and regulating gene expression
WO2023242155A1 (en)2022-06-142023-12-21Janssen Vaccines & Prevention B.V.Compositions and methods for the diagnosis of hiv infection
US12077569B2 (en)2020-06-222024-09-03Ramot At Tel-Aviv University Ltd.Multi subunit protein modules, cells expressing same and uses thereof
US12116416B2 (en)2012-03-302024-10-15The United States Government As Represented By The Department Of Veterans AffairsTargeting intracellular target-binding determinants with intracellular antibodies
EP4461356A2 (en)2017-10-242024-11-13Elani, DaliaMethods of treating an ischemic disease
EP4484956A2 (en)2020-01-292025-01-01MeMed Diagnostics Ltd.Methods of diagnosing and classifying viral infections
US12195531B2 (en)2013-03-212025-01-14Code Biotherapeutics, Inc.Cellular delivery of DNA intercalating agents
US12203113B2 (en)2009-07-092025-01-21Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2025017036A1 (en)2023-07-172025-01-23Institut National de la Santé et de la Recherche MédicaleAlphavirus nsp3 helical tubular scaffolds
WO2025027492A1 (en)2023-07-312025-02-06Pfizer Inc.Coronavirus antigen variants
EP4521115A2 (en)2020-06-102025-03-12Ramot at Tel-Aviv University Ltd.Methods of detecting methylated cpg
US12281328B2 (en)2017-02-082025-04-22Hadasit Medical Research Services And Development Ltd.Photoreceptor cells for the treatment of retinal diseases
US12338435B2 (en)2016-02-192025-06-24Code Biotherapeutics, Inc.Nucleic acid carriers and therapeutic methods of use
WO2025150045A1 (en)2024-01-122025-07-17Gabriel NussbaumBacterial targets, therapeutics, compositions, kits and methods of use in treating and/or preventing cancer
EP4610372A2 (en)2018-01-292025-09-03Lavie Bio Ltd.Plant microbial preparations, compositions and formulations comprising same and uses thereof
US12428637B2 (en)2017-08-082025-09-30Technology Innovation Momentum Fund (Israel) Limited PartnershipChloramphenicol resistant split protein and uses thereof
US12441776B2 (en)2019-11-272025-10-14Eirgen Pharma Ltd.Oxyntomodulin peptide analog formulations

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
SE388694B (en)*1975-01-271976-10-11Kabi Ab WAY TO PROVIDE AN ANTIGEN EXV IN SAMPLES OF BODY WHEATS, USING POROST BERAR MATERIAL BONDED OR ADSORBING ANTIBODIES
IN142734B (en)*1975-04-281977-08-20Miles Lab
GB1549069A (en)*1976-12-101979-08-01Erba FarmitaliaEnzyme linked immunoassay
IT1153999B (en)*1977-03-151987-01-21Snam Progetti COMPOSITION SUITABLE FOR DETERMINING TRIIODOTHYRONIN AND DIAGNOSTIC METHOD USING THE SAME
CA1108516A (en)*1977-11-211981-09-08Stanley E. CharmAntibiotic detection method
NZ190452A (en)*1978-05-191981-04-24Becton Dickinson CoSolid phase assay receptor contacted with analyte and then with labeled analyte
JPS54170918U (en)*1978-05-231979-12-03
US4273756A (en)*1978-07-281981-06-16Abbott LaboratoriesImmunoassay for class specific antibodies
US4292296A (en)*1978-09-121981-09-29Baxter Travenol Laboratories, Inc.Diagnostic method
US4446231A (en)*1979-10-031984-05-01Self Colin HImmunoassay using an amplified cyclic detection system
GB2059421A (en)*1979-10-031981-04-23Self C HAssay method and reagents therefor
JPS56143955A (en)*1980-04-101981-11-10Fujirebio IncMethod for diagnosis of initial infection of syphilis
DE3016575A1 (en)*1980-04-301981-11-05Merck Patent Gmbh, 6100 Darmstadt METHOD FOR THE IMMUNOLOGICAL DETERMINATION OF ENZYMES, MEANS FOR CARRYING OUT THE METHOD AND ITS RELATIONSHIP
NZ199286A (en)*1980-12-221986-05-09Commw Serum Lab CommissionA method of detecting antibodies or an antigenic or haptenic substance in a sample
JPS57193643U (en)*1981-06-031982-12-08
US4447528A (en)*1981-08-101984-05-08Corning Glass WorksDetecting intrinsic factor blocking site antibody
US4837395A (en)*1985-05-101989-06-06Syntex (U.S.A.) Inc.Single step heterogeneous assay

Citations (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3654090A (en)*1968-09-241972-04-04OrganonMethod for the determination of antigens and antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
SE341239B (en)*1967-09-061971-12-20Pharmacia Ab

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3654090A (en)*1968-09-241972-04-04OrganonMethod for the determination of antigens and antibodies
US3654090B1 (en)*1968-09-241982-07-20

Cited By (1412)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
USRE31006E (en)*1968-09-241982-08-03Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
US4203802A (en)*1971-05-141980-05-20Syva CompanyInhibitable enzyme amplification assay
US3875011A (en)*1972-11-061975-04-01Syva CoEnzyme immunoassays with glucose-6-phosphate dehydrogenase
US3904367A (en)*1973-08-151975-09-09Gen ElectricContrast enhancement for immunological film detection
US4039652A (en)*1973-10-111977-08-02Miles Laboratories, Inc.Column method of immunoassay employing an immobilized binding partner
US3951748A (en)*1974-11-111976-04-20Medical Products, Inc.Sensitized matrix for detection of disease
US4343896A (en)*1975-02-011982-08-10Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
US4016043A (en)*1975-09-041977-04-05Akzona IncorporatedEnzymatic immunological method for the determination of antigens and antibodies
USRE32696E (en)*1975-09-041988-06-14Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
FR2325934A1 (en)*1975-09-291977-04-22Cordis Corp METHOD OF DETECTION OF THE PRESENCE OF AN ANTIGEN ASSOCIATED WITH HEPATITIS
US4642285A (en)*1975-09-291987-02-10Diamedix CorporationSandwich EIA for antigen
US4474878A (en)*1975-09-291984-10-02Cordis Laboratories, Inc.Sandwich EIA for antigen associated with hepatitis
DE2643829A1 (en)*1975-09-291977-04-14Cordis Corp PROCEDURE FOR DETERMINING THE PRESENCE OF ANTIGENT ASSOCIATED WITH HEPATITIS
US4116776A (en)*1976-04-191978-09-26International Radioimmune Systems, Inc.Diagnostic blood test and kit for detecting human chorionic gonadotropin
US4248965A (en)*1976-10-071981-02-03Mochida Seiyaku Kabushiki KaishaImmunochemical process of measuring physiologically active substances
FR2367286A1 (en)*1976-10-071978-05-05Mochida Pharm Co Ltd NEW PROCESS AND REAGENTS FOR IMMUNOCHEMICAL DOSAGE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES
US4200508A (en)*1977-02-091980-04-29Hidematsu HiraiMethod and composition for detecting antigenic substances
US4302534A (en)*1977-03-161981-11-24Israel Institute For Biological ResearchChemiluminescent enzyme immunoassay
US4254223A (en)*1978-04-181981-03-03Akzona IncorporatedApparatus for colorimetric determination
US4240751A (en)*1978-11-091980-12-23Akzona IncorporatedMethod and apparatus for specific binding substances
US4318707A (en)*1978-11-241982-03-09Syva CompanyMacromolecular fluorescent quencher particle in specific receptor assays
US4374925A (en)*1978-11-241983-02-22Syva CompanyMacromolecular environment control in specific receptor assays
US4275149A (en)*1978-11-241981-06-23Syva CompanyMacromolecular environment control in specific receptor assays
US4331444A (en)*1979-03-011982-05-25Fuji Photo Film Co., Ltd.Competitive immunoassay using silver halide fogging agent
US4337063A (en)*1979-03-011982-06-29Fuji Photo Film Co., Ltd.Competitive immunoassay using spectral sensitizer label
US4269938A (en)*1979-03-081981-05-26Eastman Kodak CompanyAssay of peroxidatively active materials
WO1980002747A1 (en)*1979-05-311980-12-11Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
US4289748A (en)*1979-05-311981-09-15United States Of AmericaUltrasensitive enzymatic radioimmunoassay method
WO1981002792A1 (en)*1980-03-201981-10-01Res Triangle InstDetection of antibiotics in milk
US4362531A (en)*1980-04-151982-12-07Technicon Instruments CorporationAgglutination immunoassays carried out with agent to reduce non-specific interferences
US5610077A (en)*1980-06-201997-03-11Unilever Patent Holdings B.V.Processes and apparatus for carrying out specific binding assays
US6406920B1 (en)1980-06-202002-06-18Inverness Medical Switzerland GmbhProcesses and apparatus for carrying out specific binding assays
US6391563B1 (en)1980-07-282002-05-21Akzo Nobel N.V.Method for the determination of antigens with the aid of three or more monoclonal antibodies
US4376110A (en)*1980-08-041983-03-08Hybritech, IncorporatedImmunometric assays using monoclonal antibodies
US4486530A (en)*1980-08-041984-12-04Hybritech IncorporatedImmunometric assays using monoclonal antibodies
US4323647A (en)*1980-10-151982-04-06University Of MiamiSteric hindrance enzyme immunoassay
WO1982002601A1 (en)*1981-01-231982-08-05Hospital Supply Corp AmericanSolid phase system for ligand assay
US4517288A (en)*1981-01-231985-05-14American Hospital Supply Corp.Solid phase system for ligand assay
EP0060700A1 (en)*1981-03-131982-09-22Immuno-Mycologics, Inc.Assay method and device
US4446238A (en)*1981-03-191984-05-01Janssen Pharmaceutica N.V.Bright field light microscopic method of localizing tissue antigens
US4592995A (en)*1981-03-301986-06-03Dainippon Pharmaceutical Co., Ltd.Reagent for streptococcal anti-esterase assay
US4604365A (en)*1981-06-021986-08-05Electro-Nucleonics, Inc.Immunoprecipitation assay
WO1983000877A1 (en)*1981-08-311983-03-17Icl ScientGlucose oxidase immunohistochemical detection of antinuclear antibodies
US4452886A (en)*1981-09-211984-06-05Henry Robert PNovel photon absorbing or emitting polymers and their use as reagents in immunoassay systems
US4446232A (en)*1981-10-131984-05-01Liotta Lance AEnzyme immunoassay with two-zoned device having bound antigens
US4753875A (en)*1981-11-021988-06-28Ryan James WMethod for assaying proteases with tagged proteinaceous inhibitors
US4506009A (en)*1982-03-301985-03-19University Of CaliforniaHeterogeneous immunoassay method
US4469787A (en)*1982-05-141984-09-04Mallinckrodt Inc.Immunoassay involving soluble complex of second antibody and labeled binding protein
US4424279A (en)1982-08-121984-01-03QuidelRapid plunger immunoassay method and apparatus
WO1986004421A1 (en)*1982-08-201986-07-31Hygeia Sciences Limited PartnershipEnzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
US4503143A (en)*1982-08-201985-03-05Btc Diagnostics Limited PartnershipEnzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
US4530900A (en)*1982-09-131985-07-23Seragen Diagnostics Inc.Soluble insoluble polymers in enzymeimmunoassay
US5047330A (en)*1983-08-171991-09-10Commissariat A L'energie AtomiqueCompound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
WO1985002260A1 (en)*1983-11-081985-05-23QuidelRapid plunger immunoassay method and apparatus
US5534405A (en)*1984-03-081996-07-09The Scripps Research InstituteAntibodies, diagnostic systems and methods for assaying HBxAg
WO1985003950A1 (en)*1984-03-081985-09-12Scripps Clinic And Research FoundationA sv40 expression vector containing hbxag as an expression marker
WO1985004397A1 (en)1984-03-231985-10-10OncogenPlatelet related growth regulator
US4665020A (en)*1984-05-301987-05-12United States Department Of EnergyFlow cytometer measurement of binding assays
US4812395A (en)*1984-11-051989-03-14E. I. Du Pont De Nemours And CompanyMethod for detecting enzymatic activity using particle agglutination
US4812396A (en)*1984-11-051989-03-14E. I. Du Pont De Nemours And CompanyMethod for detecting enzymatic activity using particle agglutination
US4713347A (en)*1985-01-141987-12-15Sensor Diagnostics, Inc.Measurement of ligand/anti-ligand interactions using bulk conductance
US4824784A (en)*1985-04-081989-04-25Hygeia Sciences, IncorporatedChromogenic solution for immunoassay
US4931385A (en)*1985-06-241990-06-05Hygeia Sciences, IncorporatedEnzyme immunoassays and immunologic reagents
US4868108A (en)*1985-12-121989-09-19Hygeia Sciences, IncorporatedMultiple-antibody detection of antigen
US4808522A (en)*1986-04-241989-02-28Moskovsky Gosudarstvennx Universitet Imeni M. V. Lomonoso VAEnzyme immunoassays using inorganic pyrophosphatase
US5624809A (en)*1988-05-171997-04-29Behringwerke AgDevice for immunochromatographic analysis
US5451507A (en)*1988-05-171995-09-19Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5334513A (en)*1988-05-171994-08-02Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5468647A (en)*1988-05-171995-11-21Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5102788A (en)*1988-11-211992-04-07Hygeia Sciences, Inc.Immunoassay including lyophilized reactant mixture
US5328828A (en)*1988-12-231994-07-12Syntex (U.S.A.) Inc.Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
US5614504A (en)*1990-08-011997-03-25The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5726015A (en)*1991-05-151998-03-10Vanderbilt UniversityMethod to determine metastatic potential of tumor cells
US5348867A (en)*1991-11-151994-09-20George GeorgiouExpression of proteins on bacterial surface
US5874423A (en)*1992-09-101999-02-23Yissum Research Development Co. Of The Hebrew University Of JerusalemDigitalis-like compounds
US8524491B2 (en)1993-03-172013-09-03University Of Washington Through Its Center For CommercializationCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US7247703B2 (en)1993-03-172007-07-24University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7655239B2 (en)1993-03-172010-02-02University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5801005A (en)*1993-03-171998-09-01University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US7601697B2 (en)1993-03-172009-10-13University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US6664370B2 (en)1993-03-172003-12-16University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6953573B1 (en)1993-03-172005-10-11University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050191285A1 (en)*1993-03-172005-09-01University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5846538A (en)*1993-03-171998-12-08University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US20080076904A1 (en)*1993-03-172008-03-27University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en)*1993-03-171999-02-09University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US5726023A (en)*1993-03-171998-03-10University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5876712A (en)*1993-03-171999-03-02University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20040082758A1 (en)*1993-03-172004-04-29University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6075122A (en)*1993-03-172000-06-13University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5672475A (en)*1993-05-061997-09-30Chiron Diagnostics CorporationMixed luminescent conjugate test
US5837535A (en)*1994-06-131998-11-17Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5698686A (en)*1994-10-201997-12-16Arch Development CorporationYeast telomerase compositions
US5916752A (en)*1994-10-201999-06-29Arch Development CorporationTelomerase screening methods
US6387619B1 (en)1994-10-202002-05-14Arch DevelopmentTelomerase compositions and methods
US6531277B2 (en)1994-10-252003-03-11The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US5843673A (en)*1994-10-251998-12-01Curators Of The University Of MissouriMethod of screening for endometriosis
US20030152909A1 (en)*1994-11-162003-08-14Mitrani Eduardo N.In vitro micro-organs, and uses related thereto
US5858661A (en)*1995-05-161999-01-12Ramot-University Authority For Applied Research And Industrial DevelopmentAtaxia-telangiectasia gene and its genomic organization
US6200749B1 (en)1995-05-162001-03-13Ramot-University Authority For Applied Research And Industrial Development Ltd.Mutated forms of the ataxia-telangiectasia gene and method to screen for a partial A-T phenotype
US5728807A (en)*1995-05-161998-03-17Ramot-University Authority For Applied Research And Industrial Development, Ltd.Mutated proteins associated with ataxia-telangiectasia
US5777093A (en)*1995-05-161998-07-07Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
WO1997005886A1 (en)*1995-08-041997-02-20Board Of Regents, The University Of Texas SystemCompositions for conferring immunogenicity to a peptide
US5807552A (en)*1995-08-041998-09-15Board Of Regents, The University Of Texas SystemCompositions for conferring immunogenicity to a substance and uses thereof
US6689757B1 (en)1996-02-122004-02-10M.L. Laboratories PlcMethods for vaccination and vaccines therefor
US20060008479A1 (en)*1996-04-012006-01-12University Of WashingtonMethods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6331275B1 (en)1996-07-082001-12-18Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US6342349B1 (en)1996-07-082002-01-29Burstein Technologies, Inc.Optical disk-based assay devices and methods
US20050069923A1 (en)*1996-07-082005-03-31Mullis Kary BanksDual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US20050214827A1 (en)*1996-07-082005-09-29Burstein Technologies, Inc.Assay device and method
US6312901B2 (en)1996-07-082001-11-06Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US20020106661A1 (en)*1996-07-082002-08-08Burstein Laboratories, Inc.Optical disk-based assay devices and methods
US5840322A (en)*1996-12-191998-11-24Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
US20030124116A1 (en)*1997-08-212003-07-03Quark Biotech, Inc.Hypoxia-regulated genes
US6740738B2 (en)1997-08-212004-05-25Quark Biotech, Inc.Antibody against hypoxia proteins
US6610838B1 (en)1997-09-102003-08-26Symbicom AktiebolagP13 antigens from Borrelia
US6284496B1 (en)1997-10-032001-09-04University Of South FloridaDNA vector for determining the presence of out-of-reading-frame mutations
US6482389B1 (en)1997-10-172002-11-19University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US7687057B2 (en)1998-01-092010-03-30Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
US8202724B2 (en)1998-02-172012-06-19Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US7855075B2 (en)1998-02-172010-12-21Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US20090004158A1 (en)*1998-02-172009-01-01Tony PeledMethods of controlling proliferation and differentiation of stem and progenitor cells
US20110045589A1 (en)*1998-02-172011-02-24Gamida Cell Ltd.Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
US6344443B1 (en)1998-07-082002-02-05University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US7605149B1 (en)1998-07-132009-10-20University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
US7347972B1 (en)1998-07-222008-03-25Jin Po LeeMultiple analyte assay device
US6187563B1 (en)1998-08-072001-02-13Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US6656471B1 (en)1998-11-172003-12-02Board Of Regents, The University Of Texas SystemHIV-specific T-cell induction
US7306804B2 (en)1998-11-172007-12-11Board Of Regents, The University Of Texas SystemHIV-specific T-cell induction
US20050032039A1 (en)*1998-11-172005-02-10Sastry K. JagannadhaHIV-specific T-cell induction
EP2311938A1 (en)1999-02-042011-04-20Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7678573B2 (en)1999-02-042010-03-16Pluristem Ltd.Method of preparing a conditioned medium from a confluent stromal cell culture
EP2208782A2 (en)1999-02-042010-07-21Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050181504A1 (en)*1999-02-042005-08-18Technion Research & DevelopmentMethod and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050180958A1 (en)*1999-02-042005-08-18Technion Research & Development Foundation Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US7534609B2 (en)1999-02-042009-05-19Pluristem Life Systems Inc.Method of expanding undifferentiated hemopoietic stem cells
US20050176137A1 (en)*1999-02-042005-08-11Technion Research & Development Foundation Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050176143A1 (en)*1999-02-042005-08-11Technion Research & DevelopmentMethod and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US6440682B1 (en)*1999-05-282002-08-27Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US6787318B1 (en)1999-06-012004-09-07Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20050089939A1 (en)*1999-06-012005-04-28Jun TanAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20060019340A1 (en)*1999-06-082006-01-26David NaorCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US8193311B2 (en)1999-06-082012-06-05Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US7534605B2 (en)1999-06-082009-05-19Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20030086914A1 (en)*1999-06-252003-05-08Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organs
US20060127366A1 (en)*1999-06-252006-06-15Mitrani Eduardo NMethod and device for inducing biological processes by micro-organs
US6875582B1 (en)1999-08-192005-04-05Omniscience Pharmaceuticals, Inc.Methods and targets of antibiotic resistance
US20050113327A1 (en)*1999-08-302005-05-26Levava RoizMethods of and compositions for inhibiting the proliferation of mammalian cells
US8236543B2 (en)1999-08-302012-08-07Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US7811981B2 (en)1999-08-302010-10-12Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US20110008314A1 (en)*1999-08-302011-01-13Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US7101839B1 (en)1999-08-302006-09-05Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8617867B2 (en)1999-08-302013-12-31Yissum Research Develpment Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US8735127B2 (en)1999-08-302014-05-27Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US6998232B1 (en)1999-09-272006-02-14Quark Biotech, Inc.Methods of diagnosing bladder cancer
US10359573B2 (en)1999-11-052019-07-23Board Of Regents, The University Of Texas SystemResonant waveguide-granting devices and methods for using same
US7223902B1 (en)1999-11-192007-05-29Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US20070292930A1 (en)*1999-11-192007-12-20Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger beta-glucosidase and an aroma spreading plant
US20070264274A1 (en)*2000-01-052007-11-15Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US7270810B2 (en)2000-01-052007-09-18Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20030211490A1 (en)*2000-01-242003-11-13Hanan SteinPlants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US7385106B2 (en)2000-01-242008-06-10Ramot At Tel Aviv University Ltd.Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US9095533B2 (en)2000-03-272015-08-04Technion Research & Development Foundation LimitedAntigen-presenting complex-binding compositions and uses thereof
EP2316950A1 (en)2000-03-272011-05-04Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20030104491A1 (en)*2000-04-302003-06-05Cabantchik Ioav ZviMolecules and methods using same for measuring non-transferrin bound iron
US8088160B2 (en)2000-07-202012-01-03Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
EP2359854A1 (en)2000-08-082011-08-24Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359853A1 (en)2000-08-082011-08-24Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
US20030114410A1 (en)*2000-08-082003-06-19Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1683874A2 (en)2000-08-292006-07-26YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US20070281037A9 (en)*2000-09-282007-12-06Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US7632522B2 (en)2000-09-282009-12-15Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US8062660B2 (en)2000-09-282011-11-22Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060159769A1 (en)*2000-09-282006-07-20Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060099273A1 (en)*2000-09-282006-05-11Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20070160546A1 (en)*2000-09-282007-07-12Tamar LotanUse of stinging cells/capsules for the delivery of active agents to keratinous substances
US7060462B2 (en)2000-11-022006-06-13National University Of SingaporeAopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
US20040076976A1 (en)*2000-11-022004-04-22Pan Shen QuanAopb gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
EP2186530A1 (en)2000-11-172010-05-19Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
EP2425841A1 (en)2000-11-242012-03-07Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
US20030003464A1 (en)*2000-11-272003-01-02Phan Brigitte C.Dual bead assays including optical biodiscs and methods relating thereto
US20020172980A1 (en)*2000-11-272002-11-21Phan Brigitte ChauMethods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20040248093A1 (en)*2000-11-272004-12-09Coombs James HowardMagneto-optical bio-discs and systems including related methods
EP2357478A2 (en)2000-11-302011-08-17Crawford Healthcare Holdings LimitedDiagnosis of disease
WO2002044736A2 (en)2000-11-302002-06-06Molecular Skincare LimitedDiagnosis and treatment of epidermal or skin diseases
US20040052769A1 (en)*2000-11-302004-03-18Yair ReisnerMethods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20020142287A1 (en)*2000-12-142002-10-03Hirotaka YamamotoHigh throughput assay to detect inhibitors of the map kinase pathway
US7087395B1 (en)2001-01-162006-08-08Quest Diagnostics Investments IncorporatedVitamin D assay
US20050202098A1 (en)*2001-01-312005-09-15TolarenDisease therapy using dying or dead cells
US20050031618A1 (en)*2001-01-312005-02-10Dror MevorachInduction of tolerance by apoptotic and/or necrotic cells
EP2308994A1 (en)2001-03-232011-04-13Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
US7033747B2 (en)2001-04-112006-04-25Nagaoka & Co., LtdMulti-parameter assays including analysis discs and methods relating thereto
US6770622B2 (en)2001-06-082004-08-03Gary A. JarvisN-terminally truncated galectin-3 for use in treating cancer
US20050022269A1 (en)*2001-07-192005-01-27Joseph HirschbergPolypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US7442781B2 (en)2001-08-162008-10-28Urifer Ltd.Diagnosis, prevention and treatment of cancer
US20030064058A1 (en)*2001-09-072003-04-03Nadir AskenasyMethods of utilizing bone marrow stem cells for inducing immunological tolerance
US7138144B2 (en)2001-09-072006-11-21Nadir AskenasyMethod of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US8415318B2 (en)2001-10-192013-04-09Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US20100088037A1 (en)*2001-10-232010-04-08Epipop Pty Ltd.Method for Identification and Development of Therapeutic Agents
US20060257865A1 (en)*2001-10-232006-11-16Simon MallalMethod for identification and development of therapeutic agents
US6867005B2 (en)2001-10-242005-03-15Beckman Coulter, Inc.Method and apparatus for increasing the dynamic range and accuracy of binding assays
WO2003046201A2 (en)2001-11-212003-06-05Kimberly-Clark Worldwide, Inc.Detection and identification of enteric bacteria
US20060051426A1 (en)*2001-12-052006-03-09Gershon GolombNanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US8178128B2 (en)2001-12-052012-05-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Nanoparticles containing polymeric nucleic acid homologs
US20050085432A1 (en)*2001-12-262005-04-21Aviva LapidotMethods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20050008624A1 (en)*2002-01-242005-01-13Tony PeledExpansion of renewable stem cell populations
US20110033427A1 (en)*2002-01-242011-02-10Gamida Cell Ltd.Expansion Of Renewable Stem Cell Populations
EP2305794A1 (en)2002-01-242011-04-06Gamida Cell Ltd.Expansion of renewable stem cell populations
US7955852B2 (en)2002-01-242011-06-07Gamida Cell Ltd.Expansion of renewable stem cell populations
US7655225B2 (en)2002-01-252010-02-02Gamida Cell, Ltd.Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20080279828A1 (en)*2002-01-252008-11-13Tony PeledMethods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20100022459A1 (en)*2002-01-312010-01-28Tel Aviv University Future Technology Development L.PPeptides directed for diagnosis and treatment of amyloid-associated diseases
US8697634B2 (en)2002-01-312014-04-15Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US8012929B2 (en)2002-01-312011-09-06Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated diseases
US20100105608A1 (en)*2002-01-312010-04-29Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20060234947A1 (en)*2002-01-312006-10-19Tel Aviv University Future Technology Development L.PPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US8993510B2 (en)2002-01-312015-03-31Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US7781396B2 (en)2002-01-312010-08-24Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated disease
US20050287141A1 (en)*2002-02-132005-12-29Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2329814A1 (en)2002-02-132011-06-08Technion Research and Development Foundation, Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer
US20050255101A1 (en)*2002-02-132005-11-17Technion Research And Development Foundation Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US6992176B2 (en)2002-02-132006-01-31Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2072045A2 (en)2002-02-132009-06-24Technion Research and Development Foundation, Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20100228007A1 (en)*2002-02-202010-09-09Technion Research & Development Foundation Ltd.Mhc-peptide complex binding ligands
US20070196369A1 (en)*2002-02-202007-08-23Hoogenboom Henricus Renerus JMHC-peptide complex binding ligands
US7718777B2 (en)2002-02-202010-05-18Technion Research & Development Foundation Ltd.MHC-peptide complex binding ligands
EP2508596A2 (en)2002-02-212012-10-10Bayer HealthcareMN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
EP3031910A1 (en)2002-02-212016-06-15Institute Of VirologyMn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
US20050220774A1 (en)*2002-03-182005-10-06Tony PeledMethods of inducing differentiation in ex vivo expanded stem cells
US7611723B2 (en)2002-03-262009-11-03Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060039897A1 (en)*2002-03-262006-02-23Tamar LotanStinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20050158809A1 (en)*2002-04-162005-07-21The Regents Of The University Of CaliforinaMethods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
US8936914B2 (en)2002-04-162015-01-20The Regents Of The University Of CaliforniaMethods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
US20040121442A1 (en)*2002-05-052004-06-24Ilan ChetFungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
EP2561889A2 (en)2002-08-012013-02-27Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2004018698A2 (en)2002-08-202004-03-04Genitrix, LlcLectin compositions and methods for modulating an immune response to an antigen
US20090209041A1 (en)*2002-09-062009-08-20Tel Aviv University Future Technology Development L.P.Peptides and methods for inhibiting amyloid formation
US8563273B2 (en)2002-09-062013-10-22Tel Aviv University Future Technology Development L.P.Method of screening for compounds that disaggregate amyloid aggregates
EP2182052A1 (en)2002-10-072010-05-05Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
US20040146949A1 (en)*2002-10-252004-07-29Jun TanMethods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
EP2295980A1 (en)2002-10-302011-03-16Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
US20050054097A1 (en)*2002-11-172005-03-10Tony PeledEX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
EP2062919A2 (en)2002-11-272009-05-27Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US8815823B2 (en)2002-11-272014-08-26Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US8168180B2 (en)2002-11-272012-05-01Technion Research & Development Foundation Ltd.Methods and compositions for modulating angiogenesis
US8163494B2 (en)2002-11-272012-04-24Technion Research & Development Foundation Ltd.Method for assessing metastatic properties of breast cancer
EP2062918A2 (en)2002-11-272009-05-27Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20060127402A1 (en)*2002-11-272006-06-15Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20100119515A1 (en)*2002-11-272010-05-13Gera NeufeldPharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20110027887A1 (en)*2002-11-292011-02-03Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US7947499B2 (en)2002-11-292011-05-24Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US20060148078A1 (en)*2002-11-292006-07-06Sharon Gerecht-NirMethod of dynamically culturing embryonic stem cells
US8053554B2 (en)2002-12-092011-11-08Ramot At Tel-Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US20090123553A1 (en)*2002-12-092009-05-14Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
EP2338896A2 (en)2002-12-122011-06-29R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
EP2457999A2 (en)2002-12-162012-05-30Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
EP2292762A2 (en)2002-12-202011-03-09Board of Regents, The University of Texas SystemVMP-like sequences of pathogenic Borrelia species and strains
WO2004060135A2 (en)2003-01-022004-07-22Rappaport Family Institute For Research In The Medical SciencesMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US20090121709A1 (en)*2003-01-072009-05-14Ramot At Tel Aviv University Ltd.Peptide nanostructures encapsulating A foreign material and method of manufacturing same
EP2058275A1 (en)2003-01-072009-05-13Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US8017586B2 (en)2003-01-072011-09-13Ramot At Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US20050032126A1 (en)*2003-03-032005-02-10Coombs James H.Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
EP2319857A2 (en)2003-03-042011-05-11Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
EP2216033A2 (en)2003-03-062010-08-11Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
US20050054103A1 (en)*2003-03-072005-03-10Tony PeledExpansion of renewable stem cell populations using modulators of PI 3-kinase
US20100080805A1 (en)*2003-03-262010-04-01Technion Research & DevelopmentCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7632923B2 (en)2003-03-262009-12-15Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US9023348B2 (en)2003-03-262015-05-05Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060083735A1 (en)*2003-03-262006-04-20Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US7638124B2 (en)2003-03-262009-12-29Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US20050152912A1 (en)*2003-03-262005-07-14Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US9616112B2 (en)2003-03-262017-04-11Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20040197334A1 (en)*2003-04-022004-10-07Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US7294701B2 (en)2003-04-022007-11-13Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
EP2330132A1 (en)2003-04-042011-06-08Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US8252588B2 (en)2003-04-082012-08-28Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
US9463241B2 (en)2003-04-092016-10-11Laboratoire Francais Du Fractionnement Et Des BiotechnologiesMethod for stabilising an immunoglobulin G composition in liquid form
US8388954B2 (en)2003-04-092013-03-05Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
US7355079B2 (en)2003-04-182008-04-08The Regents Of The University Of CaliforniaThyronamine derivatives and analogs and methods of use thereof
US20060035980A1 (en)*2003-04-182006-02-16Scanlan Thomas SThyronamine derivatives and analogs and methods of use thereof
US20050002953A1 (en)*2003-05-062005-01-06Jens HeroldSARS-coronavirus virus-like particles and methods of use
US9303269B2 (en)2003-05-222016-04-05Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US7554007B2 (en)2003-05-222009-06-30Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US8481812B2 (en)2003-05-222013-07-09Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants generated thereby
US20060123516A1 (en)*2003-05-222006-06-08Gil RonenMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2365087A2 (en)2003-05-222011-09-14Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US10184132B2 (en)2003-05-222019-01-22Evogene Ltd.Methods of increasing abiotic stress tolerance, yield and/or biomass in plants
US20090260109A1 (en)*2003-05-222009-10-15Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants genterated thereby
US9567579B2 (en)2003-05-232017-02-14Board Of Regents, The University Of Texas SystemStructure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
US20050020499A1 (en)*2003-05-272005-01-27Bar Ilan UniversityMethods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20090253170A1 (en)*2003-06-192009-10-08Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US8129514B2 (en)2003-06-192012-03-06Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7498428B2 (en)2003-06-192009-03-03Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20060260002A1 (en)*2003-06-192006-11-16Gil RonenNucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
EP2719394A1 (en)2003-06-302014-04-16Tel Aviv University Future Technology Development L.P.Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases
US20110229495A1 (en)*2003-07-072011-09-22Wagner David HMethods for predicting development of auto-immune diseases and treatment of same
EP2540301A2 (en)2003-07-152013-01-02Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2540302A1 (en)2003-07-152013-01-02Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526952A1 (en)2003-07-152012-11-28Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526953A1 (en)2003-07-152012-11-28Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
US20050271643A1 (en)*2003-08-142005-12-08Iryna SorokulovaBacterial strains, compositions including same and probiotic use thereof
US7625707B2 (en)2003-10-022009-12-01Ramot At Tel Aviv University Ltd.Antibacterial agents and methods of identifying and utilizing same
EP2354164A1 (en)2003-10-072011-08-10Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2322561A1 (en)2003-10-072011-05-18Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
WO2005033142A2 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Anti-nik antibodies and uses thereof
WO2005033145A1 (en)2003-10-072005-04-14Yeda Research And Development Co. Ltd.Antibodies to nik, their preparation and use
US20060257429A1 (en)*2003-10-232006-11-16Dreier Kimberly JVaccine for periodontal disease
EP2301575A1 (en)2003-11-042011-03-30Novartis Vaccines and Diagnostics, Inc.Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
EP2248830A1 (en)2003-11-042010-11-10Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP2243492A1 (en)2003-11-042010-10-27Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2149585A1 (en)2003-11-042010-02-03Novartis Vaccines and Diagnostics, Inc.Antagonist anti-CD40 monoclonal antibodies and methods for their use
EP2243491A1 (en)2003-11-042010-10-27Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
WO2005051423A2 (en)2003-11-302005-06-09Yeda Research And Development Co. LtdMethods and agents for immune modulation and methods for identifying immune modulators
US7790673B2 (en)2003-12-122010-09-07New York UniversityMethods and compositions relating to cystatin C
US20070032421A1 (en)*2003-12-122007-02-08Efrat LevyMethods and compositions relating to cystatin C
US20100221233A1 (en)*2003-12-152010-09-02University Of South FloridaCompositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
EP2289567A2 (en)2003-12-222011-03-02Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
US8007847B2 (en)2004-01-132011-08-30Eytan BidermanFeeding formula appliance
US20060278093A1 (en)*2004-01-132006-12-14Eytan BidermanFeeding formula appliance
US7893240B2 (en)2004-01-202011-02-22Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20080312179A1 (en)*2004-01-202008-12-18Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20050158822A1 (en)*2004-01-202005-07-21Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US7423139B2 (en)2004-01-202008-09-09Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20110091454A1 (en)*2004-01-272011-04-21Alex DiberMethods and systems for annotating biomolecular sequences
EP3006039A1 (en)2004-03-022016-04-13Acceleron Pharma Inc.Alk7 polypeptides for use in promoting fat loss
US8352031B2 (en)2004-03-102013-01-08Impulse Dynamics NvProtein activity modification
US20100281571A1 (en)*2004-06-142010-11-04Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090126042A1 (en)*2004-06-142009-05-14Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2343373A1 (en)2004-06-142011-07-13Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US9012728B2 (en)2004-06-142015-04-21Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8962915B2 (en)2004-06-142015-02-24Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
EP2336330A2 (en)2004-06-142011-06-22Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20080004234A1 (en)*2004-07-062008-01-03Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US8680062B2 (en)2004-07-062014-03-25Deliversir Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US20090156471A1 (en)*2004-07-152009-06-18Ramot At Tel Aviv University Ltd.Use of anti-amyloid agents for treating and typing pathogen infections
US20110201035A1 (en)*2004-09-082011-08-18The United States Of America As Represented By The Secretary Of Health And Human Services, NihCompositions and methods for the detection of hiv-1/hiv-2 infection
EP2295973A1 (en)2004-09-082011-03-16THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesCompositions and methods for the detection of HIV-1/HIV-2 infection.
US20110151436A1 (en)*2004-09-082011-06-23The Government of the United States of America as represented by the Secretary, Dept. of HealthCompositions and methods for the detection of hiv-1/hiv-2 infection
EP2309269A1 (en)2004-09-082011-04-13THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESCompositions and methods for the detection of HIV-1/HIV-2 infection.
US9121855B2 (en)2004-09-082015-09-01The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMethod for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
US7888003B2 (en)2004-09-082011-02-15The United States Of America As Represented By The Department Of Health And Human ServicesMethods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
US8722324B2 (en)2004-09-082014-05-13The United States Of America, As Represented By The Secretary Department Of Health And Human ServicesMethods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
EP2295974A1 (en)2004-09-082011-03-16THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESCompositions and methods for the detection of HIV-1/HIV-2 infection
US20070077652A1 (en)*2004-09-162007-04-05Tony PeledMethods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8080417B2 (en)2004-09-162011-12-20Gamida-Cell Ltd.Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
US8000900B2 (en)2004-09-212011-08-16Microsoft CorporationAssociation-based predictions of pathogen characteristics
EP3088528A1 (en)2004-09-292016-11-02Collplant Ltd.Collagen producing plants and methods of generating and using same
EP2816117A2 (en)2004-09-292014-12-24Collplant Ltd.Collagen producing plants and methods of generating and using same
US20080131419A1 (en)*2004-09-292008-06-05Yissum Research Development Company Of The Hebrew University Of JerusalemRecombinant Human T2 Rnase and Uses Thereof
US8039240B2 (en)2004-09-292011-10-18Yissum Reseach Development Company Of The Hebrew University Of JerusalemRecombinant human T2 RNase and uses thereof
US7781402B2 (en)2004-10-122010-08-24Closed Loop Therapies Ltd.Methods and implantable devices for treating supraventricular arrhythmias
US20060079941A1 (en)*2004-10-122006-04-13Eli OvsyshcherMethods and implantable devices for treating supraventricular arrhythmias
US20110040248A1 (en)*2004-10-122011-02-17Closed Loop Therapies BvMethods and implantable devices for treating supraventricular arrhythmias
US20060095241A1 (en)*2004-10-292006-05-04Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8478535B2 (en)2004-10-292013-07-02Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060190226A1 (en)*2004-10-292006-08-24Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20090118132A1 (en)*2004-11-042009-05-07Roche Molecular Systems, Inc.Classification of Acute Myeloid Leukemia
EP2174668A2 (en)2004-11-142010-04-14Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20060134680A1 (en)*2004-12-222006-06-22Alexander KotlyarHomogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US8375327B2 (en)2005-01-162013-02-12Zlango Ltd.Iconic communication
US20080082678A1 (en)*2005-01-162008-04-03Zlango Ltd.Communications Network System and Methods for Using Same
US20080216022A1 (en)*2005-01-162008-09-04Zlango Ltd.Iconic Communication
US20090013087A1 (en)*2005-01-182009-01-08Zlango Ltd.Communications Network System and Methods For Using Same
US8019818B2 (en)2005-01-182011-09-13Zlango Ltd.Communications network system and methods for using same
US10335783B2 (en)2005-01-312019-07-02Realbio Technologies, Ltd.Multistep reaction lateral flow capillary device
EP2316441A1 (en)2005-02-172011-05-04Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
WO2006090388A2 (en)2005-02-252006-08-31The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterFruit cell culture extract for treating inflammation
US7695927B2 (en)2005-03-182010-04-13Detroit R & DDetection of hypertension using glucuronidated metabolic products
US20060211064A1 (en)*2005-03-182006-09-21Hyesook KimDetection of hypertension using glucuronidated metabolic products
US20090068207A1 (en)*2005-04-152009-03-12Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US8834862B2 (en)2005-04-192014-09-16Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060234203A1 (en)*2005-04-192006-10-19Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US9567568B2 (en)2005-05-042017-02-14Enlivex Therapeutics Ltd.Method of preparing apoptotic monocytes
EP2312315A1 (en)2005-05-182011-04-20Novartis AGMethods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
EP2279726A2 (en)2005-05-262011-02-02Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2006134602A2 (en)2005-06-162006-12-21Ramot At Tel Aviv University Ltd.Isolated cells and populations comprising same for the treatment of cns diseases
EP2465924A2 (en)2005-06-162012-06-20Ramot at Tel-Aviv University Ltd.Isolated cells and populations comprising same for the treament of cns diseases
US20070225242A1 (en)*2005-06-212007-09-27The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
US20060292559A1 (en)*2005-06-232006-12-28Beckman Coulter, Inc.Cell-based microarrays, and methods for their preparation and use
US8067574B2 (en)2005-07-072011-11-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19, and methods of using same
US20090143321A1 (en)*2005-07-072009-06-04Avraham HochbergNucleic acid agents for downregulating h19 and methods of using same
EP2487182A2 (en)2005-07-072012-08-15FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
US8067573B2 (en)2005-07-072011-11-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19 and methods of using same
EP2441840A1 (en)2005-07-182012-04-18Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2484768A2 (en)2005-07-182012-08-08Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2889041A1 (en)2005-07-262015-07-01Rutgers, The State University of New JerseyKit of reagents for tuberculosis assay
US8642330B2 (en)2005-08-082014-02-04Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20100068135A1 (en)*2005-08-082010-03-18Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
WO2007020638A2 (en)2005-08-152007-02-22Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2995194A1 (en)2005-08-152016-03-16Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US9487796B2 (en)2005-08-152016-11-08Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US7910800B2 (en)2005-08-152011-03-22Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20090089898A1 (en)*2005-08-152009-04-02Hagai KarchiMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20110126323A1 (en)*2005-08-152011-05-26Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A2 (en)2005-08-242007-03-01Yeda Research And Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP2514315A2 (en)2005-08-242012-10-24Yeda Research and Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP3354723A1 (en)2005-08-292018-08-01Technion Research & Development Foundation Ltd.Media for culturing stem cells
WO2007031996A1 (en)2005-09-122007-03-22Rappaport Family Institute For Research In The Medical SciencesCompositions and methods for diagnosing and treating an inflammation
US20090221681A1 (en)*2005-09-222009-09-03Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US8034914B2 (en)2005-09-222011-10-11Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2007034487A1 (en)2005-09-222007-03-29Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20070087437A1 (en)*2005-10-142007-04-19Jifan HuMethods for rejuvenating cells in vitro and in vivo
EP2716654A1 (en)2005-10-242014-04-09Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US8846393B2 (en)2005-11-292014-09-30Gamida-Cell Ltd.Methods of improving stem cell homing and engraftment
EP2390312A1 (en)2005-11-292011-11-30Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
US8775526B2 (en)2006-01-162014-07-08Zlango Ltd.Iconic communication
EP2368570A2 (en)2006-01-182011-09-28University Of ChicagoCompositions and methods related to staphylococcal bacterium proteins
EP2368569A2 (en)2006-01-182011-09-28University Of ChicagoCompositions and methods related to staphylococcal bacterium proteins
US7553941B2 (en)2006-02-032009-06-30Modigene IncLong-acting polypeptides and methods of producing same
US7553940B2 (en)2006-02-032009-06-30Modigene IncLong-acting EPO polypeptides and derivatives thereof and methods thereof
US10119132B2 (en)2006-02-032018-11-06Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US8465948B2 (en)2006-02-032013-06-18Prolor Biotech Ltd.Long-acting veterinary polypeptides and methods of producing and administering same
US8450269B2 (en)2006-02-032013-05-28Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
EP2471807A1 (en)2006-02-032012-07-04Modigene IncLong-acting polypeptides and methods of producing and administering same
WO2007094985A2 (en)2006-02-032007-08-23Modigene IncLong-acting polypeptides and methods of producing and administering same
US8426166B2 (en)2006-02-032013-04-23Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
US8999670B2 (en)2006-02-032015-04-07Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US9884901B2 (en)2006-02-032018-02-06Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
EP3202779A2 (en)2006-02-032017-08-09OPKO Biologics Ltd.Long-acting hgh polypeptides and uses thereof
US10144921B2 (en)2006-02-032018-12-04Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US9458444B2 (en)2006-02-032016-10-04Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
EP2853541A1 (en)2006-02-032015-04-01OPKO Biologics Ltd.Long-acting polypeptides and uses thereof
US20070190610A1 (en)*2006-02-032007-08-16Fuad FaresLong-acting EPO polypeptides and derivatives thereof and methods thereof
US20070190611A1 (en)*2006-02-032007-08-16Fuad FaresLong-acting polypeptides and methods of producing same
US8759292B2 (en)2006-02-032014-06-24Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
EP2853536A1 (en)2006-02-032015-04-01OPKO Biologics Ltd.Long-acting erythropoietin polypeptides and uses thereof
US8946155B2 (en)2006-02-032015-02-03Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
EP3663312A1 (en)2006-02-032020-06-10OPKO Biologics Ltd.Long-acting polypeptides and uses thereof
US10221228B2 (en)2006-02-032019-03-05Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US11066658B2 (en)2006-02-032021-07-20Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US9896494B2 (en)2006-02-032018-02-20Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US20070184530A1 (en)*2006-02-032007-08-09Fuad FaresLong-acting veterinary polypeptides and methods of producing and administering same
US10640758B2 (en)2006-02-032020-05-05Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US9908924B2 (en)2006-02-032018-03-06Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en)2006-02-032016-02-02Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
EP2532675A1 (en)2006-02-032012-12-12Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2532674A1 (en)2006-02-032012-12-12Modigene IncLong-acting polypeptides and methods of producing and administering same
US10351615B2 (en)2006-02-032019-07-16Opko Biologics Ltd.Methods of treatment with long-acting growth hormone
US8323636B2 (en)2006-02-032012-12-04Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
US9828417B2 (en)2006-02-032017-11-28Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US10030060B2 (en)2006-02-032018-07-24Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
WO2007091254A1 (en)2006-02-062007-08-16Rappaport Family Institute For Research In The Medical SciencesMethods and kit for diagnosing t1dm
US10018622B2 (en)2006-03-062018-07-10Zetiq Technologies Ltd.Methods and kits for differential staining of abnormal urinary system cells
US9057092B2 (en)2006-03-062015-06-16Zetiq Technologies Ltd.Methods and compositions for identifying a cell phenotype
EP2366775A1 (en)2006-03-232011-09-21Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP3091071A1 (en)2006-03-232016-11-09Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2548951A1 (en)2006-03-232013-01-23Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2626417A1 (en)2006-03-232013-08-14Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
WO2007110869A2 (en)2006-03-282007-10-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to warfarin resistance
US8071323B2 (en)2006-04-072011-12-06The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesHuman monoclonal antibodies that bind human insulin like growth factors and their use
US20100055033A1 (en)*2006-04-072010-03-04The Government Of The United States Of America As Represented By The SecretaryAntibody compositions and methods for treatment of neoplastic disease
WO2007124299A2 (en)2006-04-212007-11-01Novartis AgAntagonist anti-cd40 antibody pharmaceutical compositions
US20110150874A1 (en)*2006-05-192011-06-23Teva Pharmaceutical Industries Ltd.Fusion proteins, uses thereof and processes for producing same
US20070281883A1 (en)*2006-06-052007-12-06Hanna RosenfeldDevelopment of follicle stimulating hormone agonists and antagonists in fish
WO2008010228A2 (en)2006-07-202008-01-24Yeda Research And Development Co. Ltd.Photosyntheticorganisms and compositions and methods of generating same
WO2008026198A2 (en)2006-08-282008-03-06Yeda Research And Development Co. Ltd.Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US20080138840A1 (en)*2006-09-082008-06-12Collins Michael TAssay for antibodies to mycobacterium paratuberculosis
US20110027812A1 (en)*2006-09-082011-02-03Wisconsin Alumni Research FoundationAssay for antibodies to mycobacterium paratuberculosis
US8158371B2 (en)2006-09-082012-04-17Wisconsin Alumni Research FoundationAssay for antibodies to Mycobacterium paratuberculosis
WO2008041183A2 (en)2006-10-052008-04-10Technion Research & Development Foundation Ltd.Microtubes and methods of producing same
US20080199895A1 (en)*2006-10-052008-08-21Yeda Research And Development Co. Ltd.Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20090293146A1 (en)*2006-12-202009-11-26Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8168857B2 (en)2006-12-202012-05-01Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2383345A1 (en)2006-12-202011-11-02Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US9631000B2 (en)2006-12-202017-04-25Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2487187A2 (en)2007-01-042012-08-15Institute for Research in BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
EP2860189A2 (en)2007-01-042015-04-15Institute for Research in BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
WO2008084410A2 (en)2007-01-042008-07-17Humabs LlcHuman cytomegalovirus neutralising antibodies and use thereof
US20100105759A1 (en)*2007-01-162010-04-29Abraham HochbergH19 silencing nucleic acid agents for treating rheumatoid arthritis
US7928083B2 (en)2007-01-162011-04-19Yissum Research Development Company Of The Hebrew University Of JerusalemH19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100196403A1 (en)*2007-01-292010-08-05Jacob HochmanAntibody conjugates for circumventing multi-drug resistance
WO2008093341A2 (en)2007-01-312008-08-07Technion Research & Development Foundation Ltd.Electrospun scaffolds and methods of generating and using same
EP2478924A1 (en)2007-02-012012-07-25Technion Research & Development FoundationAlbumin fibers and fabrics and methods of generating and using same
WO2008093342A2 (en)2007-02-012008-08-07Technion Research & Development Foundation Ltd.Albumin fibers and fabrics and methods of generating and using same
US8057798B2 (en)2007-02-022011-11-15Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US12016915B2 (en)2007-02-022024-06-25Baylor Research InstituteAgents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US20080254044A1 (en)*2007-02-022008-10-16Baylor Research InstituteMultivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
US11173202B2 (en)2007-02-022021-11-16Baylor Research InstituteAgents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US9102730B2 (en)2007-02-022015-08-11Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US9234040B2 (en)2007-02-022016-01-12Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US9453074B2 (en)2007-02-022016-09-27Baylor Research InstituteAgents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US7786267B2 (en)2007-02-022010-08-31Baylor Research InstituteMultivariable antigens complexed with targeting humanized monoclonal antibody
WO2008097870A2 (en)2007-02-022008-08-14Baylor Research InstituteAgents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc- asgpr)
US8728481B2 (en)2007-02-022014-05-20Baylor Research InstituteAgents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US8236934B2 (en)2007-02-022012-08-07Baylore Research InstituteAgents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US10279030B2 (en)2007-02-022019-05-07Baylor Research InstituteAgents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US20080241170A1 (en)*2007-02-022008-10-02Baylor Research InstituteVaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells
US8586052B2 (en)2007-02-022013-11-19Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
EP2684889A2 (en)2007-02-022014-01-15Baylor Research InstituteMultivariable antigens complexed with targeting humanized monoclonal antibody
US8449888B2 (en)2007-02-022013-05-28Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
EP2527363A1 (en)2007-02-022012-11-28Baylor Research InstituteVaccines based on targeting antigen to dcir expressed on antigen-presenting cells
US20080206262A1 (en)*2007-02-022008-08-28Baylor Research InstituteAgents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR)
US20100330115A1 (en)*2007-02-022010-12-30Baylor Research InstituteMultivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
US20080254047A1 (en)*2007-02-232008-10-16Baylor Research InstituteActivation of Human Antigen-Presenting Cells Through CLEC-6
EP3489260A1 (en)2007-02-232019-05-29Baylor Research InstituteActivation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
US20080233140A1 (en)*2007-02-232008-09-25Baylor Research InstituteTherapeutic Applications of Activation of Human Antigen-Presenting Cells Through Dectin-1
EP2522718A1 (en)2007-02-232012-11-14Baylor Research InstituteTherapeutic applications of activation of human antigen-presenting cells through dectin-1
US20080267984A1 (en)*2007-02-232008-10-30Baylor Research InstituteActivation of Human Antigen-Presenting Cells Through Dendritic Cell Lectin-Like Oxidized LDL Receptor-1 (LOX-1)
US9339556B2 (en)2007-02-232016-05-17Baylor Research InstituteActivation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
US8481314B2 (en)2007-02-232013-07-09Baylor Research InstituteActivation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
EP2839839A1 (en)2007-02-282015-02-25Yeda Research And Development Company LimitedNuclear targeting sequences
EP2514766A2 (en)2007-03-292012-10-24Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120202A2 (en)2007-03-292008-10-09Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A1 (en)2007-04-022008-10-09Ramot At Tel Aviv University Ltd.Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
US20100154077A1 (en)*2007-04-092010-06-17Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US9487793B2 (en)2007-04-092016-11-08Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US8513488B2 (en)2007-04-092013-08-20Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US20100092386A1 (en)*2007-04-232010-04-15David SegevSystem for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en)2007-04-232017-01-31Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US8293209B2 (en)2007-04-232012-10-23Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en)2007-04-232015-10-13Deliversir LtdSystem for delivering therapeutic agents into living cells and cells nuclei
EP3032259A1 (en)2007-05-012016-06-15Tel Hashomer Medical Research Infrastructure and Services Ltd.Methods for detecting trophoblast cells in maternal blood based on cytokeratin-7
WO2008132753A2 (en)2007-05-012008-11-06Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for detecting fetal cells in the maternal blood
EP3360571A1 (en)2007-05-032018-08-15Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
EP2529754A1 (en)2007-05-032012-12-05Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP3366762A1 (en)2007-05-072018-08-29Protalix Ltd.Large scale disposable bioreactor
EP2500428A2 (en)2007-07-112012-09-19Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
EP2527441A2 (en)2007-07-152012-11-28Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP3075854A1 (en)2007-07-152016-10-05Technion Research & Development Foundation Ltd.Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
WO2009010968A2 (en)2007-07-152009-01-22Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
US9518267B2 (en)2007-07-242016-12-13Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2910638A2 (en)2007-07-242015-08-26Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US20100319088A1 (en)*2007-07-242010-12-16Gil RonenPolynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US8686227B2 (en)2007-07-242014-04-01Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US20090053224A1 (en)*2007-08-022009-02-26Arresto BiosciencesLox and loxl2 inhibitors and uses thereof
US8679485B2 (en)2007-08-022014-03-25Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US9176139B2 (en)2007-08-022015-11-03Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US8461303B2 (en)2007-08-022013-06-11Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US20090104201A1 (en)*2007-08-022009-04-23Victoria SmithMethods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US10494443B2 (en)2007-08-022019-12-03Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US8658167B2 (en)2007-08-022014-02-25Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
EP2581445A1 (en)2007-08-152013-04-17Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
WO2009034574A2 (en)2007-09-122009-03-19Yeda Research And Development Co. Ltd.Methods of treating tumors in immune-privileged sites
US20090068669A1 (en)*2007-09-122009-03-12Elias GeorgesSlc9a3r1 directed diagnostics for neoplastic disease
EP2591789A2 (en)2007-09-192013-05-15Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP3103463A1 (en)2007-09-192016-12-14Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2050826A2 (en)2007-10-162009-04-22Roche Diagnostics GmbHReagents and methods for detecting neisseria gonorrhoeae
EP2781223A1 (en)2007-10-192014-09-24Rappaport Family Institute for Research in the Medical SciencesCompositions comprising semaphorins for the treatment of angiogenesis related diseases
US20110177112A1 (en)*2007-11-022011-07-21The Johns Hopkins UniversityMulti- component l2 vaccine for prevention of human papilloma virus infection
US9138470B2 (en)2007-11-022015-09-22The Johns Hopkins UniversityMulti-component L2 vaccine for prevention of human papilloma virus infection
EP2599790A1 (en)2007-11-262013-06-05Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
EP2071021A2 (en)2007-12-122009-06-17University of South FloridaBone marrow-derived neuronal cells
US9670501B2 (en)2007-12-272017-06-06Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009083958A2 (en)2007-12-272009-07-09Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US8426682B2 (en)2007-12-272013-04-23Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US20090233295A1 (en)*2008-01-292009-09-17Elias GeorgesTrim59 directed diagnostics for neoplastic disease
US20110052501A1 (en)*2008-01-312011-03-03Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009104174A2 (en)2008-02-212009-08-27Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
US8153383B2 (en)2008-03-182012-04-10Wisconsin Alumni Research FoundationMycobacterial culture screening test for Mycobacterium avium complex bacteria
US20090305302A1 (en)*2008-03-182009-12-10Collins Michael TMycobacterial culture screening test for mycobacterium avium complex bacteria
US8747855B2 (en)2008-04-092014-06-10Technion Research & Development Foundation LimitedAnti human immunodeficiency antibodies and uses thereof
US20110033473A1 (en)*2008-04-092011-02-10Yoram ReiterAnti influenza antibodies and uses thereof
US20110020357A1 (en)*2008-04-092011-01-27Technion Research & Development Foundation Ltd.Anti human immunodeficiency antibodies and uses thereof
US20110147993A1 (en)*2008-04-102011-06-23Objet Geometries Ltd.System and method for three dimensional model printing
US9132587B2 (en)2008-04-102015-09-15Stratasys Ltd.System and method for three dimensional model printing
EP3020410A1 (en)2008-04-182016-05-18Collplant Ltd.Methods of generating and using procollagen
EP2936976A1 (en)2008-04-212015-10-28Danziger Innovations Ltd.Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
EP2116618A1 (en)2008-05-092009-11-11Agency for Science, Technology And ResearchDiagnosis and treatment of Kawasaki disease
US8847008B2 (en)2008-05-222014-09-30Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
US20110097771A1 (en)*2008-05-222011-04-28Eyal EmmanuelIsolated polynucleotides and polypeptides and methods of using same for increasing plant utility
EP2641606A1 (en)2008-05-272013-09-25Pluristem Ltd.Methods of treating inflammatory colon diseases
EP3514229A1 (en)2008-05-282019-07-24Ramot at Tel-Aviv University Ltd.Mesenchymal stem cells for the treatment of cns diseases
EP2620493A1 (en)2008-05-282013-07-31Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
US11280785B2 (en)2008-06-292022-03-22Realbio Technologies Ltd.Liquid-transfer device particularly useful as a capturing device in a biological assay process
US9952211B2 (en)2008-06-292018-04-24Realbio Technologies Ltd.Liquid-transfer device particularly useful as a capturing device in a biological assay process
EP3178845A1 (en)2008-07-162017-06-14Institute for Research in BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
EP3388450A1 (en)2008-07-162018-10-17Baylor Research InstituteHiv vaccine based on targeting maximized gag and nef to dendritic cells
EP3009449A1 (en)2008-07-162016-04-20Institute for Research in BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
US9109011B2 (en)2008-07-162015-08-18Baylor Research InstituteDendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
US20100135994A1 (en)*2008-07-162010-06-03Baylor Research InstituteHiv vaccine based on targeting maximized gag and nef to dendritic cells
EP2960250A1 (en)2008-07-162015-12-30Institute for Research in BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
EP2966091A1 (en)2008-07-162016-01-13Baylor Research InstituteAgonistic anti-cd40 antibodies
US8685402B2 (en)2008-07-252014-04-01Institute For Research In BiomedicineNeutralizing anti-influenza A virus antibodies and uses thereof
US8871207B2 (en)2008-07-252014-10-28Humabs, LLCNeutralizing anti-influenza A virus antibodies and uses thereof
US20100080813A1 (en)*2008-07-252010-04-01Institute For Research In BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
US9340603B2 (en)2008-07-252016-05-17Institute For Research In BiomedicineNeutralizing anti-influenza A virus antibodies and uses thereof
US20100086555A1 (en)*2008-07-252010-04-08Institute For Research In BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
EP2657342A1 (en)2008-08-082013-10-30Genisphere Inc.DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA
WO2010016806A1 (en)2008-08-082010-02-11Agency For Science, Technology And Research (A*Star)Vhz for diagnosis and treatment of cancers
WO2010017544A2 (en)2008-08-082010-02-11Genisphere, Inc.Long-acting dna dendrimers and methods thereof
US20110145946A1 (en)*2008-08-182011-06-16Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
EP3616504A2 (en)2008-08-182020-03-04Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
EP3072972A2 (en)2008-08-182016-09-28Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
US9018445B2 (en)2008-08-182015-04-28Evogene Ltd.Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
EP3115451A1 (en)2008-09-022017-01-11Pluristem Ltd.Adherent cells from placenta tissue and use thereof in therapy
US8367392B2 (en)2008-09-052013-02-05Transalgae Ltd.Genetic transformation of algal and cyanobacteria cells by microporation
US20100081177A1 (en)*2008-09-052010-04-01TransAlgae LtdDecreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
WO2010029545A2 (en)2008-09-112010-03-18Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
WO2010031006A1 (en)2008-09-122010-03-18Cryopraxis Criobiologia Ltda.Ischemic tissue cell therapy
EP2789626A2 (en)2008-09-242014-10-15Tel Hashomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
EP3670524A1 (en)2008-09-242020-06-24Tel HaShomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010035261A2 (en)2008-09-292010-04-01Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereof
WO2010042481A1 (en)2008-10-062010-04-15University Of ChicagoCompositions and methods related to bacterial eap, emp, and/or adsa proteins
US8921658B2 (en)2008-10-302014-12-30Evogene Ltd.Isolated polynucleotides encoding a MAP65 polypeptide and methods of using same for increasing plant yield
US20110197315A1 (en)*2008-10-302011-08-11Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield
WO2010049897A2 (en)2008-10-302010-05-06Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
WO2010055525A1 (en)2008-11-172010-05-20Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en)2008-11-192010-05-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A1 (en)2008-11-262010-06-03Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
WO2010064231A1 (en)2008-12-022010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A1 (en)2008-12-032010-06-10Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
EP2633854A1 (en)2008-12-052013-09-04Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
WO2010071610A1 (en)2008-12-192010-06-24Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
WO2010076788A2 (en)2008-12-292010-07-08Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
EP2808402A2 (en)2008-12-292014-12-03Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment
WO2010076756A2 (en)2008-12-292010-07-08Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076642A1 (en)2008-12-292010-07-08Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
EP3244189A1 (en)2008-12-302017-11-15Jin Po LeeQuantitative analyte assay device and method
WO2010076794A1 (en)2008-12-312010-07-08Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
US20100209415A1 (en)*2009-01-062010-08-19Victoria SmithChemotherapeutic methods and compositions
US9107935B2 (en)2009-01-062015-08-18Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US9289447B2 (en)2009-01-062016-03-22Gilead Biologics, Inc.Chemotherapeutic methods and compositions
WO2010086856A2 (en)2009-02-012010-08-05Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
US12060574B2 (en)2009-02-012024-08-13Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
US10093896B2 (en)2009-02-012018-10-09Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A2 (en)2009-02-022010-08-05Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A1 (en)2009-02-042010-08-12Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010097794A1 (en)2009-02-262010-09-02Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
WO2010097793A2 (en)2009-02-262010-09-02Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
EP2465920A2 (en)2009-02-262012-06-20Tel HaShomer Medical Research Infrastructure and Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
EP3000889A2 (en)2009-03-022016-03-30Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010100595A2 (en)2009-03-022010-09-10Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
US8937220B2 (en)2009-03-022015-01-20Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield, biomass, vigor and/or growth rate of a plant
EP3026057A2 (en)2009-03-092016-06-01Ramot at Tel Aviv University Ltd.Compositions for prevention and treatment of neurodegenerative diseases
WO2010103517A1 (en)2009-03-122010-09-16Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A1 (en)2009-03-302010-10-07Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A1 (en)2009-04-012010-10-07The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
US9907850B2 (en)2009-04-032018-03-06The University Of ChicagoCompositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
WO2011005341A2 (en)2009-04-032011-01-13University Of ChicagoCompositions and methods related to protein a (spa) variants
EP3281947A1 (en)2009-04-032018-02-14The University of ChicagoCompositions and methods related to protein a (spa) variants
US9212219B2 (en)2009-04-032015-12-15The University Of ChicagoCompositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
EP3002293A1 (en)2009-04-032016-04-06The University of ChicagoCompositions and methods related to protein a (spa) variants
WO2010116375A1 (en)2009-04-082010-10-14Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
EP2990421A1 (en)2009-04-302016-03-02Tel HaShomer Medical Research Infrastructure and Services Ltd.Anti ceacam1 antibodies and methods of using same
US9182403B2 (en)2009-05-192015-11-10Zetiq Technologies Ltd.Kits for and methods of differential staining of cervical cancer cells and/or tissues
WO2010135663A2 (en)2009-05-212010-11-25The United States Of America , As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods for the detection of hiv-1/hiv-2 infection
WO2010137017A2 (en)2009-05-272010-12-02Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137013A1 (en)2009-05-272010-12-02Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137021A2 (en)2009-05-272010-12-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
WO2010137020A1 (en)2009-05-282010-12-02Yeda Research And Development Co. Ltd.Methods of treating inflammation
US9096865B2 (en)2009-06-102015-08-04Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
EP3238534A2 (en)2009-06-102017-11-01Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
EP3626051A2 (en)2009-06-102020-03-25Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2010150259A1 (en)2009-06-242010-12-29Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2011004361A2 (en)2009-07-092011-01-13Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
US10538755B2 (en)2009-07-092020-01-21Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
EP3130346A1 (en)2009-07-092017-02-15OPKO Biologics Ltd.Long-acting factor vii coagulation factors
US9663778B2 (en)2009-07-092017-05-30OPKO Biologies Ltd.Long-acting coagulation factors and methods of producing same
US12203113B2 (en)2009-07-092025-01-21Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2011004379A1 (en)2009-07-102011-01-13Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
WO2011010309A1 (en)2009-07-212011-01-27Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
US10179113B2 (en)2009-07-312019-01-15Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011013130A2 (en)2009-07-312011-02-03Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US9574210B2 (en)2009-07-312017-02-21Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011021194A2 (en)2009-08-172011-02-24Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
US20110076739A1 (en)*2009-08-212011-03-31Mccauley ScottCatalytic domains from lysyl oxidase and loxl2
US8512990B2 (en)2009-08-212013-08-20Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US20110207144A1 (en)*2009-08-212011-08-25Derek MarshallIn vitro screening assays
WO2011021171A1 (en)2009-08-212011-02-24Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
US20110044907A1 (en)*2009-08-212011-02-24Derek MarshallIn vivo screening assays
US8927700B2 (en)2009-08-212015-01-06Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US20110044981A1 (en)*2009-08-212011-02-24Spangler RhyannonMethods and compositions for treatment of pulmonary fibrotic disorders
US20110076272A1 (en)*2009-08-212011-03-31Victoria SmithTherapeutic methods and compositions
WO2011024172A2 (en)2009-08-272011-03-03Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
WO2011030332A2 (en)2009-09-082011-03-17Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A1 (en)2009-09-082011-03-17Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011030329A1 (en)2009-09-102011-03-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011033511A1 (en)2009-09-172011-03-24Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011033506A2 (en)2009-09-172011-03-24Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
US20110081706A1 (en)*2009-10-022011-04-07TransAlgae LtdMethod and system for efficient harvesting of microalgae and cyanobacteria
EP3272869A1 (en)2009-10-142018-01-24Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2011045796A1 (en)2009-10-142011-04-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
US10801028B2 (en)2009-10-142020-10-13Beeologics Inc.Compositions for controlling Varroa mites in bees
WO2011046570A1 (en)2009-10-162011-04-21The University Of Medicine And Dentistry Of New JerseyMethod for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A1 (en)2009-10-212011-04-28Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
WO2011055366A1 (en)2009-11-082011-05-12Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
WO2011058557A1 (en)2009-11-122011-05-19Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011058555A1 (en)2009-11-122011-05-19Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
EP4166652A1 (en)2009-11-122023-04-19Technion Research & Development Foundation Ltd.Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP3633025A1 (en)2009-11-122020-04-08Technion Research & Development Foundation Ltd.Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011061736A1 (en)2009-11-172011-05-26Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
WO2011063198A2 (en)2009-11-202011-05-26St. Jude Children's Research HospitalMethods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011064773A1 (en)2009-11-242011-06-03Collplant Ltd.Method of generating collagen fibers
EP2977445A2 (en)2009-11-302016-01-27Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
WO2011064669A2 (en)2009-11-302011-06-03Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2806023A2 (en)2009-11-302014-11-26Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
US9562235B2 (en)2009-12-062017-02-07A.B. Seeds Ltd.MicroRNA compositions and methods for enhancing plant resistance to abiotic stress
WO2011067745A2 (en)2009-12-062011-06-09Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
WO2011072091A1 (en)2009-12-092011-06-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
EP2862929A1 (en)2009-12-092015-04-22Quark Pharmaceuticals, Inc.Compositions and methods for treating diseases, disorders or injury of the CNS
EP3056569A2 (en)2009-12-282016-08-17Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080674A2 (en)2009-12-282011-07-07Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US9493785B2 (en)2009-12-282016-11-15Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
EP3785712A1 (en)2009-12-292021-03-03Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
WO2011080740A1 (en)2009-12-292011-07-07Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
EP3184109A1 (en)2009-12-292017-06-28Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
EP3159405A1 (en)2010-01-052017-04-26Vascular Biogenics Ltd.Methods for use of a specific anti-angiogenic adenoviral agent
WO2011086509A1 (en)2010-01-122011-07-21Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011092700A1 (en)2010-01-272011-08-04Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
EP3216805A1 (en)2010-01-272017-09-13Yeda Research and Development Co. LtdAntibodies that inhibit metalloproteins
US8680246B2 (en)2010-02-042014-03-25Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2011099006A2 (en)2010-02-112011-08-18Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
US10080799B2 (en)2010-02-122018-09-25Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods and compositions related to glycoprotein-immunoglobulin fusions
WO2011104708A2 (en)2010-02-242011-09-01Ben Gurion University Of The Negev Research And Development AuthorityMethods for inhibiting necrosis
WO2011107939A1 (en)2010-03-012011-09-09Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en)2010-03-042011-09-09Yeda Research And Development Co. Ltd.Methods of measuring protein stability
US9121022B2 (en)2010-03-082015-09-01Monsanto Technology LlcMethod for controlling herbicide-resistant plants
US11812738B2 (en)2010-03-082023-11-14Monsanto Technology LlcPolynucleotide molecules for gene regulation in plants
WO2011111034A1 (en)2010-03-082011-09-15Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
US9988634B2 (en)2010-03-082018-06-05Monsanto Technology LlcPolynucleotide molecules for gene regulation in plants
WO2011111050A2 (en)2010-03-112011-09-15Jacob EdreiMethods of generating hydrogen
US8808699B2 (en)2010-04-052014-08-19The University Of ChicagoCompositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
WO2011125015A2 (en)2010-04-052011-10-13Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011127032A1 (en)2010-04-052011-10-13University Of ChicagoCompositions and methods related to protein a (spa) antibodies as an enhancer of immune response
WO2011128897A1 (en)2010-04-122011-10-20Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
US9458438B2 (en)2010-04-122016-10-04Ben Gurion University Of The Negev Research And Development AuthoritySulfotransferase of a red microalga and uses thereof
WO2011132182A1 (en)2010-04-182011-10-27Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US9328353B2 (en)2010-04-282016-05-03Evogene Ltd.Isolated polynucleotides and polypeptides for increasing plant yield and/or agricultural characteristics
WO2011135527A2 (en)2010-04-282011-11-03Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2011138778A2 (en)2010-05-042011-11-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A2 (en)2010-05-052011-11-10Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011138776A2 (en)2010-05-062011-11-10Hervana Ltd.Biologic female contraceptives
WO2011141914A1 (en)2010-05-132011-11-17Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
WO2011151833A1 (en)2010-06-032011-12-08Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
WO2011154940A1 (en)2010-06-072011-12-15Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
WO2011158243A2 (en)2010-06-162011-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
WO2011158242A2 (en)2010-06-162011-12-22Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2012003474A2 (en)2010-07-022012-01-05The University Of ChicagoCompositions and methods related to protein a (spa) variants
WO2012007945A2 (en)2010-07-122012-01-19The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterIsolated polynucleotides and methods and plants using same for regulating plant acidity
WO2012007919A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007950A2 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007951A1 (en)2010-07-152012-01-19Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012011113A2 (en)2010-07-222012-01-26Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012014205A1 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A2 (en)2010-07-272012-02-02Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A2 (en)2010-07-272012-02-02Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012017439A2 (en)2010-08-042012-02-09Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012025914A1 (en)2010-08-222012-03-01Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1 (en)2010-08-242012-03-01Rappaport Family Institute For Research In The Medical SciencesMethods of improving transplantation using sdf-1alpha
US10457954B2 (en)2010-08-302019-10-29Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2012032519A2 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of diagnosing parkinson's disease
WO2012032510A1 (en)2010-09-072012-03-15Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012032521A2 (en)2010-09-072012-03-15Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032520A1 (en)2010-09-072012-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032526A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012032525A2 (en)2010-09-082012-03-15Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
US9095540B2 (en)2010-09-092015-08-04The University Of ChicagoMethods and compositions involving protective staphylococcal antigens
WO2012034067A1 (en)2010-09-092012-03-15The University Of ChicagoMethods and compositions involving protective staphylococcal antigens
WO2012035539A1 (en)2010-09-152012-03-22Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
WO2012038956A1 (en)2010-09-202012-03-29Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
WO2012052872A2 (en)2010-10-172012-04-26Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
EP3075396A1 (en)2010-10-172016-10-05Yeda Research and Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en)2010-10-192012-04-26Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012056452A2 (en)2010-10-272012-05-03Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A1 (en)2010-10-282012-05-03Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
WO2012059922A2 (en)2010-11-032012-05-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012059925A2 (en)2010-11-042012-05-10Ben-Gurion University Of The Negev Research And Development AuthorityAcyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
US9630989B2 (en)2010-11-152017-04-25Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US9096645B2 (en)2010-11-152015-08-04Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2012066495A2 (en)2010-11-172012-05-24Ben Gurion University Of The Negev Research And Development AuthorityT-cell therapy to neurodegenerative diseases
WO2012075111A1 (en)2010-11-302012-06-07Novartis AgUses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012073238A1 (en)2010-12-022012-06-07Technion Research & Development Foundation Ltd.Methods of generating corneal cells and cell populations comprising same
EP2463382A1 (en)2010-12-072012-06-13Enterologics, Inc.Method for identifying E. Coli M-17
WO2012081029A1 (en)2010-12-152012-06-21Kadimastem Ltd.Insulin producing cells derived from pluripotent stem cells
US9551006B2 (en)2010-12-222017-01-24Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
WO2012090205A2 (en)2010-12-282012-07-05Kamedis Ltd.Plant extracts for the treatment and prevention of infections
WO2012098537A1 (en)2011-01-202012-07-26Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012104851A1 (en)2011-01-312012-08-09Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
WO2012114339A1 (en)2011-02-232012-08-30Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
EP2492279A1 (en)2011-02-252012-08-29Laboratorios Del. Dr. Esteve, S.A.Rapid immunogen selection method using lentiviral display
WO2012113921A1 (en)2011-02-252012-08-30Laboratorios Del Dr. Esteve, S.A.Rapid selection method for hiv gp-120 variants
WO2012117406A2 (en)2011-03-022012-09-07Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012117373A1 (en)2011-03-032012-09-07Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012120500A2 (en)2011-03-062012-09-13Merck Serono S.A.Low fucose cell lines and uses thereof
WO2012120518A1 (en)2011-03-082012-09-13Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012123938A1 (en)2011-03-172012-09-20Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012123949A1 (en)2011-03-172012-09-20Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012127320A1 (en)2011-03-222012-09-27Pluristem Ltd.Methods for treating radiation or chemical injury
EP3260533A1 (en)2011-03-222017-12-27Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012127475A1 (en)2011-03-242012-09-27Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012131680A2 (en)2011-03-282012-10-04Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
WO2012137202A1 (en)2011-04-052012-10-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A1 (en)2011-04-062012-10-11Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
US9676846B2 (en)2011-04-122017-06-13The United States Of America As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9150644B2 (en)2011-04-122015-10-06The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
WO2012140519A2 (en)2011-04-152012-10-18Pluristem Ltd.Methods and systems for harvesting cells
US10760088B2 (en)2011-05-032020-09-01Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2012150600A2 (en)2011-05-042012-11-08Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
US8945588B2 (en)2011-05-062015-02-03The University Of ChicagoMethods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2012153333A1 (en)2011-05-092012-11-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en)2011-05-122012-11-15Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012156976A1 (en)2011-05-162012-11-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
EP3263127A1 (en)2011-05-232018-01-03Yeda Research and Development Co. LtdUse of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2012160526A2 (en)2011-05-232012-11-29Ofir MenasheFormulations of microorganism comprising particles and uses of same
EP3527581A2 (en)2011-05-312019-08-21Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012164380A2 (en)2011-05-312012-12-06Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012164565A1 (en)2011-06-012012-12-06Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
US10166295B2 (en)2011-06-022019-01-01Opko Biologics Ltd.Pegylated OXM variants
WO2012172555A1 (en)2011-06-142012-12-20Yeda Research And Development Co. Ltd.Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A1 (en)2011-06-232012-12-27Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
WO2013011347A1 (en)2011-07-182013-01-24Institute For Research In BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
US10815294B2 (en)2011-07-182020-10-27Institute For Research In BiomedicineNeutralizing anti-influenza A virus antibodies and uses thereof
US9587010B2 (en)2011-07-182017-03-07The Institute For Research In BiomedicineNeutralizing anti-influenza A virus antibodies and uses thereof
EP3418300A1 (en)2011-07-182018-12-26Institute for Research in BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
EP3812397A1 (en)2011-07-182021-04-28Institute for Research in BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
WO2013011507A1 (en)2011-07-202013-01-24Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
EP2550982A1 (en)2011-07-272013-01-30Technion Research & Development Foundation Ltd.Devices for surgical applications
EP3482765A1 (en)2011-08-022019-05-15OPKO Biologics Ltd.Long-acting growth hormone and methods of producing same
WO2013018098A2 (en)2011-08-022013-02-07Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
EP3208338A1 (en)2011-08-042017-08-23Yeda Research and Development Co., Ltd.Micro-rna mir-15 and compositions comprising same for the treatment of corticotropin-releasing hormone- associated medical conditions
WO2013018060A2 (en)2011-08-042013-02-07Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
EP3524679A1 (en)2011-08-042019-08-14Yeda Research and Development Co., Ltd.Micro-rna mir-19 and compositions comprising same for the treatment of medical conditions in which low adrenaline or noradrenaline level is therapeutically beneficial
WO2013021389A2 (en)2011-08-092013-02-14Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013024481A1 (en)2011-08-142013-02-21Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013035070A1 (en)2011-09-072013-03-14Yeda Research And Development Co. Ltd.Olfactory signature and odorant mixture having the same
WO2013035071A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Novel risk biomarkers for lung cancer
WO2013035099A1 (en)2011-09-082013-03-14Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9422557B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
US9416363B2 (en)2011-09-132016-08-16Monsanto Technology LlcMethods and compositions for weed control
US9422558B2 (en)2011-09-132016-08-23Monsanto Technology LlcMethods and compositions for weed control
US10760086B2 (en)2011-09-132020-09-01Monsanto Technology LlcMethods and compositions for weed control
US10829828B2 (en)2011-09-132020-11-10Monsanto Technology LlcMethods and compositions for weed control
US10806146B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
US10808249B2 (en)2011-09-132020-10-20Monsanto Technology LlcMethods and compositions for weed control
US11891453B2 (en)2011-10-112024-02-06Famewave Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
US9771431B2 (en)2011-10-112017-09-26Ccam Biotherapeutics Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
WO2013054331A1 (en)2011-10-112013-04-18Tel Hashomer Medical Research Infrastructure And Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP3360899A1 (en)2011-10-112018-08-15Tel HaShomer Medical Research Infrastructure and Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013056377A1 (en)2011-10-212013-04-25Augurex Life Sciences CorporationAntigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en)2011-10-272013-05-02Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013067076A2 (en)2011-11-032013-05-10Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
WO2013070821A1 (en)2011-11-082013-05-16Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A1 (en)2011-11-232013-05-30Danziger Dan Flower FarmOtomeria plants
WO2013076730A1 (en)2011-11-272013-05-30Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
WO2013084190A1 (en)2011-12-082013-06-13Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
EP3034087A1 (en)2011-12-082016-06-22Yeda Research and Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A1 (en)2011-12-202013-06-27Collplant Ltd.Collagen coated synthetic polymer fibers
US10598572B2 (en)2011-12-222020-03-24Realbio Technologies, Ltd.Sequential lateral capillary flow device for analyte determination
WO2013093920A2 (en)2011-12-222013-06-27Yeda Research And Development Co. Ltd.A combination therapy for a stable and long term engraftment
US9726581B2 (en)2011-12-222017-08-08Realbio Technologies Ltd.Sequential lateral flow capillary device for analyte determination
WO2013098820A1 (en)2011-12-282013-07-04Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013098813A1 (en)2012-01-012013-07-04Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013114363A2 (en)2012-01-302013-08-08Yeda Research And Development Co.Ltd.Antimicrobial agents
WO2013114373A1 (en)2012-02-012013-08-08Protalix Ltd.Inhalable liquid formulations of dnase i
WO2013114371A1 (en)2012-02-012013-08-08Protalix Ltd.Dry powder formulations of dnase i
WO2013114374A1 (en)2012-02-012013-08-08Protalix Ltd.Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US10184131B2 (en)2012-02-062019-01-22A.B. Seeds Ltd.Isolated polynucleotides expressing or modulating microRNAs or targets of same, transgenic plants comprising same and uses thereof
US10047345B2 (en)2012-02-132018-08-14Gamida-Cell Ltd.Culturing of mesenchymal stem cells with FGF4 and nicotinamide
WO2013121427A1 (en)2012-02-132013-08-22Gamida-Cell Ltd.Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013121426A1 (en)2012-02-132013-08-22Gamida-Cell Ltd.Culturing of mesenchymal stem cells
EP3326642A1 (en)2012-02-142018-05-30OPKO Biologics Ltd.Long-acting coagulation factors and uses thereof
EP4488289A2 (en)2012-02-142025-01-08OPKO Biologics Ltd.Long-acting coagulation factors and uses thereof
WO2013121416A1 (en)2012-02-142013-08-22Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
EP3791890A1 (en)2012-02-142021-03-17OPKO Biologics Ltd.Long-acting coagulation factors and uses thereof
WO2013121405A1 (en)2012-02-192013-08-22Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
EP3401393A1 (en)2012-02-222018-11-14Exostem Biotec LtdMicrornas for the generation of astrocytes
EP3401394A1 (en)2012-02-222018-11-14Exostem Biotec LtdGeneration of neural stem cells
WO2013124817A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013124816A2 (en)2012-02-222013-08-29Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
WO2013128454A1 (en)2012-03-012013-09-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
EP3483184A1 (en)2012-03-072019-05-15Yeda Research and Development Co. LtdCompositions for inhibition of quiescinsulfhydryl oxidase (qsox1) and uses of same
WO2013132495A1 (en)2012-03-072013-09-12Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1 (en)2012-03-152013-09-19Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2013140247A1 (en)2012-03-202013-09-26Humabs Biomed SaAntibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013140389A1 (en)2012-03-222013-09-26Ramot At Tel-Aviv University Ltd.Plif multimeric peptides and uses thereof
US10683363B2 (en)2012-03-302020-06-16The United States Of America As Represented By The Department Of Veteran AffairsTargeting intracellular target-binding determinants with intracellular antibodies
US12195550B2 (en)2012-03-302025-01-14The United States Of America As Represented By The Department Of Veterans AffairsTargeting intracellular target-binding determinants with intracellular antibodies
US12116416B2 (en)2012-03-302024-10-15The United States Government As Represented By The Department Of Veterans AffairsTargeting intracellular target-binding determinants with intracellular antibodies
WO2013153553A2 (en)2012-04-132013-10-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
US9925143B2 (en)2012-04-182018-03-27Ramot At Tel-Aviv University Ltd.Lipidated glycosaminoglycan particles for the delivery of nucleic acids
US9522945B2 (en)2012-04-192016-12-20Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
WO2013160895A1 (en)2012-04-242013-10-31Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
EP3805395A1 (en)2012-04-262021-04-14University Of ChicagoStaphylococcal coagulase antigens and methods of their use
WO2013162746A1 (en)2012-04-262013-10-31University Of ChicagoStaphylococcal coagulase antigens and methods of their use
WO2013168164A1 (en)2012-05-092013-11-14Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
US8865158B2 (en)2012-05-222014-10-21Ramot At Tel-Aviv University Ltd.Bacteriophages for reducing toxicity of bacteria
EP3508497A1 (en)2012-05-242019-07-10Mountgate Group LimitedCompositions and methods related to prevention and treatment of rabies infection
US9290564B2 (en)2012-05-242016-03-22Mountgate Group LimitedCompositions and methods related to the prevention and treatment of rabies infection
US10240162B2 (en)2012-05-242019-03-26A.B. Seeds Ltd.Compositions and methods for silencing gene expression
US10934555B2 (en)2012-05-242021-03-02Monsanto Technology LlcCompositions and methods for silencing gene expression
WO2013175480A1 (en)2012-05-242013-11-28A.B. Seeds Ltd.Compositions and methods for silencing gene expression
WO2013174003A1 (en)2012-05-242013-11-28Mountgate Group LimitedCompositions and methods related to prevention and treatment of rabies infection
US10240161B2 (en)2012-05-242019-03-26A.B. Seeds Ltd.Compositions and methods for silencing gene expression
WO2013183048A1 (en)2012-06-032013-12-12Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
WO2013183052A1 (en)2012-06-042013-12-12Prolor Biotech Inc.Pegylated oxm variants
US9821070B2 (en)2012-06-042017-11-21Opko Biologics Ltd.Pegylated OXM variants
US10537646B2 (en)2012-06-042020-01-21Opko Biologics Ltd.Pegylated OXM variants
WO2014006621A1 (en)2012-07-032014-01-09Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
US9567569B2 (en)2012-07-232017-02-14Gamida Cell Ltd.Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en)2012-07-232015-11-03Gamida Cell Ltd.Enhancement of natural killer (NK) cell proliferation and activity
EP3594331A1 (en)2012-07-292020-01-15Yeda Research and Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020599A1 (en)2012-07-292014-02-06Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A1 (en)2012-07-312014-02-06Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014024183A1 (en)2012-08-062014-02-13Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
WO2014027082A1 (en)2012-08-172014-02-20Laboratorios Del Dr. Esteve, S.A.Enhanced rapid immunogen selection method for hiv gp120 variants
EP2698377A1 (en)2012-08-172014-02-19Laboratorios Del. Dr. Esteve, S.A.Enhanced rapid immunogen selection method for HIV gp120 variants
WO2014033723A1 (en)2012-09-032014-03-06A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A1 (en)2012-09-122014-03-20Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
WO2014052588A1 (en)2012-09-272014-04-03Research Development FoundationAttenuated chikungunya virus
WO2014057490A1 (en)2012-10-092014-04-17Ramot At Tel-Aviv University Ltd.Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
US9822134B2 (en)2012-10-222017-11-21Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
WO2014064682A1 (en)2012-10-242014-05-01Yeda Research And Development Co. Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
EP3584259A1 (en)2012-10-242019-12-25Yeda Research and Development Co., Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A1 (en)2012-10-292014-05-08Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
US9808534B2 (en)2012-11-202017-11-07Opko Biologics Ltd.Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2014083567A2 (en)2012-11-292014-06-05Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
US10683505B2 (en)2013-01-012020-06-16Monsanto Technology LlcMethods of introducing dsRNA to plant seeds for modulating gene expression
WO2014106838A2 (en)2013-01-012014-07-10A.B. Seeds Ltd.Methods of introducing dsrna to plant seeds for modulating gene expression
WO2014106837A2 (en)2013-01-012014-07-10A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
US10041068B2 (en)2013-01-012018-08-07A. B. Seeds Ltd.Isolated dsRNA molecules and methods of using same for silencing target molecules of interest
WO2014108854A1 (en)2013-01-092014-07-17Fusimab Ltd.Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014108850A2 (en)2013-01-092014-07-17Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
WO2014111936A1 (en)2013-01-172014-07-24Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
US10047356B2 (en)2013-01-172018-08-14Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
EP3431985A1 (en)2013-01-172019-01-23Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
US10815477B2 (en)2013-01-172020-10-27Novellusdx Ltd.Methods and systems for identifying patient specific driver mutations
WO2014118785A1 (en)2013-02-042014-08-07Ramot At Tel-Aviv University Ltd.Generation of cytotoxic tumor specific cell lines and uses thereof
WO2014136113A1 (en)2013-03-062014-09-12Protalix Ltd.Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136114A1 (en)2013-03-062014-09-12Protalix Ltd.TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
WO2014136117A1 (en)2013-03-062014-09-12Protalix Ltd.USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014138696A1 (en)2013-03-072014-09-12University Of Maryland, BaltimoreImmunotherapeutic potential of modified lipooligosaccharides/lipid a
US10612019B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
US10609930B2 (en)2013-03-132020-04-07Monsanto Technology LlcMethods and compositions for weed control
US10568328B2 (en)2013-03-152020-02-25Monsanto Technology LlcMethods and compositions for weed control
US12195531B2 (en)2013-03-212025-01-14Code Biotherapeutics, Inc.Cellular delivery of DNA intercalating agents
WO2014147622A1 (en)2013-03-212014-09-25Collplant Ltd.Compositions comprising collagen and prp for tissue regeneration
WO2014155376A1 (en)2013-03-242014-10-02Biokine Therapeutics Ltd.Methods of treating myeloid leukemia
WO2014174511A1 (en)2013-04-212014-10-30Yeda Research And Development Co. Ltd.Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014174470A1 (en)2013-04-232014-10-30Yeda Research And Development Co. Ltd.Isolated naive pluripotent stem cells and methods of generating same
WO2014174520A1 (en)2013-04-252014-10-30Yeda Research And Development Co. Ltd.Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014188423A1 (en)2013-05-212014-11-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Treatment of mast cell related pathologies
EP3626310A1 (en)2013-05-272020-03-25Rakuto Bio Technologies Ltd.Enzymatic system containing cosmetic compositions
WO2014191995A2 (en)2013-05-272014-12-04Rakuto Bio Technologies Ltd.Enzymatic system-containing cosmetic compositions
WO2014207744A1 (en)2013-06-242014-12-31Ramot At Tel-Aviv University Ltd.Omentum based scaffold and delivery system
US9856495B2 (en)2013-07-192018-01-02Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US11377667B2 (en)2013-07-192022-07-05Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US10597676B2 (en)2013-07-192020-03-24Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US9850496B2 (en)2013-07-192017-12-26Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
US9777288B2 (en)2013-07-192017-10-03Monsanto Technology LlcCompositions and methods for controlling leptinotarsa
WO2015015489A1 (en)2013-07-302015-02-05Biolinerx Ltd.Antibody for treating diabetes and autoimmune diseases
US9938316B2 (en)2013-08-292018-04-10Yeda Research And Development Co. Ltd.Selective inhibitors of α2 isoform of Na,K-ATPase and use thereof for reduction of intra-ocular pressure and as cardiotonic agents
WO2015033337A1 (en)2013-09-032015-03-12Technion Research & Development Foundation Limited.A flap for de-novo tissue regeneration
WO2015033343A1 (en)2013-09-032015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for expressing recombinant polypeptides
WO2015033344A1 (en)2013-09-052015-03-12Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en)2013-09-162015-03-19Plexicure Ltd.Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015040609A1 (en)2013-09-172015-03-26Yeda Research And Development Co. Ltd.Erk-derived peptides and uses thereof
WO2015049677A1 (en)2013-10-012015-04-09Kadimastem Ltd.Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)
US10494419B2 (en)2013-10-022019-12-03Medimmune, LlcNeutralizing anti-influenza A antibodies and uses thereof
US11932682B2 (en)2013-10-022024-03-19Medimmune, LlcNeutralizing anti-influenza A antibodies and uses thereof
US11186627B2 (en)2013-10-022021-11-30Medimmune, LlcNeutralizing anti-influenza A antibodies and uses thereof
EP3763733A1 (en)2013-10-212021-01-13OPKO Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2015059695A1 (en)2013-10-212015-04-30Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US12029780B2 (en)2013-10-212024-07-09Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US11197915B2 (en)2013-10-212021-12-14Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
WO2015059690A1 (en)2013-10-242015-04-30Yeda Research And Development Co. Ltd.Polynucleotides encoding brex system polypeptides and methods of using s ame
US10767156B2 (en)2013-10-242020-09-08Yeda Research And Development Co., Ltd.Polynucleotides encoding BREX system polypeptides and methods of using same
WO2015063768A1 (en)2013-10-312015-05-07Biokine Therapeutics Ltd.Methods of treating acute myeloid leukemia with a flt3 mutation
US10927374B2 (en)2013-11-042021-02-23Monsanto Technology LlcCompositions and methods for controlling arthropod parasite and pest infestations
US10100306B2 (en)2013-11-042018-10-16Monsanto Technology LlcCompositions and methods for controlling arthropod parasite and pest infestations
US9540642B2 (en)2013-11-042017-01-10The United States Of America, As Represented By The Secretary Of AgricultureCompositions and methods for controlling arthropod parasite and pest infestations
WO2015079411A1 (en)2013-11-282015-06-04Tel Hashomer Medical Research Infrastructure And Services Ltd.Rna polymerase i inhibitors and uses thereof
WO2015079413A2 (en)2013-11-282015-06-04Yeda Research And Development Co. Ltd.Synaptojanin-2 inhibitors and uses thereof
WO2015087327A1 (en)2013-12-102015-06-18Yeda Research And Development Co. Ltd.Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-coa and bacteria expressing same
US10557138B2 (en)2013-12-102020-02-11Beeologics, Inc.Compositions and methods for virus control in Varroa mite and bees
US10334848B2 (en)2014-01-152019-07-02Monsanto Technology LlcMethods and compositions for weed control using EPSPS polynucleotides
WO2015114633A1 (en)2014-01-302015-08-06Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd.Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A2 (en)2014-02-032015-08-06Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of eliminating stem cells
WO2015118537A2 (en)2014-02-052015-08-13Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A1 (en)2014-02-062015-08-13Yeda Research And Development Co. Ltd.Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015118547A1 (en)2014-02-102015-08-13Protalix Ltd.Method of maintaining disease stability in a subject having gaucher's disease
WO2015121859A1 (en)2014-02-112015-08-20Brainstorm Cell Therapeutics Ltd.Method of qualifying cells
WO2015132784A1 (en)2014-03-032015-09-11Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method and device for detection of pseudomonas aeruginosa
EP2923709A1 (en)2014-03-282015-09-30Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccine
WO2015144874A1 (en)2014-03-282015-10-01Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccines
US10183066B2 (en)2014-03-282019-01-22Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.VMulti-component-multistage malaria vaccines
US11091770B2 (en)2014-04-012021-08-17Monsanto Technology LlcCompositions and methods for controlling insect pests
US11433163B2 (en)2014-04-102022-09-06Bonus Therapeutics Ltd.Bone repair compositions
EP3643795A1 (en)2014-04-142020-04-29Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.A method for determining the death of cells or tissue by dna methylation analysis
WO2015159293A2 (en)2014-04-142015-10-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159292A2 (en)2014-04-142015-10-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
EP4306659A2 (en)2014-04-142024-01-17Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
EP4026917A1 (en)2014-04-142022-07-13Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.A method and kit for determining the death of cells or tissue or the tissue or cell origin of dna by dna methylation analysis
WO2015159295A1 (en)2014-04-172015-10-22Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
US10550196B2 (en)2014-04-272020-02-04Famewave Ltd.Humanized antibodies against CEACAM1
US11427647B2 (en)2014-04-272022-08-30Famewave Ltd.Polynucleotides encoding humanized antibodies against CEACAM1
US11866509B2 (en)2014-04-272024-01-09Famewave Ltd.Humanized antibodies against CEACAM1
WO2015166492A2 (en)2014-04-282015-11-05Yeda Research And Development Co. Ltd.Microbiome response to agents
WO2015170324A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions for mosquito control and uses of same
WO2015170323A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods of using same for reducing resistance to mosquito larvicides
WO2015170325A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods for reducing pathogen-induced citrus greening
WO2015170322A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods of using same for increasing resistance of infected mosquitoes
WO2015170320A2 (en)2014-05-042015-11-12Forrest Innovations Ltd.Compositions and methods of using same for controlling pathogenically infected mosquitoes
US10993990B2 (en)2014-05-162021-05-04Baylor Research InstituteMethods and compositions for treating autoimmune and inflammatory conditions
US11957734B2 (en)2014-05-162024-04-16Baylor Research InstituteMethods and compositions for treating autoimmune and inflammatory conditions
WO2015177800A2 (en)2014-05-222015-11-26Yeda Research And Development Co. Ltd.Recombinant microorganisms capable of carbon fixation
WO2015186129A1 (en)2014-06-022015-12-10Technion Research & Development Foundation Limited.Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015186128A1 (en)2014-06-022015-12-10Kadimastem Ltd.Methods of inducing myelination and maturation of oligodendrocytes
US10988764B2 (en)2014-06-232021-04-27Monsanto Technology LlcCompositions and methods for regulating gene expression via RNA interference
WO2015198320A1 (en)2014-06-242015-12-30Insight Biopharmaceuticals Ltd.Methods of purifying antibodies
WO2015198334A2 (en)2014-06-252015-12-30Tel Hashomer Medical Research Infrastructure And Services Ltd.Identification of cancer stem cells and use of same for diagnosis and treatment
US11807857B2 (en)2014-06-252023-11-07Monsanto Technology LlcMethods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10583084B2 (en)2014-06-262020-03-10Ramot At Tel-Aviv University Ltd.Liposomal formulations for delivery of nucleic acids
WO2016005985A2 (en)2014-07-092016-01-14Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming cells
US11787853B2 (en)2014-07-152023-10-17Medimmune, LlcNeutralizing anti-influenza b antibodies and uses thereof
US11174304B2 (en)2014-07-152021-11-16Medimmune, LlcNeutralizing anti-influenza B antibodies and uses thereof
US10519221B2 (en)2014-07-152019-12-31Medimmune, LlcNeutralizing anti-influenza B antibodies and uses thereof
WO2016009436A1 (en)2014-07-152016-01-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of cd44 and uses thereof
US12325740B2 (en)2014-07-152025-06-10Medimmune, LlcNeutralizing anti-influenza B antibodies and uses thereof
US10611819B2 (en)2014-07-152020-04-07Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of CD44 and uses thereof
US11560417B2 (en)2014-07-152023-01-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of CD44 and uses thereof
US10294292B2 (en)2014-07-152019-05-21Medimmune, LlcNeutralizing anti-influenza B antibodies and uses thereof
US11015229B2 (en)2014-07-212021-05-25Novellusdx Ltd.Methods and systems for determining oncogenic index of patient specific mutations
US10550439B2 (en)2014-07-212020-02-04Novellusdx Ltd.Methods for determining drug response of patient specific mutations
US10378012B2 (en)2014-07-292019-08-13Monsanto Technology LlcCompositions and methods for controlling insect pests
US11124792B2 (en)2014-07-292021-09-21Monsanto Technology LlcCompositions and methods for controlling insect pests
WO2016016894A1 (en)2014-07-302016-02-04Yeda Research And Development Co. Ltd.Media for culturing pluripotent stem cells
EP3699930A2 (en)2014-08-142020-08-26MeMed Diagnostics Ltd.Computational analysis of biological data using manifold and a hyperplane
WO2016024278A1 (en)2014-08-142016-02-18Memed Diagnostics Ltd.Computational analysis of biological data using manifold and a hyperplane
WO2016030899A1 (en)2014-08-282016-03-03Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral scleroses
US10213501B2 (en)2014-09-082019-02-26Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.Three-component-multistage malaria vaccine
WO2016038610A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en)2014-09-082016-03-17Yeda Research And Development Co. Ltd.Anti-her3 antibodies and uses of same
EP2992895A1 (en)2014-09-082016-03-09Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Three-component-multistage malaria vaccine
WO2016038617A1 (en)2014-09-112016-03-17The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of producing mogrosides and compositions comprising same and uses thereof
WO2016038616A1 (en)2014-09-142016-03-17Yeda Research And Development Co. Ltd.Nmda receptor antagonists for treating gaucher disease
WO2016042561A2 (en)2014-09-212016-03-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Downregulating mir-132 for the treatment of lipid related disorders
WO2016055950A1 (en)2014-10-082016-04-14Novartis AgCombination of human cytomegalovirus neutralizing antibodies
EP3739062A1 (en)2014-10-202020-11-18Gen-Probe IncorporatedRed blood cell lysis solution
WO2016064887A1 (en)2014-10-202016-04-28Gen-Probe IncorporatedRed blood cell lysis solution
DE102015220401A1 (en)2014-10-202016-05-19Gen-Probe Incorporated Erythrocyte lysis solution
WO2016075697A1 (en)2014-11-132016-05-19Enzootic Holdings Ltd.Functional sex-reversal of decapod crustacean females
US11624052B2 (en)2014-11-132023-04-11Enzootic Holdings Ltd.Functional sex-reversal of decapod crustacean females
WO2016075546A2 (en)2014-11-142016-05-19Antonio LanzavecchiaAntibodies that neutralize ebola virus and uses thereof
WO2016079731A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Method of analyzing microbiome
WO2016079736A2 (en)2014-11-172016-05-26Yeda Research And Development Co. Ltd.Methods of treating diseases related to mitochondrial function
EP3831404A1 (en)2014-11-182021-06-09Humabs Biomed S.A.Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
WO2016079739A2 (en)2014-11-202016-05-26Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
US11697819B2 (en)2014-11-202023-07-11Yissum Research Development Company Of The Hebrew University Of Jerusalem LtdCompositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
WO2016084088A1 (en)2014-11-262016-06-02Ramot At Tel-Aviv University Ltd.Targeted elimination of bacterial genes
WO2016084084A1 (en)2014-11-272016-06-02Danziger Innovations Ltd.Nucleic acid constructs for genome editing
WO2016092555A2 (en)2014-12-112016-06-16Yeda Research And Development Co. Ltd.Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016092554A1 (en)2014-12-112016-06-16Memed Diagnostics Ltd.Marker combinations for diagnosing infections and methods of use thereof
WO2016103269A1 (en)2014-12-232016-06-30Ramot At Tel-Aviv University Ltd.Populations of neural progenitor cells and methods of producing and using same
WO2016108219A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Methods of treating retinal diseases
WO2016108240A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
US11891622B2 (en)2014-12-302024-02-06Cell Cure Neurosciences Ltd.RPE cell populations and methods of generating same
WO2016108239A1 (en)2014-12-302016-07-07Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
US11987810B2 (en)2014-12-302024-05-21Cell Cure Neurosciences Ltd.RPE cell populations and methods of generating same
EP3916085A1 (en)2014-12-302021-12-01Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
EP3674397A1 (en)2014-12-302020-07-01Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
WO2016108244A1 (en)2015-01-042016-07-07Protalix Ltd.Modified dnase and uses thereof
WO2016116935A1 (en)2015-01-212016-07-28Yeda Research And Development Co. Ltd.Use of rasa2 as a prognostic and therapeutic marker for melanoma
US10968449B2 (en)2015-01-222021-04-06Monsanto Technology LlcCompositions and methods for controlling Leptinotarsa
WO2016135732A1 (en)2015-02-262016-09-01Yeda Research And Development Co. Ltd.Method of promoting hair growth
WO2016142948A1 (en)2015-03-112016-09-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Decoy oligonucleotides for the treatment of diseases
WO2016147194A1 (en)2015-03-192016-09-22Yeda Research And Development Co. Ltd.Anti amphiregulin antibodies, compositions comprising same and uses thereof
EP4218771A1 (en)2015-03-272023-08-02Yeda Research and Development Co. LtdMethods of treating motor neuron diseases
WO2016160618A2 (en)2015-03-272016-10-06University Of Southern CaliforniaCar t-cell therapy directed to lhr for the treatment of solid tumors
WO2016157190A1 (en)2015-03-312016-10-06Yeda Research And Development Co. Ltd.Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
WO2016157192A1 (en)2015-04-012016-10-06The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Erodium crassifolium l'her plant extracts and uses thereof
EP4005569A2 (en)2015-04-072022-06-01ELA Pharma LtdCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2016162870A1 (en)2015-04-072016-10-13Ilana NathanCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
US10577412B2 (en)2015-04-122020-03-03Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.Anti-plasmodium parasite antibodies
WO2016174674A1 (en)2015-04-272016-11-03The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterEgr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
WO2016174673A1 (en)2015-04-292016-11-03The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Anti-phytopathogenic compositions
US10674732B2 (en)2015-04-292020-06-09The State Of Israel, Ministry Of Agriculture & Rural Development Agricultural Research OrganizationAnti-phytopathogenic compositions
WO2016174652A1 (en)2015-04-302016-11-03Technion Research & Development Foundation LimitedChimeric antigen receptors and methods of their use
WO2016178207A1 (en)2015-05-042016-11-10Ramot At Tel-Aviv University Ltd.Methods and kits for fragmenting dna
WO2016181393A1 (en)2015-05-112016-11-17Yeda Research And Development Co. Ltd.Citrin inhibitors for the treatment of cancer
WO2016185471A1 (en)2015-05-172016-11-24The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCompositions and methods for treating cancer
WO2016185457A1 (en)2015-05-192016-11-24Yeda Research And Development Co. Ltd.Methods of promoting lymphangiogenesis
WO2016185481A2 (en)2015-05-202016-11-24Yeda Research And Development Co. Ltd.Method of targeting senescent cells
WO2016185469A1 (en)2015-05-212016-11-24Yeda Research And Development Co. Ltd.Bacterial populations for promoting health
WO2016193969A2 (en)2015-05-292016-12-08Opko Biologics Ltd.Pegylated oxyntomodulin variants
US11926657B2 (en)2015-06-012024-03-12Medimmune, LlcNeutralizing anti-influenza binding molecules and uses thereof
US10442854B2 (en)2015-06-012019-10-15Medimmune, LlcNeutralizing anti-influenza binding molecules and uses thereof
US11524993B2 (en)2015-06-012022-12-13Medimmune, LlcNeutralizing anti-influenza binding molecules and uses thereof
US10882897B2 (en)2015-06-012021-01-05Medimmune, LlcNeutralizing anti-influenza binding molecules and uses thereof
US10883103B2 (en)2015-06-022021-01-05Monsanto Technology LlcCompositions and methods for delivery of a polynucleotide into a plant
US10655136B2 (en)2015-06-032020-05-19Monsanto Technology LlcMethods and compositions for introducing nucleic acids into plants
WO2016197064A1 (en)2015-06-042016-12-08Epstein Alan LLym-1 and lym-2 targeted car cell immunotherapy
WO2016199140A1 (en)2015-06-082016-12-15Adicet Bio Inc.T cell receptor like antibodies having fine specificity
EP4488293A2 (en)2015-06-082025-01-08Adicet Therapeutics, Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP4039270A1 (en)2015-06-082022-08-10Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
WO2016199141A2 (en)2015-06-082016-12-15Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP4026563A1 (en)2015-06-182022-07-13Yeda Research and Development Co. LtdConditioning protocols and use of same for tissue regeneration
WO2016203476A1 (en)2015-06-182016-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and compositions for diagnosing and treating urothelial cancer
WO2016203477A1 (en)2015-06-182016-12-22Yeda Research And Development Co. Ltd.Conditioning protocols and use of same for tissue regeneration
EP3988113A1 (en)2015-06-192022-04-27OPKO Biologics Ltd.Long-acting coagulation factors and methods of producing same
US10960058B2 (en)2015-06-192021-03-30Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016203482A2 (en)2015-06-192016-12-22Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2016207402A1 (en)2015-06-262016-12-29Institute For Research In BiomedicineProteins comprising a mutated lair-1 fragment and uses thereof
WO2017009852A1 (en)2015-07-162017-01-19Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells
EP3744340A2 (en)2015-07-162020-12-02Biokine Therapeutics Ltd.Compositions and methods for treating cancer
WO2017009842A2 (en)2015-07-162017-01-19Biokine Therapeutics Ltd.Compositions and methods for treating cancer
EP3943098A2 (en)2015-07-162022-01-26Biokine Therapeutics Ltd.Compositions and methods for treating cancer
WO2017009853A1 (en)2015-07-162017-01-19Yeda Research And Development Co. Ltd.Genetically modified anti-third party central memory t cells and use of same in immunotherapy
US10668094B2 (en)2015-07-192020-06-02Yeda Research And Development Co. Ltd.Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure
US11077128B2 (en)2015-07-192021-08-03Yeda Research And Development Co. Ltd.Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure
WO2017013661A1 (en)2015-07-222017-01-26Phytopharma International Ltd.Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US11230696B2 (en)2015-07-292022-01-25Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
EP3862425A1 (en)2015-07-292021-08-11Hadasit Medical Research Services and Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017017686A1 (en)2015-07-292017-02-02Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017021963A1 (en)2015-08-032017-02-09Biokine Therapeutics Ltd.Cxcr4 binding agents for treatment of diseases
WO2017021961A1 (en)2015-08-042017-02-09Yeda Research And Development Co. Ltd.Methods of screening for riboswitches and attenuators
US12203097B2 (en)2015-08-052025-01-21Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017021972A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of photoreceptors for the treatment of retinal diseases
WO2017021973A1 (en)2015-08-052017-02-09Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
US11066642B2 (en)2015-08-052021-07-20Cell Cure Neurosciences LtdPreparation of retinal pigment epithelium cells
US11090337B2 (en)2015-08-052021-08-17Cell Cure Neurosciences LtdPreparation of photoreceptors for the treatment of retinal diseases
EP4155391A1 (en)2015-08-052023-03-29Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017025963A1 (en)2015-08-102017-02-16The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods and pharmaceutical compositions for improving wound healing using cd24
WO2017025967A1 (en)2015-08-132017-02-16Forrest Innovations Ltd.Formulations and compositions for delivery of nucleic acids to plant cells
WO2017033188A1 (en)2015-08-242017-03-02Yeda Research And Development Co. Ltd.Algal oil and biofuel and methods of producing same
US10765706B2 (en)2015-09-032020-09-08University Of South FloridaMethod of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
WO2017042814A1 (en)2015-09-102017-03-16Yeda Research And Development Co. Ltd.Use of perforin positive immature dendritic cells in disease treatment
US11390664B2 (en)2015-10-072022-07-19Humabs Biomed SaAntibodies that potently neutralize hepatitis B virus and uses thereof
EP3753949A1 (en)2015-10-072020-12-23Humabs Biomed SAAntibodies that potently neutralize hepatitis b virus and uses thereof
US10683344B2 (en)2015-10-072020-06-16Humabs Biomed SaAntibodies that potently neutralize hepatitis B virus and uses thereof
US12037381B2 (en)2015-10-072024-07-16Humabs Biomed SaAntibodies that potently neutralize hepatitis B virus and uses thereof
WO2017072757A1 (en)2015-10-252017-05-04Yeda Research And Development Co. Ltd.Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2017072763A1 (en)2015-10-262017-05-04Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
US12188047B2 (en)2015-10-262025-01-07Hadasit Medical Research Services And Development Ltd.Preparation of retinal pigment epithelium cells
EP4545633A2 (en)2015-10-262025-04-30Cell Cure Neurosciences Ltd. PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLS
WO2017072773A1 (en)2015-10-272017-05-04Ilana NathanCompositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
EP4400164A2 (en)2015-10-292024-07-17Yeda Research and Development Co. LtdA method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017072772A1 (en)2015-10-292017-05-04Yeda Research And Development Co. Ltd.A method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017077539A1 (en)2015-11-032017-05-11Ariel-University Research And Development Company Ltd.Compositions for regeneration and repair of neural tissue
WO2017081689A1 (en)2015-11-112017-05-18Ramot At Tel-Aviv University Ltd.Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer
WO2017094001A1 (en)2015-11-302017-06-08Kadimastem LtdMethods for differentiating and purifying pancreatic endocrine cells
EP4231015A1 (en)2015-11-302023-08-23Kadimastem Ltd.Methods for differentiating and purifying pancreatic endocrine cells
EP3176183A1 (en)2015-12-022017-06-07Yeda Research and Development Co. LtdCompositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
EP4059507A1 (en)2015-12-162022-09-21Ramot at Tel-Aviv University Ltd.Particles comprising decellularized omentum
US10561706B2 (en)2015-12-282020-02-18B. G. Negev Technologies And ApplicationsIsolated polypeptide and compositions comprising same
WO2017118985A1 (en)2016-01-062017-07-13Yeda Research And Development Co. Ltd.Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017122203A1 (en)2016-01-112017-07-20Technion Research & Development Foundation LimitedMethods of determining prognosis of sepsis and treating same
US12357692B2 (en)2016-01-132025-07-15Medimmune, LlcMethod of treating influenza A
US11547756B2 (en)2016-01-132023-01-10Medimmune, LlcMethod of treating influenza A
WO2017125931A1 (en)2016-01-212017-07-27The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Parthenocarpic plants and methods of producing same
US10964443B2 (en)2016-01-282021-03-30Sp Nano Ltd.Conductive yarn
US10954313B2 (en)2016-01-282021-03-23Sp Nano Ltd.Composition comprising SP1 and carbon based nanoparticles and uses thereof
WO2017130205A1 (en)2016-01-312017-08-03Hadasit Medical Research Services And Development Ltd.Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
WO2017134671A1 (en)2016-02-042017-08-10Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US11230578B2 (en)2016-02-042022-01-25Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
WO2017138007A1 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceMicrobiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017138008A2 (en)2016-02-142017-08-17Yeda Research And Development Co. Ltd.Methods of modulating protein exocytosis and uses of same in therapy
EP3708675A1 (en)2016-02-142020-09-16Yeda Research and Development Co. Ltd.Microbiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017141253A1 (en)2016-02-162017-08-24Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
US12338435B2 (en)2016-02-192025-06-24Code Biotherapeutics, Inc.Nucleic acid carriers and therapeutic methods of use
WO2017145162A1 (en)2016-02-232017-08-31Chaya BrodieGeneration of cancer stem cells and use thereof
US10906987B2 (en)2016-03-012021-02-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Antibodies specific to human poliovirus receptor (PVR)
EP3907292A1 (en)2016-03-032021-11-10Memed Diagnostics Ltd.Analyzing rna for diagnosing infection type
WO2017149547A1 (en)2016-03-032017-09-08Memed Diagnostics Ltd.Analyzing rna for diagnosing infection type
WO2017153982A1 (en)2016-03-062017-09-14Yeda Research And Development Co. Ltd.Method for modulating myelination
WO2017158610A1 (en)2016-03-172017-09-21Yeda Research And Development Co. Ltd.Methods of isolating barrel-like proteases and identifying peptides processed thereby
WO2017175228A1 (en)2016-04-062017-10-12Technion Research & Development Foundation LimitedInfiltrating immune cell proportions predict anti-tnf response in colon biopsies
US10421785B2 (en)2016-04-112019-09-24Bar-Ilan UniversityDelta receptor agonist peptides and use thereof
WO2017189746A1 (en)2016-04-272017-11-02Gen-Probe IncorporatedBlood cell lysis reagent
DE202017007129U1 (en)2016-04-272019-08-29Gen-Probe Incorporated Lysis reagent for blood cells
EP3736332A1 (en)2016-04-272020-11-11Gen-Probe IncorporatedBlood cell lysis reagent
DE202017007130U1 (en)2016-04-272019-08-29Gen-Probe Inc. Lysis reagent for blood cells
WO2017203520A1 (en)2016-05-222017-11-30Yeda Research And Development Co. Ltd.Methods of using pulmonary cells for transplantation and induction of tolerance
WO2017203532A1 (en)2016-05-252017-11-30Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceAgents for use treating drug resistant tumors and triple negative breast cancer
WO2017208247A1 (en)2016-06-022017-12-07Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Assay for the removal of methyl-cytosine residues from dna
WO2017212476A1 (en)2016-06-052017-12-14Tel Hashomer Medical Research Infrastructure And Services Ltd.Novel molecules for the treatment of inflammation
WO2017212494A1 (en)2016-06-092017-12-14Opko Biologics Ltd.Long-acting oxyntomodulin formulation and methods of producing and administering same
US11859232B2 (en)2016-06-192024-01-02Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Screening for chemotherapy resistance in human haploid cells
WO2017221225A1 (en)2016-06-192017-12-28Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Screening for chemotherapy resistance in human haploid cells
WO2018002924A1 (en)2016-06-272018-01-04Yeda Research And Development Co. Ltd.Veto cells generated from memory t cells
WO2018011796A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Early diagnosis of infections
EP4184167A1 (en)2016-07-102023-05-24MeMed Diagnostics Ltd.Early diagnosis of infections
EP4141448A1 (en)2016-07-102023-03-01MeMed Diagnostics Ltd.Protein signatures for distinguishing between bacterial and viral infections
WO2018011795A1 (en)2016-07-102018-01-18Memed Diagnostics Ltd.Protein signatures for distinguishing between bacterial and viral infections
US12325866B2 (en)2016-07-112025-06-10Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Systems and methods for growing cells in vitro
WO2018011804A1 (en)2016-07-112018-01-18Bonus Therapeutics Ltd.Cell compositions for tissue regeneration
WO2018011799A1 (en)2016-07-112018-01-18Opko Biologics Ltd.Long-acting coagulation factor vii and methods of producing same
WO2018011806A1 (en)2016-07-112018-01-18Yeda Research And Development Co. Ltd.Combination therapy to increase endogenous nitric oxide (no) synthesis
EP4303228A2 (en)2016-07-112024-01-10OPKO Biologics Ltd.Long-acting coagulation factor vii and methods of producing same
US11976106B2 (en)2016-07-112024-05-07Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
WO2018011805A2 (en)2016-07-112018-01-18Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Systems and methods for growing cells in vitro
US11117954B2 (en)2016-07-132021-09-14Humabs Biomed SaAntibodies specifically binding to zika virus epitopes and uses thereof
WO2018011283A1 (en)2016-07-132018-01-18Humabs Biomed SaNovel antibodies specifically binding to zika virus epitopes and uses thereof
EP4342911A1 (en)2016-07-132024-03-27Humabs Biomed SANovel antibodies specifically binding to zika virus epitopes and uses thereof
US11912757B2 (en)2016-07-132024-02-27Humabs Biomed SaAntibodies specifically binding to Zika virus epitopes and uses thereof
EP4434516A2 (en)2016-07-182024-09-25Ramot at Tel-Aviv University Ltd.Modular platform for targeted therapeutics
WO2018015881A1 (en)2016-07-182018-01-25Ramot At Tel-Aviv University Ltd.Modular platform for targeted therapeutics
WO2018020489A1 (en)2016-07-242018-02-01Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
WO2018029682A1 (en)2016-08-082018-02-15Ramot At Tel-Aviv University Ltd.Bacterial systems for analyzing ubiquitylated polypeptides
WO2018029693A1 (en)2016-08-102018-02-15Ramot At Tel-Aviv University Ltd.Analysis of methylation status and copy number
WO2018029690A1 (en)2016-08-102018-02-15Memed Diagnostics Ltd.System and method for analysis of biological data
EP4033248A1 (en)2016-08-102022-07-27MeMed Diagnostics Ltd.System and method for analysis of biological data
WO2018033911A1 (en)2016-08-142018-02-22Ramot At Tel-Aviv University Ltd.Mesenchymal cell-derived exosomes to treat neurological disorders
US11129852B2 (en)2016-08-142021-09-28Ramot At Tel Aviv University Ltd.Mesenchymal cell-derived exosomes to treat neurological disorders
WO2018033929A1 (en)2016-08-182018-02-22Yeda Research And Development Co. Ltd.Diagnostic and therapeutic uses of exosomes
WO2018037416A1 (en)2016-08-252018-03-01Yeda Research And Development Co. Ltd.Methods and compositions for treating autoimmune diseases
EP3503729A1 (en)2016-08-282019-07-03The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO)Method of controlling fungal infections in plants
US10716864B2 (en)2016-09-072020-07-21Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same
WO2018047154A1 (en)2016-09-072018-03-15Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Anti-nkp46 antibodies and therapeutic use of same
WO2018051347A1 (en)2016-09-142018-03-22Yeda Research And Development Co. Ltd.Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
WO2018060998A1 (en)2016-09-292018-04-05Memed Diagnostics Ltd.Methods of prognosis and treatment
WO2018069885A1 (en)2016-10-132018-04-19Technion Research & Development Foundation LimitedUse of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
WO2018073823A2 (en)2016-10-182018-04-26Yeda Research And Development Co. Ltd.Treatment of a circadian rhythm disorder
US11319348B2 (en)2016-10-282022-05-03The Regents Of The University Of CaliforniaSynthetic beta-amyloid peptides capable of forming stable antigenic oligomers
US10662226B2 (en)2016-10-282020-05-26The Regents of the University of CaiifomiaSynthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2018087759A1 (en)2016-11-102018-05-17Yeda Research And Development Co. Ltd.Phosphotriesterases for treating or preventing organophosphate exposure associated damage
WO2018096547A1 (en)2016-11-282018-05-31Yeda Research And Development Co. Ltd.Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest
WO2018100574A1 (en)2016-11-302018-06-07Yeda Research And Development Co. Ltd.Methods of treating liver toxicity and disorders
WO2018100511A1 (en)2016-12-012018-06-07Ramot At Tel-Aviv University Ltd.Combined treatment for nerve injuries
WO2018134824A1 (en)2017-01-182018-07-26Yeda Research And Development Co. Ltd.Genetically modified veto cells and use of same in immunotherapy
WO2018138668A1 (en)2017-01-252018-08-02Mor Research Applications Ltd.Methods of diagnosing malignant diseases
WO2018142416A1 (en)2017-02-062018-08-09Yeda Research And Development Co. Ltd.Isolated cells genetically modified to express a disarm system having an anti-phage activity and methods of producing same
US12281328B2 (en)2017-02-082025-04-22Hadasit Medical Research Services And Development Ltd.Photoreceptor cells for the treatment of retinal diseases
WO2018158775A1 (en)2017-03-022018-09-07Yeda Research And Development Co. Ltd.Methods of culturing t cells and uses of same
WO2018167780A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of prognosing and treating cancer
WO2018167778A1 (en)2017-03-122018-09-20Yeda Research And Development Co. Ltd.Methods of diagnosing and prognosing cancer
WO2018170494A1 (en)2017-03-162018-09-20Bio Time, Inc.Methods for measuring therapeutic effects of retinal disease therapies
WO2018185760A1 (en)2017-04-052018-10-11Yeda Research And Development Co. Ltd.Ex-vivo culture system and methods of using same
EP4317971A2 (en)2017-04-052024-02-07Yeda Research and Development Co. LtdEx-vivo culture system and methods of using same
WO2018193063A2 (en)2017-04-192018-10-25Institute For Research In BiomedicineNovel malaria vaccines and antibodies binding to plasmodium sporozoites
EP3821888A1 (en)2017-05-072021-05-19Yeda Research and Development Co. LtdLxr agonists for treating psychiatric stress disorders
WO2018207178A1 (en)2017-05-072018-11-15Yeda Research And Development Co. Ltd.Methods of treating psychiatric stress disorders
WO2018207184A2 (en)2017-05-102018-11-15Ariel Scientific Innovations Ltd.Methods of purifying antibodies
WO2018216006A1 (en)2017-05-212018-11-29The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterCombination of markers for diagnosing cancer
WO2018216011A1 (en)2017-05-232018-11-29Technion Research & Development Foundation LimitedAgents which inhibit gads dimerization and methods of use thereof
EP4461813A2 (en)2017-05-312024-11-13Tropic Biosciences UK LimitedCompositions and methods for increasing shelf-life of banana
WO2018220581A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing shelf-life of banana
WO2018220579A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedCompositions and methods for increasing extractability of solids from coffee beans
WO2018220582A1 (en)2017-05-312018-12-06Tropic Biosciences UK LimitedMethods of selecting cells comprising genome editing events
WO2018229764A1 (en)2017-06-132018-12-20Yeda Research And Development Co. Ltd.Treatment of advanced or progressive multiple sclerosis
WO2019012544A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dual-probe digital droplet pcr strategy for specific detection of tissue-specific circulating dna molecules
WO2019012542A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Detecting tissue-specific dna
WO2019012543A1 (en)2017-07-132019-01-17Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Dna targets as tissue-specific methylation markers
EP4403646A2 (en)2017-07-132024-07-24Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.Dna targets as tissue-specific methylation markers
WO2019021284A1 (en)2017-07-242019-01-31Yeda Research And Development Co. Ltd.Combination therapy for the treatment of cancer
US12428637B2 (en)2017-08-082025-09-30Technology Innovation Momentum Fund (Israel) Limited PartnershipChloramphenicol resistant split protein and uses thereof
WO2019035128A1 (en)2017-08-142019-02-21Yeda Research And Development Co. Ltd.Immunotherapy against transferrin receptor 1 (tfr1)-tropic arenaviruses
WO2019038761A1 (en)2017-08-212019-02-28Savicell Diagnostic Ltd.Methods of diagnosing and treating lung cancer
WO2019038771A1 (en)2017-08-232019-02-28Technion Research & Development Foundation LimitedCompositions and methods for improving alcohol tolerance in yeast
US11926658B2 (en)2017-08-312024-03-12Humabs Biomed SaMultispecific antibodies specifically binding to Zika virus epitopes
WO2019042555A1 (en)2017-08-312019-03-07Humabs Biomed SaMultispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2019043166A1 (en)2017-08-312019-03-07Humabs Biomed SaMultispecific antibodies specifically binding to zika virus epitopes and uses thereof
US11555199B2 (en)2017-09-192023-01-17Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
US12275939B2 (en)2017-09-192025-04-15Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
EP4170029A2 (en)2017-09-192023-04-26Tropic Biosciences UK LimitedModifying the specifity of plant non-coding rna molecules for silencing gene expression
WO2019058376A1 (en)2017-09-192019-03-28The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
US12331295B2 (en)2017-09-192025-06-17Tropic Biosciences UK LimitedModifying the specificity of plant non-coding RNA molecules for silencing gene expression
EP4461356A2 (en)2017-10-242024-11-13Elani, DaliaMethods of treating an ischemic disease
WO2019094595A2 (en)2017-11-092019-05-16Pinteon Therapeutics Inc.Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019097514A1 (en)2017-11-142019-05-23Yeda Research And Development Co. Ltd.Hematopoietic stem cells with improved properties
WO2019106671A1 (en)2017-11-292019-06-06Ramot At Tel-Aviv University Ltd.Methods of preventing or treating neurogenic shock
WO2019106667A1 (en)2017-11-292019-06-06Weedout Ltd.Compositions, kits and methods for controlling weed of the amaranthus genus
WO2019106680A1 (en)2017-12-032019-06-06Yeda Research And Development Co. Ltd.Treatment of an ischemic heart disease
WO2019116376A1 (en)2017-12-172019-06-20Yeda Research And Development Co. Ltd.Cop9 signalosome (csn) complex modulators and uses thereof
WO2019130313A1 (en)2017-12-282019-07-04Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method to reproduce circadian rhythms on a microfluidic chip
WO2019145964A1 (en)2018-01-292019-08-01Yeda Research And Development Co. Ltd.Combination of a mek inhibitor and a cdk4/6 inhibitor for the treatment of sarcoma
EP4610372A2 (en)2018-01-292025-09-03Lavie Bio Ltd.Plant microbial preparations, compositions and formulations comprising same and uses thereof
WO2019150373A1 (en)2018-01-312019-08-08Yeda Research And Development Co. Ltd.Endoplasmic reticulum targeting signal
WO2019155459A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Inhibitors of the 20s proteasome
WO2019155465A1 (en)2018-02-082019-08-15Yeda Research And Development Co. Ltd.Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
US11571433B2 (en)2018-02-232023-02-07Carmel Haifa University Economic Corporation Ltd.Methods for treating memory impairment and cognitive dysfunction
WO2019167047A1 (en)2018-02-282019-09-06The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterMethods of diagnosing and treating bladder cancer
WO2019175869A1 (en)2018-03-122019-09-19Yeda Research And Development Co. LtdTreatment of a heart disease
US11413336B2 (en)2018-03-232022-08-16Board Of Regents, The University Of Texas SystemCoccidioides antigens and methods of their use
WO2019186569A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Use of electric field gradients to control gene expression
WO2019186570A1 (en)2018-03-292019-10-03Yeda Research And Development Co. Ltd.Methods of disrupting a biofilm and/or preventing formation of same
US11648260B2 (en)2018-03-292023-05-16Technion Research And Development Foundation LimittedVesicles comprising a PTEN inhibitor and uses of same
WO2019211750A1 (en)2018-05-012019-11-07Tropic Biosciences UK LimitedCompositions and methods for reducing caffeine content in coffee beans
WO2019220441A1 (en)2018-05-152019-11-21Hadasit Medical Research Services And Development Ltd.Compositions and methods for treating cancer resistant to an anti-cancer agent
WO2019220437A1 (en)2018-05-152019-11-21Yeda Research And Development Co. Ltd.Vaccination with cancer neoantigens
WO2019229745A1 (en)2018-05-272019-12-05Biolinerx Ltd.Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
WO2019234754A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Nucleic acid constructs and methods of using same
WO2019234750A1 (en)2018-06-072019-12-12The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of regenerating and transforming cannabis
WO2020003311A1 (en)2018-06-252020-01-02Yeda Research And Development Co. Ltd.Systems and methods for increasing efficiency of genome editing
WO2020008412A1 (en)2018-07-042020-01-09Ukko Inc.Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
WO2020012467A2 (en)2018-07-082020-01-16Yeda Research And Development Co. Ltd.Person-specific assessment of probiotics responsiveness
EP4566617A2 (en)2018-07-112025-06-11Immunity Pharma Ltd.Peptide compounds and therapeutic uses of same
WO2020012486A1 (en)2018-07-112020-01-16Kahr Medical Ltd.SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
WO2020012478A2 (en)2018-07-112020-01-16Immunity Pharma Ltd.Peptide compounds and therapeutic uses of same
WO2020026241A1 (en)2018-07-312020-02-06Collplant Ltd.Tobacco transgenic event and methods for detection and use thereof
WO2020035863A1 (en)2018-08-142020-02-20Yeda Research And Development Co. Ltd.Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
WO2020041360A1 (en)2018-08-212020-02-27Quidel CorporationDbpa antibodies and uses thereof
WO2020039440A1 (en)2018-08-242020-02-27Yeda Research And Development Co. Ltd.Methods of modulating m2 macrophage polarization and use of same in therapy
WO2020058979A2 (en)2018-09-202020-03-26Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral sclerosis
WO2020065647A1 (en)2018-09-252020-04-02Biolinerx Ltd.Methods of selecting treatment for cxcr4-associated cancer
WO2020089892A1 (en)2018-10-282020-05-07Yeda Research And Development Co. Ltd.Prevention of age related clonal hematopoiesis and diseases associated therewith
WO2020105050A2 (en)2018-11-212020-05-28Yeda Research And Development Co. Ltd.Method of treating cancer and compositions for same
WO2020132091A2 (en)2018-12-192020-06-25Humabs Biomed SaAntibodies that neutralize hepatitis b virus and uses thereof
EP4292659A2 (en)2018-12-192023-12-20Humabs Biomed SAAntibodies that neutralize hepatitis b virus and uses thereof
WO2020152686A1 (en)2019-01-232020-07-30Yeda Research And Development Co. Ltd.Culture media for pluripotent stem cells
WO2020161724A1 (en)2019-02-102020-08-13Yeda Research And Development Co. Ltd.Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
WO2020165907A1 (en)2019-02-142020-08-20Yeda Research And Development Co. Ltd.Spt5 inhibitors and uses thereof
WO2020170239A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating organoids for high throughput screening of drugs
WO2020170240A1 (en)2019-02-212020-08-27Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reduction drug-induced nephrotoxicity
WO2020178822A1 (en)2019-03-052020-09-10The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Genome-edited birds
WO2020185763A1 (en)2019-03-112020-09-17Memorial Sloan Kettering Cancer CenterCd22 antibodies and methods of using the same
WO2020183414A2 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedModifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
WO2020183419A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedIntroducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
WO2020183416A1 (en)2019-03-142020-09-17Tropic Biosciences UK LimitedPRODUCTION OF dsRNA IN PLANT CELLS FOR PEST PROTECTION VIA GENE SILENCING
WO2020188572A1 (en)2019-03-192020-09-24Yeda Research And Development Co. Ltd.Bistable type ii opsins and uses thereof
WO2020193718A1 (en)2019-03-272020-10-01INSERM (Institut National de la Santé et de la Recherche Médicale)Recombinant proteins with cd40 activating properties
WO2020194317A1 (en)2019-03-282020-10-01Yeda Research And Development Co. Ltd.Method of treating lipid-related disorders
US12419902B2 (en)2019-03-312025-09-23Yeda Research And Development Co. Ltd.Anti-viral and anti-tumoral compounds
WO2020202142A2 (en)2019-03-312020-10-08Yeda Research And Development Co. Ltd.Anti-viral and anti-tumoral compounds
WO2020222241A1 (en)2019-05-022020-11-05Yeda Research And Development Co. Ltd.Compositions comprising the propeptide of lysyl oxidase and uses thereof
WO2020230133A1 (en)2019-05-132020-11-19Yeda Research And Development Co. Ltd.Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
WO2020234875A2 (en)2019-05-192020-11-26Yeda Research And Development Co. Ltd.Identification of recurrent mutated neopeptides
WO2020234888A1 (en)2019-05-222020-11-26Hadasit Medical Research Services And Development Ltd.Methods of culturing human pluripotent cells
WO2020237491A1 (en)2019-05-282020-12-03Shanghaitech UniversityComposition and methods to treat ectodermal dysplasia 2, clouston type
WO2020250232A1 (en)2019-06-122020-12-17Hadasit Medical Research Services And Development Ltd.Methods of generating oligodendrocytes
WO2020255124A1 (en)2019-06-162020-12-24Yeda Research And Development Co. Ltd.Method for stabilizing intracellular rna
WO2020261281A1 (en)2019-06-272020-12-30Ramot At Tel-Aviv University Ltd.Semaphorin 3a antibodies and uses thereof
WO2021001784A1 (en)2019-07-042021-01-07Ukko Inc.De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
WO2021005599A1 (en)2019-07-112021-01-14Kahr Medical Ltd.Heterodimers and methods of use thereof
WO2021009740A1 (en)2019-07-162021-01-21Ramot At Tel-Aviv University Ltd.Compositions and methods for the treatment of tuberculosis
WO2021009763A1 (en)2019-07-162021-01-21Yeda Research And Development Co. Ltd.Methods of treating pain
WO2021019526A1 (en)2019-07-292021-02-04Yeda Research And Development Co. Ltd.Methods of treating and diagnosing lung cancer
WO2021019536A1 (en)2019-07-302021-02-04The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center)Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021028909A1 (en)2019-08-122021-02-18Yeda Research And Development Co. Ltd.Dna repair blood test for predicting response of lung cancer patients to immunotherapy
WO2021033176A1 (en)2019-08-222021-02-25Ariel Scientific Innovations Ltd.Scaled-up methods for purifying antibodies
WO2021038569A1 (en)2019-08-272021-03-04Yeda Research And Development Co. Ltd.Treatment of bacterial vaginosis
WO2021042000A1 (en)2019-08-292021-03-04Vir Biotechnology, Inc.Antibody compositions and methods for treating hepatitis b virus infection
WO2021048852A1 (en)2019-09-112021-03-18Yeda Research And Development Co. Ltd.Methods of treating breast cancer
WO2021059269A1 (en)2019-09-252021-04-01Yeda Research And Development Co. Ltd.Assembly of protein complexes on a chip
WO2021084540A1 (en)2019-10-302021-05-06Yeda Research And Development Co. Ltd.Inhibitors of mmej pathway for prevention and treatment of pre-myeloid and myeloid malignancies
WO2021084526A1 (en)2019-10-312021-05-06Yeda Research And Development Co. Ltd.Engineered autotrophic bacteria for co2 conversion to organic materials
WO2021095031A2 (en)2019-11-112021-05-20Ibi-Ag Innovative Bio Insecticides Ltd.Insect control nanobodies and uses thereof
WO2021100034A1 (en)2019-11-192021-05-27Protalix Ltd.Removal of constructs from transformed cells
WO2021100041A1 (en)2019-11-202021-05-27Yeda Research And Development Co. Ltd.Treating alzheimer's disease
WO2021099576A1 (en)2019-11-212021-05-27INSERM (Institut National de la Santé et de la Recherche Médicale)Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
US12441776B2 (en)2019-11-272025-10-14Eirgen Pharma Ltd.Oxyntomodulin peptide analog formulations
WO2021110126A1 (en)2019-12-042021-06-10珠海泰诺麦博生物技术有限公司Antibody against human cytomegalovirus and use thereof
WO2021130753A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Diagnosis of frontotemporal dementia
WO2021130752A1 (en)2019-12-222021-07-01Yeda Research And Development Co. Ltd.Systems and methods for identifying cells that have undergone genome editing
WO2021137231A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
WO2021137230A1 (en)2019-12-312021-07-08Kahr Medical Ltd.Methods of culturing t cells and uses of same
WO2021137222A1 (en)2019-12-312021-07-08Ichilov Tech Ltd.Methods of treating atopic dermatitis
WO2021144798A1 (en)2020-01-152021-07-22Immunity Pharma Ltd.Peptide compounds and methods of treating diseases using same
WO2021149053A1 (en)2020-01-222021-07-29Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
WO2021152584A1 (en)2020-01-282021-08-05Ariel Scientific Innovations Ltd.Methods of analyzing cell membranes
EP4484956A2 (en)2020-01-292025-01-01MeMed Diagnostics Ltd.Methods of diagnosing and classifying viral infections
WO2021152586A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of analyzing microbiome, immunoglobulin profile and physiological state
WO2021152587A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Treating acute liver disease with tlr-mik inhibitors
WO2021152590A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Articles of manufacture comprising anti pd-l1 antibodies and their use in therapy
WO2021152592A1 (en)2020-01-302021-08-05Yeda Research And Development Co. Ltd.Methods of treating cancer
WO2021156878A2 (en)2020-02-092021-08-12Nlc Pharma LtdRapid detection test for sars-cov-2
WO2021161310A1 (en)2020-02-102021-08-19Yeda Research And Development Co. Ltd.Method for analyzing cell clusters
WO2021173674A1 (en)2020-02-262021-09-02A2 Biotherapeutics, Inc.Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
WO2021178637A1 (en)2020-03-052021-09-10Iowa State University Research Foundation, Inc.IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
WO2021186431A1 (en)2020-03-162021-09-23Yeda Research And Development Co. Ltd.Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
WO2021199039A1 (en)2020-03-292021-10-07Yeda Research And Development Co. Ltd.Variants of beta-glucocerebrosidase for use in treating gaucher disease
WO2021199047A1 (en)2020-03-312021-10-07Biomuse Ltd.Bacteria for the prevention and treatment of smoke-induced lung damage
WO2021205444A1 (en)2020-04-062021-10-14Yeda Research And Development Co. Ltd.Methods of diagnosing cancer and predicting responsiveness to therapy
WO2021205459A1 (en)2020-04-072021-10-14Ramot At Tel-Aviv University Ltd.Cannabidiol-containing compositions and uses thereof
WO2021209995A1 (en)2020-04-132021-10-21Exoprother Medical Ltd.Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy
WO2021210002A1 (en)2020-04-162021-10-21Ichilov Tech Ltd.Cell-derived particles presenting heterologous cd24 and use thereof in therapy
EP3895697A1 (en)2020-04-162021-10-20Ichilov Tech Ltd.Cell-derived particles presenting heterologous cd24 and use thereof in therapy
WO2021229577A1 (en)2020-05-122021-11-18Collplant Ltd.Collagen as a delivery tool for metal-based anti-viral agents
WO2021228836A1 (en)2020-05-132021-11-18INSERM (Institut National de la Santé et de la Recherche Médicale)Recombinant proteins with ox40 activating properties
WO2021234698A1 (en)2020-05-202021-11-25Yeda Research And Development Co. Ltd.Indexing spatial information for a single-cell downstream applications
EP4521115A2 (en)2020-06-102025-03-12Ramot at Tel-Aviv University Ltd.Methods of detecting methylated cpg
US12077569B2 (en)2020-06-222024-09-03Ramot At Tel-Aviv University Ltd.Multi subunit protein modules, cells expressing same and uses thereof
WO2021260675A1 (en)2020-06-242021-12-30Yeda Research And Development Co. Ltd.Agents for sensitizing solid tumors to treatment
WO2021262840A1 (en)2020-06-242021-12-30Vir Biotechnology, Inc.Engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2022034575A1 (en)2020-08-092022-02-17Yeda Research And Development Co. Ltd.Mage-a1 specific t cell receptor and uses thereof
WO2022034588A1 (en)2020-08-102022-02-17Yeda Research And Development Co. Ltd.Compositions for diagnosis and treatment of coronavirus infections
WO2022038536A1 (en)2020-08-182022-02-24International Rice Research InstituteMethods of increasing outcrossing rates in gramineae
WO2022059015A1 (en)2020-09-212022-03-24Yeda Research And Development Co. Ltd.Method for modulating weight
WO2022064494A2 (en)2020-09-232022-03-31Yeda Research And Development Co. Ltd.Methods and compositions for treating coronaviral infections
WO2022070194A1 (en)2020-10-012022-04-07Yeda Research And Development Co. Ltd.Method of diagnosing breast cancer
WO2022074646A1 (en)2020-10-052022-04-14Protalix Ltd.Dicer-like knock-out plant cells
WO2022074656A1 (en)2020-10-072022-04-14Protalix Ltd.Long-acting dnase
WO2022079719A1 (en)2020-10-152022-04-21Yeda Research And Development Co. Ltd.Method of treating myeloid malignancies
WO2022091100A1 (en)2020-10-292022-05-05Yeda Research And Development Co. Ltd.Polynucleotides for rna editing and methods of using same
WO2022097157A2 (en)2020-11-092022-05-121E Therapeutics, Ltd.Catalytic sequence based methods of treating or preventing bacterial infections
WO2022115498A1 (en)2020-11-262022-06-02Ukko Inc.Modified high molecular weight glutenin subunit and uses thereof
WO2022130384A1 (en)2020-12-172022-06-23Yeda Research And Development Co. Ltd.Controlling ubiquitination of mlkl for treatment of disease
US11879140B2 (en)2020-12-282024-01-231E Therapeutics Ltd.P21 mRNA targeting DNAzymes
US11981896B2 (en)2020-12-282024-05-141E Therapeutics Ltd.p21 mRNA target areas for silencing
WO2022144883A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna targeting dnazymes
WO2022144882A2 (en)2020-12-282022-07-071E Therapeutics, Ltd.P21 mrna target areas for silencing
WO2022149142A2 (en)2021-01-102022-07-14Supermeat The Essence Of Meat Ltd.Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
WO2022153286A1 (en)2021-01-142022-07-21Yeda Research And Development Co. Ltd.Methods of producing vitamin d
WO2022157774A1 (en)2021-01-212022-07-28Yeda Research And Development Co. Ltd.Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
WO2022164805A1 (en)2021-01-262022-08-04Vir Biotechnology, Inc.Compositions and methods for treating hepatitis b virus infection
WO2022175951A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Genetically modified bacteria for generating vaccines
WO2022175952A1 (en)2021-02-182022-08-25Yeda Research And Development Co. Ltd.Method of generating vaccines
WO2022189558A2 (en)2021-03-102022-09-15Mabylon AgAntibodies against tdp-43 and methods of using the same
WO2022195589A2 (en)2021-03-162022-09-22Yeda Research And Development Co. Ltd.Methods and devices for ex-utero mouse embryonic development
WO2022208369A1 (en)2021-03-302022-10-06Biomx Ltd.Pseudomonas bacteriophage and uses thereof
WO2022215080A1 (en)2021-04-082022-10-13Yeda Research And Development Co. Ltd.A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
WO2022238947A1 (en)2021-05-122022-11-17Biomx Ltd.Staphylococcus bacteriophage and uses thereof
WO2022254430A1 (en)2021-05-302022-12-08Yeda Research And Development Co. Ltd.Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease
WO2022259242A1 (en)2021-06-062022-12-15Yeda Research And Development Co. Ltd.Combined treatment for cancer
WO2022264132A1 (en)2021-06-132022-12-22Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming human cells
NL2028466B1 (en)2021-06-162022-12-21Sakata Holland B VMethods of sorting matthiola seeds
WO2022264076A1 (en)2021-06-162022-12-22Seedx Technologies Inc.Methods of sorting matthiola seeds
WO2023275255A1 (en)2021-07-022023-01-05Tropic Biosciences UK LimitedDelay or prevention of browning in banana fruit
WO2023003809A1 (en)2021-07-182023-01-26Gamida-Cell Ltd.Therapeutic nk cell populations
WO2023002492A1 (en)2021-07-222023-01-26Yeda Research And Development Co. Ltd.Codon optimization of nucleic acids
EP4130028A1 (en)2021-08-032023-02-08Rhazes Therapeutics LtdEngineered tcr complex and methods of using same
WO2023012584A2 (en)2021-08-032023-02-09Genicity LimitedEngineered tcr complex and methods of using same
WO2023018621A1 (en)2021-08-102023-02-16Gamida-Cell Ltd.Engineered nk cells, methods of their production and uses thereof
GB202112865D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to black sigatoka disease in banana
GB202112866D0 (en)2021-09-092021-10-27Tropic Biosciences Uk LtdResistance to fusarium wilt in a banana
WO2023042202A1 (en)2021-09-142023-03-23Yeda Research And Development Co. Ltd.Multispecific antibodies for use in treating diseases
WO2023105526A1 (en)2021-12-082023-06-15Yeda Research And Development Co. Ltd.Multipotent lung progenitor cells for lung regeneration
WO2023144779A1 (en)2022-01-282023-08-03Pfizer Inc.Coronavirus antigen variants
WO2023209708A1 (en)2022-04-252023-11-02Yeda Research And Development Co. Ltd.Compositions for altering cyclic adp-ribose secondary messenger signalling
WO2023242155A1 (en)2022-06-142023-12-21Janssen Vaccines & Prevention B.V.Compositions and methods for the diagnosis of hiv infection
WO2025017036A1 (en)2023-07-172025-01-23Institut National de la Santé et de la Recherche MédicaleAlphavirus nsp3 helical tubular scaffolds
WO2025027492A1 (en)2023-07-312025-02-06Pfizer Inc.Coronavirus antigen variants
WO2025150045A1 (en)2024-01-122025-07-17Gabriel NussbaumBacterial targets, therapeutics, compositions, kits and methods of use in treating and/or preventing cancer

Also Published As

Publication numberPublication date
DE2206103A1 (en)1972-08-24
NL7101728A (en)1972-08-14
ES399608A1 (en)1974-11-16
FI53894B (en)1978-05-02
JPS5247011B1 (en)1977-11-29
DK150170B (en)1986-12-22
BE779209A (en)1972-05-30
AU468151B2 (en)1973-08-09
ZA72548B (en)1972-10-25
SE451098B (en)1987-08-31
DE2206103B2 (en)1975-10-16
CH573115A5 (en)1976-02-27
GB1363565A (en)1974-08-14
FI53894C (en)1978-08-10
CA1040082B (en)1978-10-10
DK150170C (en)1987-06-29
NL154600B (en)1977-09-15
FR2126760A5 (en)1972-10-06
CA958314A (en)1974-11-26
AU3855272A (en)1973-08-09
BR7200729D0 (en)1973-10-25

Similar Documents

PublicationPublication DateTitle
US3791932A (en)Process for the demonstration and determination of reaction components having specific binding affinity for each other
USRE31006E (en)Process for the demonstration and determination of reaction components having specific binding affinity for each other
USRE29169E (en)Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3850752A (en)Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3839153A (en)Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US4185084A (en)Immunochemical measuring method using second antigenic substance
US4343896A (en)Method and test pack for the demonstration and determination of an antigen or antibody
US4200436A (en)Immunochemical measuring process
US4228237A (en)Methods for the detection and determination of ligands
EP0782710B1 (en)Method for detecting antibodies
US4434236A (en)Immunoassay wherein labeled antibody is displaced from immobilized analyte-analogue
EP0177531B1 (en)Antibodies, manufacture and use
US4828985A (en)Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods
GB2074727A (en)Immunological diagnostic method
CH642458A5 (en)Immunological method
Miedema et al.Determinations of proteins and hormones in serum by an immunoassay using antigen-enzyme conjugates
US4481298A (en)Pre-precipitated double antibody immunoassay method
US4468470A (en)Method and a kit for the assay of antibodies to soluble antigens
US5459045A (en)Reagent for immunoassay, and device using the same
US4180556A (en)Pretreatment method for carcinoembryonic antigen assay
US4693969A (en)Reagent for use in a sandwich solid-phase enzyme-immunoassay and process for employing same
US4320111A (en)Immunologic compositions methods of preparation and use
EP0088974A2 (en)Homogeneous immunoassay with labelled monoclonal anti-analyte
US6352831B1 (en)Glycolipid complexes and their uses
EP0389301A2 (en)Reagent complex for immunoassay

[8]ページ先頭

©2009-2025 Movatter.jp